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Abstract 
 
Selenium (Se) is an essential nutrient for health. In mammals Se is 
incorporated into ~25 selenoproteins in the form of the amino-acid 
selenocysteine encoded by the UGA codon through a complex interacting 
with selenocysteine insertion sequence (SECIS) in the 3’Unstralated 
Region. The selenoproteins have functions in antioxidant defence and 
redox control, thyroid hormone metabolism and mitochondrial metabolism. 
Previous scientific work has found that Se also affects a group of 
downstream targets. The aim of my work is to investigate whether 
expression of selenoproteins or the downstream targets affected by Se is 
regulated through epigenetic mechanisms involving microRNAs, a small 
non-coding RNA species that regulates a gene or groups of genes by 
binding to the mRNA 3’UTR. Gut epithelial Caco-2 cells were grown in 
either Se deficient or Se-supplemented medium for 72h. RNA extracted 
and miRNA expression analysed using a custom-designed human 
genome V2 Agilent 8x15K array. In addition, global mRNA transcriptome 
expression was analysed using an Illumina HumanRef-8 v3 microarray. 
Se supply increased the expression of thirteen miRNAs and 53 
mRNAs the observed differences were confirmed by real time PCR. miR-
185 was selected as a further target of investigation because of its high 
sensitivity to Se. Bioinformatic analysis of the Se susceptible miRNAs and 
Se sensitive genes was carried out using miRWalk, MicroCosmo, 
microRNA.org, miRBase and microRNA.org algorithms and Ingenuity 
Pathway Analysis. This identified miR-185 recognition elements in the Se-
sensitive mRNAs for Glutathione peroxidise 2 (GPX2), Glutathione 
peroxidise 3 (GPX3), and Selenophosphate Synthetase 2 (SEPHS2).  
Expression of GPX2 and SEPHS2 was altered by miR-188 with a 
specific anti-miR and affected differently according to miRNA exposure. 
The data suggests that these mRNAs are targets of miR-185. 
In conclusion, the experiment indicates that miRNA expression as 
regulation of target genes is regulated by Se supply in Caco-2 cells. 
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Chapter 1 Introduction 
 
1.1 Introduction 
 
This thesis addresses the broad hypothesis that gene expression 
can be modified at the post-transcriptional level by micronutrient intake 
mediated through small non-coding RNA (sncRNA) sequences. It has 
recently been found that mRNA degradation or reduced protein expression 
can be regulated by microRNAs (miRNAs) through perfect or imperfect 
target recognition of 3’UTR sequences. My hypothesis is that since 
miRNAs are able to target multiple genes there could be a common 
miRNA-controlled pathway that regulates genes sensitive to selenium 
supplementation. To address this proposal, I used both bioinformatics and 
molecular biological approaches to investigate if miRNA expression 
changes upon Se supplementation and if they are involved in regulation of 
this pathway. For the bioinformatics approach I have searched for 
predicted miRNAs targets to those genes using several algorithms: 
mirna.org, miRBase, and GeneSet2MiRNAand later miRWalk; and 
genomic data analysis (Ingenuity Pathway Analysis) and in the laboratory I 
have isolated RNA from cells in culture for miRNA and mRNA microarray 
analysis and further functional analysis of a miRNA. On the following 
pages, the role of selenium in biological processes, the mode of action of 
miRNAs, miRNA target recognition through bioinformatics approaches and 
the possible role of selenium (Se) responsive miRNAs on changes in 
expression of Se-sensitive genes will be discussed.  
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1.2 Regulation of gene expression 
 
Cell function relies on proteins to undertake specific functions 
towards cell development and differentiation; therefore, the correct 
process of information transcription from DNA into RNA and translation 
within the ribosome to encode a polypeptide is paramount for cell function. 
The process by which the genetic code is used to synthesize proteins and 
produce the structure of cells is generally known as expression of genetic 
information and starts with the synthesis of RNA from DNA, and 
polypeptides from RNA. In general, nucleotides from DNA are decoded to 
produce linear sequences of nucleotides that can then be decoded into 
codons (3 nucleotides) that will then be decoded into amino acids forming 
a polypeptide (Strachan T and P, 1999); gene expression regulation varies 
from one organism to another; this brief introduction will focus on 
metazoans. The first step is known as transcription, it occurs mainly in the 
nucleus of eukaryotic cells where the double DNA helix unwinds and so 
one strand serves as a template for RNA synthesis in which AMP, CMP, 
GMP or UMP are added to the free hydroxyl group of the 3’ end 
(transcription begins from 5’-3’) (Strachan T and P, 1999). RNA 
polymerases I and II are responsible for this elongation. Pol I and Pol II 
elongate DNA by adding an 3’ hydroxyl group through deoxyribonucleotide 
triphosphate (dNTP) downstream of the deoxyribonucleoside 
monophosphate (dNMP) growing chain to produce a leading strand that 
could elongate by the addition of nucleotides (Strachan T and P, 1999), 
but their requirements are different. Pol I has an intrinsic hydrolysis 
activity, promotes transcript cleavage thanks to its A12.2 subunit without a 
trans-acting factor and its transcription initiation step comprises: Rrn3, a 
monomer that interact with the A43 Pol I subunit; a transcription 
termination factor (TTF-1), a six subunit complex that directs transcription 
through a specific promoter know as core factor, an upstream binding 
factor (UBF). Its ability to transcribe nucleosomal DNA is facilitated by the 
FACT (facilitates nucleosomal transcription) complex that localizes and 
extracts rDNA during cell proliferation (Schneider, 2012). Cellular 
transcription by Pol I is the most active and energetically demanding 
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process of cellular translation and it involves 3 nuclear steps before the 
ribosome is assembled and transported outside the nucleus: transcription 
of ribosomal RNA (rRNA) 28S, 18S and 5.8S; the rRNA 5S synthesised by 
Pol III; and the synthesis of other 78 rRNAs from Pol II. Once these rRNA 
transcripts encode the rRNA 25S, 18S, 5.8S, 5S, and 78 rRNA proteins 
(Schneider, 2012). 
 
Pol II requires a TFIIS (Transcription elongation factor IIS) to 
attenuate potential transcription arrest by activating the hydrolysis activity 
and RNA cleavage (Schneider, 2012); many protein coding genes are 
transcribed by Pol II have a TATA box at the promoter element, and 
undergo capping and polyadenylation after transcription (Strachan T and 
P, 1999). 
 
During RNA processing, the RNA transcript is spliced, separating 
the gene coding sequences (exons) form the noncoding segments 
(introns). This mechanism is facilitated by snRNA U1, U2, U3, U4, U5, and 
U6. To identify an intron conserved GU and AG dinucleotides, as well as 
the branch site, need to be identified. In this way, the messenger RNA is 
formed by discarding the introns and keeping the protein coding region 
and relatively short untranslated regions (5’ and 3’ UTRs). 
 
Once mRNA is synthetized, it migrates to the cytoplasm where the 
open reading frame (ORF)is translated into proteins; the 3’ and the 5’ 
UTRs function to help mRNA-ribosome binding and regulate expression of 
the gene stabilizing, modulating translation and localizing mRNA 
(Strachan T and P, 1999). Increasing evidence has discovered that these 
UTRs play a role in the regulation of gene expression by interacting with 
AU-rich elements (ARE) through ARE-binding proteins that could either 
increase or decrease RNA stability recruiting mRNA into processing 
bodies (P bodies), isolating mRNA from ribosomes.  
 
More recently, the discovery of small non-coding RNA species that 
recognise have recognition elements commonly on the 3’UTR of the gene 
sequences have arisen as a new regulatory mechanism of regulation of 
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gene expression (Carthew and Sontheimer, 2009; Gu and Kay, 2010; 
Zhao et al., 2011; Barrett et al., 2012). 
 
1.2.1 Regulation of gene expression by nutrition 
 
The changes in nutrition that can influence changes in the genome 
have been studied to find the mechanism behind human evolution and the 
path towards a healthy lifestyle. 
 
Events like increased protein and omega ω-6 and ω-3 fatty acids 
intake as food are suggested to be responsible for the development of the 
Homo erectus bigger brain. Another example of gene expression 
regulation by nutrition, is the Single Nucleotide Polymorphisms (SNP) 
caused by low essential nutrient intake; furthermore, the availability of 
methionine or choline food sources could have influenced the methylation 
of several genes (Babbitt et al., 2011) leading to a biological programming 
of the organism through evolution to react to environmental changes -such 
as dietary change- and chromatin modifications so as to ensure an 
adequate gene expression (Francis, 2011). 
 
Epigenetic mechanisms have been shown to have a role in gene 
expression through chromatin structures that carry gene expression 
patterns that can be heritable but do not incur changes to the DNA 
sequence. These include histone modification (Francis, 2011), DNA 
methylation, and miRNAs (McKay and Mathers, 2011). Research done in 
early post-natal nutrition suggests that the exposure to inadequate early 
nutrition is linked with epigenetics with the presence or absence of illness 
(Gabory et al., 2011; Wiedmeier et al., 2011). 
 
Micronutrients like the methyl donors, and vitamins pyridoxine, 
folate, and B12, as well as those nutrients involved in one-carbon 
metabolism influence DNA methylation: selenium requirements of 
homocysteine, changes in zinc metalloenzymes from the one-carbon cycle 
(McKay and Mathers, 2011).  
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Mammalian transcription has been shown to be also nutrient 
responsive. For example, effects of serum and growth factors after 
starvation can be explained by the fact that Pol I transcribes rRNA genes 
through a complex that is regulated through growth factors like MAPK-
kinase and insulin-mTOR pathways (Stefanovsky et al., 2006)  
 
Due to the fact that epigenetic mechanisms linked to nutrition can 
be reversible (Gabory et al., 2011), further is needed research in order to 
find the appropriate exogenous events that would lead to a healthy 
organism.  
 
Environment changes like nutrient availability, trigger mechanisms 
where the cells have to respond to external stimuli by controlling different 
stages of the transcription so that gene activation responds to extracellular 
signals (Weake and Workman, 2010).  
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1.3 microRNAs (miRNAs) 
 
miRNAs are part of a small non protein coding RNA family 
characterized by their ~20-30nt long strands and their regulation of gene 
expression through the formation of an RNA interference silencing 
complex (RISC). The RISC consists of a group of proteins from the 
argonaute (Ago) family (Kim et al., 2009a) and RNAs and it interferes with 
genome function through mRNA degradation or mRNA translational 
repression (van den Berg et al., 2008).  
 
Small interfering RNAs (siRNAs), microRNAs (miRNAs), and piwi 
interacting RNAs (piRNA) are closely related categories of small non-
coding RNAs (with a 21-31 nt-long sequences); from those, only siRNAs 
and miRNAs are dependent on Dicer enzymes for their biogenesis; in both 
cases as their single stranded versions are loaded into the RISC complex 
to repress mRNAs (Carthew and Sontheimer, 2009). Briefly, processing of 
piRNAs are through encoded PIWI proteins (Kim et al., 2009a); a piRNA 
locus produces an antisense piRNA transcript that will bind to Aubergine 
(Aub) to form the Aub-piRNA complex; this complex will cleave to their 
sense targets to degraded them and then loaded onto Ago3 to produce 
the Ago3-piRNA complex. Once Ago3-piRNA complexes formed, it is 
capable of cleaving antisense transcripts to degrade and process sense 
mRNAs that will be loaded again onto Ago3; this way of transcript 
degradation, is called “ping-pong” (Choudhuri, 2010; Castañeda et al., 
2011; Röther and Meister, 2011). On the other hand, miRNA and siRNA 
biogenesis have a similar mode of action, but differ from one another as 
siRNAs originate from a double stranded RNA while miRNAs come from a 
single stranded RNA loop (Carthew and Sontheimer, 2009). mRNA 
repression by double stranded siRNAs processed by Dicer (Carthew and 
Sontheimer, 2009) involves, in most cases, an endonucleotic cleavage 
(Ago 2 action) (Jackson and Standart, 2007); in mRNA depletion by 
miRNA, the RISC is formed by Ago1, and m7Gppp decapping follows 
deadenylation and leads low mRNA levels (Standart and Jackson, 2007).
  
 
7
 
 
 
 
  
 
8
 
Figure 1 Biogenesis of small RNA species. 
A) siRNA biogenesis. Endogenous siRNA are transcribed by inverted DNA repeats to form double stranded hairpins. Once transported into the cytoplasm, this 
long double stranded RNA is processed by Dicer into a 22nt double strand which will then be loaded into the RISC by its antisense strand. B) miRNA 
biogenesis is explained in more detail in Figure 2; briefly miRNAs are transcribed as pri-miRNAs by Pol II, cropped so that they fold into a 70nt single strand 
(pre-miRNA), which is then transported outside the nucleus and cleaved by Dicer to form the miRNA-miRNA* duplex; the miRNA is then loaded into the RISC. 
C) piRNA precursors are transcribed from intragenic elements which are a mixture of single strand sense and anti-sense sequences. An Aub-piRNA complex 
is formed when anti-sense piRNAs bind to Aub/Piwi; the sense Aub/Piwi complex transcript will then bind to Ago3 a forming sense piRNA (Ago3 piRNA 
complex) that will recognise an antisense transcript, creating anti-sense piRNAs susceptible to bind to Aub/Piwi to cleave complementary transcript targets 
and continue the “Ping-pong” cycle. 
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MicroRNAs are highly conserved 20- 22 nucleotide (nt) long non-
coding RNA which constitute 1-5% of the known genome (John et al., 
2004). In the majority of known cases, miRNAs regulate gene expression 
by imperfect base pairing to mRNAs through RISC and further reduction of 
protein translation due to increased mRNA degradation (Jackson and 
Standart, 2007; Cannell et al., 2008). An exception of this is miR-10a 
which enhances translation of ribosomal proteins through a 5’UTR 
interaction (Orom et al., 2008). 
 
1.3.1 miRNA biogenesis in mammals 
 
The biogenesis of miRNAs differs from other small endogenous 
RNAs that act through a silencing complex mechanism since they 
originate from a fold-back hairpin structure (Brodersen and Voinnet, 2009). 
There are eleven genes involved in miRNA biogenesis (DROSHA, 
DGCR8, RAN, XPO5, DICER, AGO1, AGO2, HIWI, GEMIN3, GEMIN4, 
and TRBP) (Kim et al., 2010). Of these, Drosha and Dicer can be found 
almost in every cell. In tumour cells, Dicer can only be found in the 
cytoplasm unlike Drosha which can also be found in the nucleus although 
not as abundant as in the cytoplasm. Cytoplasmic Dicer and Drosha have 
a higher concentration in colon tumours cells compared with non-
cancerous cells (Tchernitsa et al., 2010b). Deletion of Dicer and DGCR8 
has been linked to a deficiency of cellular self-renewal and differentiation 
(Shimono et al., 2009), several pathological states are characterized by a 
decrease in mature miRNAs probably, because miRNAs processing 
components have been compromised (Suzuki et al., 2009). 
 
As shown in Figure 2, miRNAs are most commonly transcribed by 
RNA polymerase II (Pol II) to their precursors (pri-miRNAs), then they are 
capped by 7MGpppG and polyadenylated (Saito et al., 2009). Hairpins are 
then processed in the nucleus by a drosha-DGCR8 (DiGEorge critical 
region 8) complex also called PASHA; here, the pri-miRNA is excised by 
Drosha once DGCR8 has localized the pri-miRNA stem to then bind at 
11nt from it (Kohler and Hurt, 2007; Carthew and Sontheimer, 2009). This 
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complex involves enzymes that separate double stranded RNAs from the 
DEAD box: p68 and p72 (or DDX17) (Suzuki et al., 2009). 
 
Processed pri-miRNAs are cleaved 11 base pairs from the loop by 
Drosha which is positioned by DGCR8 to cut the pri-miRNA into ~70nt 
hairpins to form the pre-miRNA. These pre-miRNAs are next transported 
to the cytoplasm by a karyopherin exportin cargo, exportin-5 (XPO5), 
which recognizes a nucleotide motif (Kohler and Hurt, 2007) of the pre-
miRNAs. Once in the cytoplasm, an RNA III enzyme, Dicer, cuts the pre-
miRNA into two single strands, the miRNA (the guide strand) and 
miRNA*(Bartel, 2004; Filipowicz et al., 2008; Ghildiyal and Zamore, 2009; 
Winter et al., 2009). This cytoplasmic cleavage leaves 2 unpaired 
nucleotides at the 3’ end and these are the target of the argonaute (Ago) 
PAZ domain; alternatively, the phosphates from the 5’ are targeted by the 
MID domain of the same protein (Hock and Meister, 2008). *MID has also 
a protein-protein interaction function. 
 
For maturation of metazoan miRNA, a single stranded miRNA has 
to bind to an RNA induced silencing complex (RISC). To this end, it has 
been suggested that for thermodynamic stability, the strand with unstable 
base pairs (GU rather than GC) at the 5’ is loaded into an Ago to become 
a mature miRNA while the other single stranded miRNA (miRNA*) is 
degraded (Brodersen and Voinnet, 2009) by nucleases. The 5’ strand is 
usually the more conserved, thus likely to bind the 3’UTR mRNA. In fact, a 
perfect 5’end miRNA-3’UTR of mRNA pairing is found in Drosophila (Lai, 
2002) and plants. The RISC is formed by Dicer and Argonaute 2 (Ago 2) -
the only endonuclease protein from the Argonaute family located on a 
different chromosome (8 rather than 1) (Hock and Meister, 2008) with an 
incision capacity (Li et al., 2006; Hock and Meister, 2008). 
 
Dicer, Ago 2, and a double stranded RNA binding protein (TRBP 
or PACT) (Kim et al., 2009a) form the RISC loading complex (RLC) that 
will assemble the single stranded miRNA (Hock and Meister, 2008; 
Ghildiyal and Zamore, 2009) after Dicer has digested the miRNAs into the 
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RISC in which mRNA is degraded by miRNA-mRNA binding, 
deadenylation, or translational repression (Winter et al., 2009). 
 
The origin of miRNA promoters is not well understood. However, 
chromatin immunoprecipitation chip (chiP-chip) assays have suggested 
that miRNA transcript start sites may be shared by the introns of their 
coding genes or that they might have their own promoter (Corcoran et al., 
2009) and behave like a protein coding Pol II transcript as transcription 
factors, transcription co activators and chromatin modifications regulate 
these miRNAs (Cannell and Bushell, 2010). Other miRNAs are originated 
from intronic regions (Hebert and De Strooper, 2009); when miRNAs are 
processed from short intronic hairpins called mirtrons, these function as 
pre-miRNAs; splicing takes the place of nuclear processing by Drosha, 
from miRNA transport to the cytoplasm onwards, mirtrons follow the 
miRNA processing pathway (Slezak-Prochazka et al., 2010). 
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Figure 2 miRNA biogenesis.  
miRNA biogenesis from RNA polymerase II starts with transcription into a hairpin 
structure, pri-miRNA. This is followed by capping and polyadenylation, and then the 
double stranded pre-miRNA is excised by Drosha The ~70nt strand is then transported 
outside the nucleus by XPO5. Once in the cytoplasm, Dicer will process the pre-miRNAs 
into 2 strands, the guide strand and the * strand. The former strand is loaded into RISC 
whereas the * strand is generally degraded. 
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1.3.2 Gene expression regulated by miRNAs 
 
For miRNAs to regulate gene expression, they need a ribonuclear 
protein complex, RISC. As described in the miRNA biogenesis section, for 
miRNA maturation, the5’ strand of the miRNA is recognised by Ago2 and 
loaded into the RISC; this protein is responsible for mRNA binding (Liu et 
al., 2012) and the slicer activity that leads to RNA interference (Kawamata 
and Tomari, 2010). The effects of miRNAs on mRNAs, once the former 
becomes mature by loading into RISC, are on mRNA degradation or 
translational repression. 
 
Their mechanism of action is still under investigation but most 
researchers agree that miRNAs affects are brought about by these 
mechanisms one of the following (Gu and Kay, 2010): 
 
a) Site specific cleavage. In this case a miRNA cleaves its target 
to a nearly perfect or perfect complementarity resulting on RNA 
interference; Ago2 is responsible for mRNA slicer activity. 
 
b) mRNA degradation, associated with mismatches on the miRNA-
mRNA binding. This mechanism has been suggested to work thorough 
ARE, a previously documented decay element (Zhao et al., 2011; 
Vasudevan, 2012) that mediate an accelerated mRNA degradation. 
 
c) Translational inhibition that happens when a an imperfect match 
occurs in the miRNA-mRNA interaction, and this can potentially be 
triggered by deadenylation (Djuranovic et al., 2011). Another factor that 
could facilitate mRNA degradation is disintegrating the poly A binding 
protein (PABPC) and removing the polyA tail leading to exonucleolytic 
degradation (Pasquinelli, 2012).  
 
miRNAs can inhibit mRNA translation by interacting with eIF4F 
complex, an eukaryotic translation-initiation factor complex formed by 
eIF4E, eIF4G, and eIF4A, that cap the mRNA structure protecting the 
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mRNA from degradation (Huntzinger and Izaurralde, 2011). mRNA 
deadenylation is another proposed mechanism of action of miRNAs, and 
this can occur either at initiation (Liu, 2008)of or post-initiation (Cannell et 
al., 2008). Reduced protein synthesis may result from mRNA decapping, 
deadenylation, or degradation in P Bodies. Alternatively, elongation 
distortion by active mRNA translocation, blocked polypeptide synthesis 
(ribosome “drop off”), or other undefined mechanisms may be involved in 
miRNA-mediated reduction in protein expression post-initiation (Standart 
and Jackson, 2007; Cannell et al., 2008; Kong et al., 2008). 
 
Elongation repression is suggested to be by RISC interactions. 
Proposed models include the competition between RISC and elF4E, in 
which case RISC would bind the mRNA 5’ cap structure while Apo2 
replaces elF4E tryptophans with phenylalanines (Carthew and 
Sontheimer, 2009). Translational repression is thought to be due to mRNA 
destabilization by poly (A) tail deadenylation initiated by either RISC or 
GW182. 
 
miRNAs interact with cis-regulatory elements as transcriptions 
factors (TF) do and this might be why the more transcription factors gen, 
the higher chance a miRNA can have of controlling that gene. (Su et al., 
2010). 
 
Although miRNAs are thought to down-regulate the expression of 
genes (due to the RISC) overexpression of genes has also been 
registered. It has been hypothesized that a saturation of the sh/miRNA 
nuclear export machinery is responsible; cell processes in which small 
RNA transport machinery or RISC saturation is suggested to occur are cell 
cycle and oncogenesis (Khan et al., 2009). 
 
Apart from their role in RNA interference, miRNAs are also thought 
to postransciptionally upregulate their targets (Krol et al., 2010; 
Vasudevan, 2012) by the relief of repression from the miRNA which occurs 
when Ago2 and GW182 cannot interact properly (Vasudevan, 2012). 
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1.3.3 miRNA target recognition 
 
miRNA-mRNA interactions are due to base pairing. In plants, this 
interaction includes perfect or almost perfect base pairing to the mRNA 
(Meng et al., 2011), whereas in animals, this interaction permits 
mismatches. Even when mismatches or wobbles are found (mostly in the 
central region of a miRNA), protein expression is downregulated 
suggesting that miRNAs can anneal to their target without the need of the 
100% complementarity required by other small RNA species. More 
research is required to understand miRNA mechanisms of action and roles 
over gene expression regulation, but it has been suggested that protein 
degradation rather than mRNA degradation can be the predominant 
mechanism, (Kong et al., 2008) as protein synthesis is reduced at a 
translational level. miRNA mediated cleavage usually involves targeting 
the 3’UTR of the mRNA (Filipowicz et al., 2008), which is the suggested 
miRNA mechanisms of action is due to the 3’UTR since it is the most 
common binding site for this small RNA species in fact this statement is 
often within the first paragraph on any miRNA publication. However, these 
interactions have also been found within the 5’ UTR or ORF. It is likely that 
3’ or 5’ UTR are more functional sites since the energy demanded for 
these particular sites requires a weak base pairing (Lee et al., 2009), but 
experiments in HeLa cells have also indicated the mRNA 5’UTR as a 
cleavage site for mediating mRNA degradation. On the other hand, ORF 
target interactions offer repression when the mRNA (susceptible to miRNA 
cleavage) has been translated.(Lytle et al., 2007). miRNA Recognition 
Elements (MREs) on the ORF are reported as less effective than the 
3’UTR MRE; however, genes that are most commonly repressed have 
several ORF MRE (Schnall-Levin et al., 2011). In fact, RISC that targets 
mRNAs at the ORF or the 5’UTR might ensure message repression after 
ribosomal translation, as these sites are less affected by decodification. 
Either way, a MRE where an mRNA has a complementary Watson-Crick 
base pairing to the seed region of an miRNA is needed for mRNA-miRNA 
interaction. 
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The understanding of mRNA target recognition began with the 
observation of multiple complementary sequences at the mRNA 3’UTR 
from lin-4 RNA and lin-7 RNA (Brodersen and Voinnet, 2009). From that 
fact, it has been thought that an expressed miRNA is able to regulate 
several proteins during translation. 
 
As several mechanisms of miRNA target recognition have been 
identified, it is important to spot the features that allow mRNA-miRNA 
cleavage. For instance, when the mRNA is in a secondary structure by 
means of intermolecular base pairing, miRNA cleavage will result in 
energy consumption to open the secondary structure. (Jackson and 
Standart, 2007). Duplex formation, however, represents energy gain. 
 
miRNA binding within the 3’UTR is more efficient if the binding site 
is located at least 15nt far from the stop codon. If the UTR binding site is 
long, the binding site is more likely to bind away from the centre (Grimson 
et al., 2007). Another factor that would facilitate miRNA annealing to at 
mRNA is the presence of AU-rich sites located next to the binding site 
(Sun et al., 2010),although RNA-binding proteins that interact with AU-rich 
element of the target mRNA protect it from degradation (Pasquinelli, 
2012). 
 
1.3.4 Seed region 
 
This 2-7nt long region is located at the 5’ end of the miRNA 
sequence. It was first discovered in D. melanogaster and is the section of 
the strand that is responsible for the most conserved binds (binding site 
similar among human, mouse, rat, dog, and chicken genome). However, 
non-conserved sites can still function as a result of competition between a 
more highly-expressed but less conserved miRNA end with a higher 
fidelity match to the target but expressed at lower level. miRNA binding 
beyond the seed region have still been recognized at the 5’UTR or codon 
mRNA region (Lytle et al., 2007). 
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Evidence of conserved interactions (and moreover, miRNAs’ 
faculty to regulate multiple mRNAs) matching the seed region was 
supported by Lim, L.P., et at., 2005 (Lim et al., 2005), who transfected 
Hela cells with miRNA-124 and a mutated 5-6 region version and obtained 
different sets of downregulated genes from the two assays. 
 
A conserved seed region is often recognized by mRNA that 
contains adenosines (Lewis et al., 2005). In fact, when multiple seed sites 
are found is the same 3’UTR, the one with the highest AU content has the 
highest cleavage possibility (Long et al., 2008). 
 
A suggested A-form helix conformation has been proposed by 
Bartel, et al (Bartel, 2009). This model suggests that nucleotides arranged 
in an A-form helix would need to be 7-8nt long miRNA segments to ensure 
effectiveness in mRNA targeting; a longer strand will result in large loops 
while a shorter single strand would not have sufficient specificity. Different 
miRNA-mRNA binding models have been suggested due to miRNAs 
flexibility to match imperfectly to their targets, there are different types of 
cleavage sites:  
 
a) Canonical. Specific Watson-Crick match of 7-8 nucleotides (nt) 
in the seed region. Ranked by microarray analysis as the most efficient 
interaction for miRNA mediated mRNA degradation (Bartel, 2009) 
potentially in the 5-6 positions (Lim et al., 2005).  
b) Dominant seed sites. Complementary at the 5’ site, but allows 
mismatches at the 3’ end. 
c) Atypical sites. Sites at 3’ miRNA could match its target if at least 
3-4 contiguous short stretches of nucleotides from a 13-14 nt long strand, 
matching the mRNA poly (A) tail. A loop between the matches and 
mismatches is formed. 
d) Conserved sites. Sites with perfect base pairing at the 3’ miRNA 
but have mismatches or loops at the 5’. 
 
On a miRNA seed pairing, minimum energy is lost during cleavage 
according to the minimum free energy model (MFE) which is based on the 
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total energy that a miRNA needs to bind an mRNA; and is measured as an 
energy-based score which relates the gained energy as an mRNA is 
bound and the lost energy result of mismatches (Chen et al., 2008).  
 
1.3.5 Non-seeded sites 
 
Although, as noted, most conserved miRNAs bind to the 3’UTR of 
their target genes, there are known instances of miRNAs targeting the 
protein coding sequence. This view is supported by computational miRNA 
predictions in Drosophila melanogaster (Stark et al., 2007) and 
experimentally validated data from HeLa Cells (Lytle et al., 2007), and let-
7 (showing three repressing human mRNA- miRNA) (Brodersen and 
Voinnet, 2009), that interact in the open reading frame (ORF) (Mazière 
and Enright, 2007). 
 
Among other species, exemplified in C. elegans, lin-4, let-7, and 
lys-6, miRNAs miR-10 in humans and AGO1-miRNA complexes in D. 
melanogaster (Brodersen and Voinnet, 2009) functional cleavage sites 
outside the seed region are commonly found. 
 
Also, pairing at the 13-16nt of the miRNA 3’ still confirmed 
alignment efficiency after microarray analysis; efficient target recognition is 
shown at 8nt site. This sites lose efficacy if located 15nt far from the stop 
codon (Grimson et al., 2007). 
 
1.3.6 miRNA conservation 
 
miRNAs that occur in multiple species are referred to as 
conserved miRNA. Conserved miRNAs generally bind to their gene target 
sequence outside the ORF, and generally in the 3’UTR. This characteristic 
is used when predicting miRNA target recognition as comparison among 
species is used to retain the most positive matches as it is thought that 
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orthologous genes could lead to anticipation of false negatives in miRNA 
predictions (Norden-Krichmar et al., 2007). However, miRNA conservation 
should not be taken as criteria of exclusion of possible mRNA target; is so, 
valuable miRNAs cleavage could be left out in cases of species that not 
necessarily present similar genes to other species (not conserved). 
 
miRNA mediated cleavage usually involves targeting the 3’UTR 
mRNA (Filipowicz et al., 2008) but experiments in HeLa cells have also 
indicated the mRNA 5’UTR as a cleavage site for mediating mRNA 
degradation. On the other hand, ORF target interactions offer repression 
when the mRNA (susceptible to miRNA cleavage) has been translated 
(Lytle et al., 2007). In fact, RISC that targets mRNAs at the ORF or the 
5’UTR might ensure message repression after ribosomal translation, as 
these sites are less affected by decodification. 
 
1.3.7 mRNA target multiplicity 
 
The percentage of the interactions between a single miRNA 
interacting with an mRNA is a roughly 10-20% (Cannell and Bushell, 
2010). However, translational silencing can be enhance when the mRNA 
is cleaved by several miRNAs (Jackson and Standart, 2007; Brodersen 
and Voinnet, 2009; Schnall-Levin et al., 2011; Subramanyam and Blelloch, 
2011). Moreover, this target multiplicity is maximized when the miRNA 
target sites are close to each other; this phenomenon is called 
“cooperativity”(Grimson et al., 2007). In miR-124, an interspace of 34nt 
between the two miRNA signals still permits this cooperativity, while 19 to 
56nt does not. According to this principle, a stronger downregulation could 
come from different miRNAs closely targeting the same mRNA (Grimson 
et al., 2007; Saetrom et al., 2007). The idea of different silencing 
complexes (belonging to the same or multiple miRNAs) confers a stronger 
downregulation relationship. This is because during translation, the 
mRNAs cleaved by miRNAs could be decoded by the ribosome and 
therefore dissociates the silencing complex. Disrupted silencing 
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complexes are frequent in the 15nt 3’UTR target sites (Saetrom et al., 
2007).  
1.3.8 mRNA network regulation by a single miRNA 
 
miRNA target prediction observes target multiplicity even within 
the same mRNA sequence which has been previously documented where 
a miRNA or miRNA network able to control several genes (Grimson et al., 
2007; Saetrom et al., 2007; Flynt and Lai, 2008; Pitto et al., 2008; 
Subramanyam and Blelloch, 2011). Single miRNAs that regulate several 
genes have been suggested to have roles in cancer processes (miR-19a; 
apoptosis, miR-14; developmental timing, lin-4, lin-28, miR-172 (Yeung et 
al., 2005)) by targeting one or several genes. On the other side of the 
argument, stronger mRNA repression is observed when multiple miRNAs 
regulate a single target gene. Moreover, groups of miRNAs that as a 
whole target group of genes can be identified, consistent with an overall 
model of regulation at the level of pathways. 
 
The existence of families or clusters of miRNA that regulate 
genes; example of this is the mir-17-92 family which have MRE for 
different protein coding genes (Juhila et al., 2011) and has been identified 
as oncogenes (Olive et al., 2010) or regulator of the of is has also been 
proposed particularly in relation to cellular processes and cancer as 
miRNA clusters seems to be needed in the regulation of cellular 
complexes. 
 
Members of an miRNA family are identified with same number but 
differing with a different lower case letter, they share a common seed 
region or a location in gene clusters present in different chromosomes 
(Park et al., 2008). 
 
Examples include the miR-200 family (found to be expressed in 
the carcinogen epithelium tissue), which represses ZEB1 and ZEB2 
mRNA (responsible for interleukin 2 expression repression) mRNA; the 
miR-302 family responsible for stem cell growth (Lin et al., 2008), and the 
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miR-16 family, which regulates cellular proteins responsible for cell 
division and cell growth (Linsley et al., 2007; Zhang et al., 2009). 
 
The miR-183-96-182 cluster has been shown to control the entire 
insulin signalling pathway whereas miR-375 alone, regulates only 
insulinemia (Zhang et al., 2009) providing an example of an effect of a 
miRNA network that contrasts with the more limited effect of a single 
miRNA with the network. 
 
Transfection of miR-124 and miR-1 in HeLa cells demonstrated 
that a single miRNA downregulates several genes.(Lim et al., 2005). miR-
24, expressed in brain tissues, down regulated 174 genes transfected 
HeLa cells. The response correlated with those expressed in lower levels 
in the brain than any other tissue. In agreement, miR-1, found in heart and 
skeletal muscles, preferably down regulated genes present in those 
tissues.  
 
1.4 Bioinformatics approaches 
 
The complexity of miRNA gene interactions introduces the 
opportunity to use interdisciplinary approaches involving computer 
science, mathematics, and statistics to identify possible mRNA targets.  
 
The prediction of miRNA targets has been possible using 
computational approaches in which miRNA target recognition has been 
taken into account from several bioinformatic tools in order to design an 
efficient algorithm. Different miRNA prediction programmes use different 
algorithms to predict mRNA-miRNA target recognition interactions. These 
include the following categories: a) Searching for complementary sites 
which also considers thermodynamic calculations; b) Thermodynamic 
based algorithms, calculate and compose the free energy of predicted 
binding interactions; c) Databases based on microarray expression studies 
or gene expression (Bartel, 2004).  
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1.4.1 Bioinformatic tools 
 
Computational predictions are often used to microRNA 
Recognition Elements (MREs) within an mRNA sequence. These 
algorithms look for miRNA-mRNA complementarily and give a high score 
according to the thermodynamics, matching miRNA seed region, 
conservation throughout species. 
 
For this project we used GeneSet2MiRNA (which collects 
information from 11 algorithms), microrna.org, miRBase (which are based 
on complementary and conserved binding predictions) and Ingenuity 
Pathways Analysis (which searches for protein-protein and protein-miRNA 
interactions) to predict miRNAs. As these miRNAs are being predicted, 
there is no published information about their interactions. Therefore, by 
comparing the results from these bioinformatic tools that employ different 
algorithms and finding an overlap on mRNA-miRNA interactions, the aim 
was to increase the probability of finding a network and validate it 
experimentally. 
 
Microrna.org is a bioinformatic tool based on a modification of the 
miRada algorithm, which focuses on almost perfect 3’UTRmRNA-5’miRNA 
complementary sites and analysed thermodynamically (Mazière and 
Enright, 2007). The microRNA library is originated from a mammalian 
microRNA expression based on small RNA library sequence data 
collected from human and rodent tissues and cell lines (Landgraf et al., 
2007). The genome library from Homo sapiens (172), Mus musculus (64), 
and Rattus norvegiocus (16) was downloaded from the University of 
California Santa Cruz (UCSC) genome browser database (Kuhn et al., 
2007).It scores to the potential alignment by allowing mismatches in the 
seed region, but seeking complementary binding in the gene from mature 
miRNAs and considering mRNA multitargeting. For a complementary 
binding, a miRNA mature and miRNA target conservation among species 
are needed; the conservation is filtered by PhastCons. The first stage to 
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determine miRNA-mRNA binding is looking for A:U and C:G interactions, it 
scans a file with the genome of interest and the miRNA sequences 
 
Microrna.org scans the possible miRNA-gene interactions from 
two files, one containing miRNA sequences (file1) and the other containing 
RNA/DNA sequence (file2), in two stages. The former stage includes 
reading sequences from files 1 and 2 to find A:U and G:C complementary 
sites. The latter stage will then score the alignment by its thermodynamical 
role.  
 
miRBase searches for complementary sites (ranking them from 0 
to 100) in the Ensembl Genome library of 37 species. It also works with 
the miRanda algorithm and contains miRNA sequences gathered from 58 
species and seeks for conservational pairing. It contains miRNA and 
miRNA* sequences; which corresponds to an miRNA mature sequence 
that is generally loaded into the RISC (miRNA), and the passenger strand 
(miRNA*) which is commonly degraded by endonucleases, but has also 
shown to play a role in gene expression regulation (Okamura et al., 2008); 
~60% of the mature miRNAs within the database are experimentally 
validated (Griffiths-Jones et al., 2008). 
 
Features when predicting miRNA-mRNA interactions include: 
perfect seed pairing, mRNA conservation at least between 2 species at 
the 3’UTR, and thermodynamic interactions are measured by Vienna RNA 
folding routines (Griffiths-Jones et al., 2008).  
 
GeneSet2MiRNA is as a web-tool that takes a list of genes (by 
accession number or gene name) and computes it with miRecords, a 
website that contains documented validated and predicted targets from 9 
species. The later targets are collected from 11 algorithms; the 
GeneSet2MiRNA score is based on the number of commonly predicted 
miRNA hits (The  University  of  Minnesota and Houston, 2008; Antonov et 
al., 2009). 
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Ingenuity Pathways Analysis (IPA) is a software rather that an 
algorithm that provides a visual analysis of gene interactions and builds 
pathways of gene interactions in health and disease. Biological and 
molecular scientific publications from Homo sapiens, Mus musculus and 
Rattus novergicus data are the source of IPA’s library; it also supports 9 
other species. The building structure pathway includes information from 
scientific articles and the chemical and physiological behaviour of the 
components (Ingenuity, 2008). 
 
miRWalk was created recently from modifying miranda algorithm, 
but it also compares its predictions with other well established 
bioinformatics tools and includes experimentally validated and 
documented miRNAs-mRNA binding (Dweep et al., 2011). 
 
1.4.2 Finding miRNAs through “hands in” laboratory 
techniques 
 
Although these miRNA computational predictions give different 
scores according to the likeliness of an miRNA-mRNA cleavage, the rate 
of a false positive miRNA-mRNA interaction is between 30-50% (Yokoi 
and Nakajima, 2011), this might be because the partial complementarity to 
the mRNA is not enough for the binding to occur or because several 
miRNA characteristics are not taken into account for this forecast: miRNA 
tissue specificity, cell compartment of the mRNA target. 
 
Several experimental approaches have been suggested, miRNA 
target cloning through RNA ligase-mediated amplification of cDNA 
end (RLM-RACE), QRT-PCR for generally recommended when 
identifying a few miRNAs, Labelled miRNA pull-down assay 
(LAMP), Photoactivatable-ribonucleoside-enhanced cross-linking 
and immunoprecipitation (PAR-CLIP) (Jin et al., 2010) luciferase 
reporter assays 
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 miRNA target cloning through RNA ligase-mediated amplification of 
cDNA end (RLM-RACE), a microarray based technology designed 
to identify miRNA-mRNA binding events in vivo by ligating the 5’ 
monophosphate ends at the 3’ of the cleaved mRNA end, polyA+ to 
an RNA oligonucleotide adapter. Once ligated, the RNA is 
synthesised into a singles stranded cDNA by reverse transcription 
and generating the cDNA second strand with an homologous RNA 
adapter sequence for the promoter of the bacteriophage T7 as 
forward primer and a gene specific reverse primers designed 
followed by PCR amplification, cDNA template removal, cDNA 
fragmentation and microarray hybridization (Franco-Zorrilla et al., 
2009). Because miRNA and siRNA contain ligation-competent 5’ 
monophosphate when the RISC bind to the small RNA, it does not 
distinguish between these two snRNA species (Jin et al., 2010). It is 
generally used for identifying plant miRNA targets (Franco-Zorrilla 
et al., 2009; Llave et al., 2011) 
 
 Luciferase reporter assays, a bioluminescence technology that 
clones and isolates luciferases to construct a reporter assay that 
would catalyse light emitting reactions by producing a photon when 
luciferin is catalysed into oxyluciferin (Thorne et al., 2010).  
 
 Labelled miRNA pull-down assay (LAMP) in which miRNA 
biogenesis is mimicked by means of inserting a digoxigenin (DIG) 
labelled pre-miRNA and once this interact with the endogenous 
DICER, the DIG-miRNA-mRNA complex can be precipitated and 
analysed by QRT-PCR;  
 
 Photoactivatable-ribonucleoside-enhanced cross-linking and 
immunoprecipitation (PAR-CLIP) an adapted cross-linking and 
immunoprecipitation assays which crosslinks RBN proteins 
facilitated by 4-thiouridine (4SU) labelled cellular transcripts to 
detect miRNA targets; cross-linked 4SU residues are the 
sequenced to recognize the T to C transitions and identify RBN 
binding, the downside of this technique is that 4SU labelling could 
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be affected by neighbour aminoacids (Hafner et al., 2010), miRNA 
profiling through PCR platforms, microarrays,  
 
The most commonly used experimental validation of In silico 
miRNA-mRNA interactions are the following approaches: 
 
a) Microarray. This method screens the expression of multiple 
mature miRNAs based on hybridization of test RNA samples to arrays of 
miRNA probes (Yin et al., 2008; Kong et al., 2009). Several commercial 
microarray platforms are available and they all produce consistent 
functional pathways according to a study in mouse kidney where mice 
treated with and without aminoacids to determine by Affymetrix, Applied 
Biosystems, Agilent, and GE health microarray platforms the pathways 
found by Ingenuity Pathway Analysis from the genes differentially 
expressed; showed that the four platforms produced an overlap of 70-80% 
on functional pathways from the top 5 ranked pathways (Li et al., 2009) 
which in reality gives limited data of the specific function of a set of genes 
as the listed functions include tumour, tumorogenesis, cancer, neoplasia, 
etc. Therefore, more specific comparisons are needed especially towards 
miRNA expression. At the time of carrying out the experimental work, 
described in this thesis, the Agilent platform offered the option to 
customize the chip probes and it had greater sensitivity for detection of 
individual member of miRNA families or clusters at it showed high 
correlations with QRT-PCR when comparing Agilent Human miRNA 
Microarray 1.0; Exiqon miRCURY Locked Nucleic Acid (LNA) microRNA 
Array, v9.2; and Illumina Sentrix Array Matrix 96-well microarray 
expression profiling (Git et al., 2010). 
 
Human genome V2 Agilent platform is a one colour microarray 
consisting of a short probe which hybridizes the target miRNA and 
contains a hairpin loop that will join the synthesized sequence to the 
miRNA, this is to standardize all the miRNAs Tm. Uses the miRNAs 
sequences from Sanger 10.1. 
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b) Massively parallel/next-generation sequencing (NGS). miRNAs 
have also been detected through next generation sequencing (Landgraf et 
al., 2007; Sato et al., 2009; Git et al., 2010) where the small non-coding 
RNAs are measured using their mature sequence independently, groups 
of miRNAs that share the mature sequence, and miRNA precursors which 
are either sharing mature sequences or organized in clusters. (Landgraf et 
al., 2007)  
 
c) Northern blot analysis. This method is used to analyse and 
quantify small RNAs. It verifies miRNA-mRNA target stabilizing 
hybridization by building a methylene bridge between the ribose and the 
nucleotides with LNA modified probes. From test samples, RNA is 
electrophoresed through a denaturing polyacrylamide gel to membrane 
and probed using specific labels miRNA probes (Castoldi et al., 2006; 
Hino et al., 2008; Kuhn et al., 2008; Várallyay et al., 2008). 
 
d) QRT-PCR. This approach involves reverse transcript followed 
by PCR amplification using primers specific to the miRNA to be quantified. 
Due to miRNA sequences being short, several approaches like 
polyadenilation, LNA technology and stem loop miRNA primers have been 
designed, to reverse transcribe the miRNAs: and technologies like LNA 
that needs modified probes to stabilise the ribose and ensures 
hybridization, and the stem loop technology that extends the miRNA using 
a universal primer are designed with a standardise the melting 
temperature of the miRNAs (Tm). PCR products could be analysed on a 
2% agars gel (Raymond et al., 2005; Kuhn et al., 2008), or monitor the 
fluorescence by QRT-PCR (Ro et al., 2006).  
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1.5 Selenium 
 
The trace element selenium (Se) is an essential micronutrient that 
has been shown to have an important function in health and disease 
processes since the early 1930s, when an excess of Se in soils was 
indicated to be the cause of alkali disease in farm animals consuming 
high-Se plants. In 1957 Se was found to be not only a toxic nutrient, but 
also an essential one, protecting liver tissue in vitamin E deficient rats 
(Burk R. F., 1994).  
 
1.5.1 Selenium and health 
 
The impact of Se on human health was first identified in Keshan 
province of China, where Se deprivation caused an endemic 
cardiomyopathy that involves circulation disorders as well as myocarditis, 
and which was related to extremely low soil Se content and viral infection; 
incidence was considerably decreased once the crops were treated with 
sodium selenite (Liu et al., 2002). Myxedematous cretinism (Zimmermann 
and Kohrle, 2002) (growth and mental retardation as well as facial 
maturation problems are found in this neurological disease common in 
Zaire) and Kashin-Beck (Moreno-Reyes et al., 2003) (joint and bone 
disorders) are also diseases related to severe selenium deficiency 
(Gromer et al., 2005); in the case of cretinism it is also related to iodine 
deficiency. More recently, Se deficiency has been associated with 
increased mortality risk in HIV (Fawzi et al., 2005). In case of an 
insufficient Se intake, the distribution of Se among the tissues will migrate 
so as to protect brain, thyroid and reproductive system (Ferguson et al., 
2012), suggesting hierarchy in order to maintain the amount of Se vital for 
this organs. For any form of Se supplementation, beneficial effects can be 
observed after a month of supplementation, this is based on dietary 
studies which are usually from 4-6 weeks since this is enough to stabilise 
epithelial kinetics (Hu et al., 2011). 
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Evidence for an influence of Se on the immune system has come 
from both observational and association studies. For example, an 
association study of serum Se and risk of mycobacteria pulmonary 
infection in an Indian population (Ramakrishnan et al., 2012) found that 
low serum Se was associated with increased risk of pulmonary 
tuberculosis. In addition a selenomethionine supplementation trial of 12 
weeks in a UK population has suggested improved immune status 
(Sanderson et al., 2010); in this study the immune response to influenza 
vaccination was assessed by measuring IgG levels in plasma and 
cytotoxicity. Immune function as assessed by cytotoxicity was enhanced 
after supplementation with 50 µg Se/d; and improved immune responses 
to vaccines observed after supplementation with at 100 µg Se/. 
 
Often, these studies investigate more than one micronutrient at a 
time. For example, a study of 25 asthmatic Taiwanese patients found low 
plasma Se possibly to compensate for antioxidant imbalance (Guo et al., 
2011). In another study elderly volunteers were fed with a 5 portions/day 
fruit and vegetables that increased plasma Se (among other 
micronutrients like retinol, carotenoids, ascorbic acid) for 12 weeks and 
after this intervention, one group was given was tetanus toxoid and 
Pneumovax while the another one was given a placebo. Natural killer cell 
cytotoxicity was higher in the immune challenged group, but no significant 
differences were found in response to the vaccine on the treated groups, 
except that patients eating the 5 portions/day diet reported a sense of well-
being against illness (Sanderson et al., 2010). 
 
A further study where Se yeast supplementation (200 µg) reduced 
the admission to hospitals in American HIV patients has been reported 
(Hurwitz et al., 2007). This effect was hypothesised as being due to Se 
increasing the production of activated T cells, increase tumour cytotoxicity 
and natural CD4 killer activity. Other studies in elderly people showed 
increased immune response (50% higher T lymphocyte count) against 
infections after a daily supplementation with 400 µg as Se yeast (Wood et 
al., 2000). More recent publication linked the incidence of viral infection 
diseases with low Se content in the soil (Harthill, 2011).  
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Further evidence of enhanced immunity has come from the 
improved offspring survival and a reduction in mortality because of 
gastrointestinal infections among women with HIV (Siegfried et al., 2012). 
In contrast, Se supplementation and drug consumption among HIV 
patients that has been reported to increases the risk of suffering from 
bacterial infection (Rayman, 2012). 
 
The proposed roles of low Se intake in the aetiology of asthma in 
children has been proposed as being partly responsible for increased 
incidence of this disease in New Zealand, a country that historically has 
had inadequate Se intake (Thomson et al., 2011). The mechanistic basis 
for this may the modulation of pro-inflammatory leukotriene metabolism, 
and thus reduced inflammatory response, by increased Se intake. 
Increased Se intake has also been reported to protect against recurrent 
wheeze from children exposed to smoke (Thomson et al., 2012). 
 
The roles of Se in humans include thyroid hormone metabolism 
(Schomburg and Kohrle, 2008), enhancement of immunity mediated by 
selenoproteins (Arthur et al., 2003), male fertility (Flohe, 2007), antioxidant 
defence, brain function (Schweizer et al., 2004), anti-proliferative effect in 
skin cancer (De Felice et al., 2011), muscle metabolism (Brown and 
Arthur, 2001), and it is even considered a favourable factor of longevity (Lv 
et al., 2011). Selenium intake recommendations are based on the amount 
of Se required to increase GPx3 activity in plasma to normal levels. 
Estimates of recommended Se intake based on GPx activity levels vary 
from 55µg/d (Burk et al., 2006) to 60-75µg/d for women and men 
respectively (Sunde et al., 2008). In contrast, a high intake of 200µg/d has 
been indicated to reduce risk of skin, prostate, lung, and colon cancer 
(Burk et al., 2006) as well to improve immune system function in HIV 
(Fawzi et al., 2005). In Australia, concentrations of Se in plasma of 95-
100µg/l are considered as adequate (Huang et al., 2011a) 
 
Se is also thought to affect musculoskeletal heath. 
Supplementation at 5 µM of sodium selenite on BMMs cells and 
macrophage such as RAW 264.7 cells, had an antioxidant effect inhibiting 
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reactive oxygen species (ROS) generation which might reduce osteoclast 
differentiation so preventing bone reabsorption (Moon et al., 2012). Low 
levels of Se are associated with the deforming musculoskeletal condition 
Kashin-Beck disease when plasma Se is from 5-27ng/ml (Downey et al., 
2009). Controversially a study of the importance of Se for bone 
development and that abnormal metabolism of postmenopausal Turkish 
women with different bone mineral densities, found little difference in 
plasma Se concentration, suggesting no relationship between 
osteoporosis and Se status (Arikan et al., 2011).  
 
In the case of thyroid function, a Se sufficient diet is required for 
optimal function of this gland, more specifically for the selenoproteins 
glutathione peroxidases and deiodinases which promote thyroxine (T4) 
and triiodothyronine (T3) synthesis by protecting iodine from oxidation; 
iodothyronine deiodinases are responsible for the catalysis of the thyroid 
hormone into active form; however supplementation in elderly people 
neither altered thyroid function on its own (Rayman et al., 2008) when Se 
and iodine supplementation were given to the same participants (Thomson 
et al., 2011) nor increased the conversion of T4 into T3 (Rayman et al., 
2008); however, Se supplementation is recommended as well as iodine to 
ensure an adequate thyroid function (Thomson et al., 2011). 
 
Se induces DNA damage response in MRC-5 normal lung 
fibroblasts (Wu et al., 2011a) where ataxia-telangiectasia mutated (ATM) 
kinase is induced by Se so as to activate senescence response and limit 
tumourogenesis (Wu et al., 2011a). In a study where human LNCaP were 
supplemented with sodium selenite and SeMet, a higher cell survival was 
observed after ROS exposure (de Rosa et al., 2012). 
 
1.5.2 Food sources 
 
Dietary Se intake is dependent on the Se content of the soil on 
which food is grown (Harthill, 2011).. For example, Scottish soil is 
considered Se deficient being 0.34-0.48 mg/kg (Fordyce et al., 2010) 
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when the recommended threshold by the Food Standards Agency is 0.6 
mg/k; soil Se levels were was found to correlate with the Se concentration 
in potatoes, broccoli, beef, and milk (Fordyce et al., 2010). The most 
common sources of Se for UK population are bread and cereals with a 
0.01-30 mg/kg (26%) and meat where the Se content in muscle is 0.2 
mg/kg and up to 0.6 mg/kg (26%); followed by a 0.01-0.03 mg/kg of Se 
from milk and dairy products (21%), fish (10%), and vegetables and fruit 
(7%). Eggs containing 3-25 µg/kg and up to 0.58 mg/kg on supplemented 
Se (4%) hens and finally other sources like Se enriched food and 
supplements (6%) (Fairweather-Tait et al., 2011). Se content in fruits and 
vegetables is rather low in those that have not been supplemented, apart 
from garlic with a natural Se content of ~0.5 mg/kg in the forms of 
selenomethionine (12%) and seletane (4%); for example, potatoes contain 
0.5 mg/kg in equal distribution of selenomethionine and selenite. An 
exceptionally high Se source are Brazilian nuts (Bertholletia excelsa) with 
3800ng/g (Navarro-Alarcon and Cabrera-Vique, 2008). As a result of Se 
food content depending on soil Se levels food tables are notoriously 
inadequate for calculated Se intake. 
 
In the UK, the main Se compounds contained in bread and cereals 
are selenomethionine (up to 85%) and as selenite or selenate (up to a 
19%). Cattle, chickens and lambs are often supplemented with Se-
enriched yeast and their meat is 60% of selenomethionine; while up to 
30% in chicken and 50% in lamb of the total Se is in the form of 
selenocysteine. Cod fish and canned tuna are high Se fish (~1.8 and 5.6 
mg/kg respectively) in the form of selenomethionine (29-70%) or 
selenite/selenate (12-45%). The most common Se-enriched fruits and 
vegetables are broccoli, brussel sprouts and onions (Fairweather-Tait et 
al., 2011). 
1.5.3 Organic or inorganic Se compounds? 
 
Se supplementation can be implemented with organic (e.g. 
selenocysteine, selenomethionine, selenised-yeast) or inorganic sources 
(sodium selenite or selenate); all these sources are subsequently used in 
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the body for selenoprotein biosynthesis. Increased activity of the 
selenoprotein glutathione peroxidase can be achieved by inorganic Se, 
SeCys, or SeMet (Finley, 2006). Activity of the plasma selenoprotein 
glutathione peroxidase (GPx3) is often used as a measure to assess Se 
status because the activity of this enzyme is proportional to Se obtained 
from diet (Brown and Arthur, 2001). 
 
The inorganic Se compounds sodium selenate and sodium 
selenite are both approved as supplements for animals and humans; in 
addition, sodium selenite is used for anticancer treatment due to its 
chemopreventive effect (Nafisi et al., 2012). Both are efficiently absorbed 
in the small intestine but their different effects on liver suggest that they 
may be absorbed and metabolized differently; in rats supplemented with 
either sodium selenate or sodium selenite, liver gene microarray analysis 
showed that using a cut off of 2.5 fold change, 300 genes were 
significantly regulated by selenate whereas 43 genes were regulated by 
selenite (and selenoproteins GPX1, SELP, 15kDa SEP, SELW, DIO1, or 
GPX4 were unaffected)(Bosse et al., 2009). However, the effects of 
organic or inorganic Se compounds differ according to the organ, species, 
length of exposure and concentration used. Example of this is the 
expression of GPX3 in Cos7 (monkey kidney cells) which were subjected 
to inorganic and organic selenium supplementation; up to a 145nM 
concentration sodium selenite increased GPX3 expression by ~50% 
compared to the organic compounds whereas in comparison 
supplementation with selenomethionine or Se-methylselenocysteine 
hydrochloride required 580nM to increase the expression of GPX3 to a 
similar extent (Ottaviano et al., 2009). Human prostate cancer cells, 
LNCaP cells, treated with sodium selenite had a higher cell survival after 
the cells had been exposed to oxidative agents than the cells treated with 
SeMet (de Rosa et al., 2012). Se in milk has been found in human 
intervention studies to have greater impact on plasma selenoproteins than 
supplementation with selenised-yeast (selenomethionine and Se-
methylselenocysteine and γ-glutamyl-Se-methylselenocysteine). This 
could be due to milk proteins helping with the absorption or colorectal 
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retention of Se compounds. Se compounds in milk are of a molecular size 
greater than 10kDa because of their preparation (Hu et al., 2011). 
 
Se from diet comes in both organic and inorganic forms and often, 
human and cell models attempt to investigate the effects of these 
selenium compounds; however, as described in Figure 4, Se compounds 
are incorporated into selenoproteins. In vivo, both SeMet and selenite 
have been shown to increase the levels of SEPP when Se intake is limited 
(Xia et al., 2005), and in vitro viability of HepG2 cells is similar at 24 and 
72 h after supplementation with 150 µg/L of either SeMet or selenite 
(Hoefig et al., 2011). A human study in the US involved supplementation 
of both male and female volunteers with150 µg of stable isotopic tracers of 
selenite and selenomethionine for 10 days and then followed over 4 
months where selenite estimated absorption was about 57% whereas 
SeMet was 97% measured by triple isotope dilution; in terms of excretion 
high levels of SelMet were found in urine while selenite concentration was 
higher in faeces; overall, Se urinary excretion was 70 µg/d (Wastney et al., 
2011). A study in which Danish participants were given 74.4 µg of sodium 
selenite had a urinary excretion of ~32 µg/d after 24 h (Gammelgaard et 
al., 2012b). Nonetheless, the different levels of absorption in these studies 
could be due to a competition of Se incorporation as all the Se compounds 
were administrated at a rather high concentration at the same time.  
 
1.5.4 Selenoproteins  
 
Selenoproteins are a group of proteins present across species 
(except yeast) that contain selenocysteine (Sec) as the amino acid 
analogue to cysteine with Se replacing sulphur (Mariotti and Guigo, 2010) 
(Bellinger et al., 2009). 25 selenoproteins have been identified and 
classified, including glutathione peroxidises, iodothyronine deiodinases, 
thioredoxin reductases and selenoprotein P (SELP).  
 
These selenoproteins respond to lower Se supply in a hierarchal 
manner that is presumed to reflect functionality in cell survival and cell 
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cycle regulation (Mariotti et al., 2012). It is also commonly paralleled by  
the effect of Se status on selenoprotein mRNA expression (Driscoll and 
Copeland, 2003). Figure 3 shows the minimum Se requirement for rats 
supplemented with sodium selenite in order to obtain an mRNA breakpoint 
expression of 12 selenoproteins (Sunde and Raines, 2011). As shown in 
Figure 3, the relatively low Se intake is needed to maximise GPx4 mRNA 
levels in liver is Gpx4, followed by Selk and Selt; in contrastGpx1 and 
Selw require a higher concentration of Se. This was also supported by 
data from a feeding experiment in mice which showed that in the colon 
SelW, GPx1, (in addition to SelH, and SelM) mRNAs levels are most 
sensitive to low Se intake (Kipp et al., 2009). Such findings are consistent 
with the use of GPX1 (Pagmantidis et al., 2005; Combs et al., 2012) and 
SELW (Pagmantidis et al., 2005) as biomarkers of Se status in human 
models. It has been suggested that the selenoprotein hierarchy could be 
explained through a high selenophosphate synthetase (SEPHS2) (Squires 
et al., 2007) and/or methylation of Sec tRNASec that facilitates the 
biosynthesis of GPx1, GPx3, SelR, and SelT (Reszka et al., 2012). 
 
 
Figure 3 Minimum dietary Se necessary to reach plateau levels in liver from 
rodents. 
This figure adapted from (Sunde and Raines, 2011).represents the amount of sodium 
selenite required for rats to reach plateau levels of different selenoprotein mRNAs. 
Values are representative of the hierarchy in the rat liver, where the selenoproteins 
situated on the left occupy a higher hierarchy.  
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The characterization of selenoproteins has not been completed 
(de Rosa et al., 2012). However, the major functions of several families 
have been identified. The role of the iodothyronine deionase family is the 
regulation of T3 and T4 metabolism. It has been found that thioredoxin 
reductases have a redox function and in addition have roles in 
transcription factor regulation (Gromer et al., 2005). 
 
Glutathione peroxidises (GPxs), the most studied group, confer 
protection against oxidative stress at a cellular level (Méplan C., 2006; Lu 
and Holmgren, 2009), and have a structural role in spermatozoa (GPx4); 
reduced glutathione peroxidase levels lead to an increased viral virulence 
(Moghadaszadeh and Beggs, 2006). From which GPX1, GPX2, GPX3, 
and GPX4 will be addressed in this thesis. 
 
One of the most abundant GPxs (Reeves and Hoffmann, 2009) 
highly expressed in neurons, astrocytes, nervous system, brain (Gardaneh 
et al., 2011)and high sensitive to Se supply is glutathione peroxidase 
1(GPX1) (Pagmantidis et al., 2005; Reeves and Hoffmann, 2009), a 
homotetramer (The UniProt, 2012) of cytosolic localization and the most 
abundant intracellular GPX (Felice et al., 2010) acting as oxidative stress 
protector where GPx is oxidised to reduce H2O2 to H2O, maintaining the 
equilibrium between free radicals and superoxide dismutase enzymes 
(Gardaneh et al., 2011). GPX1 deficiency is associated with NFκB and 
JNK activation, atherogenesis, and proinflamatory response (Lubos et al., 
2011). Similarly, increased levels of lipopolysaccharide-induced ROS on 
human microvascular and coronary endothelial cells, was achieved by 
GPX1 knockdown (Lubos et al., 2010). The overexpression of GPX1with a 
pLV-GPX construct protected astrocytes from the toxicological effects of 
the parkinsonian neurotoxin 6-hydroxydopamine, and improving cell 
survival (Gardaneh et al., 2011). ROS were induced after 24 h of 25nM of 
D-glucose exposure which decreased at 48 h of treatment possibly due to 
the endogenous increase of GPX1 activity and expression (Felice et al., 
2010). 
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Gastrointestinal glutathione peroxidase or glutathione peroxidase 
2 (GPX2) is an homotetramer with cytosolic localization (The UniProt, 
2012), mostly expressed in the gastrointestinal tract to confer antioxidant 
stress protection (Reeves and Hoffmann, 2009) and it has been suggested 
to regulate intestinal renewal as a Wnt signalling pathway target (Kipp et 
al., 2012). 
 
GPx2- Knockout (KO) mice fed with 0.086, 0.15, or 0.64 mg/kg as 
selenomethionine developed colitis (particularly affected at 0.086 mg 
Se/kg) and showed faster tumour growth with no big differences with 
among Se diets (Krehl et al., 2012). Further work on these mice fed with 
the same diet described above, showed increased apoptosis in colonic 
crypts (Florian et al., 2010) suggesting antiproliferative and 
antiinflammatory roles. 
 
Glutathione peroxidase 3 (GPX3) is an homotetramer (The 
UniProt, 2012) extracellular enzyme produced by the kidney and thyroid, 
and secreted into plasma and body fluids in general (Brigelius-Flohe and 
Kipp, 2009). GPX3 is usually downregulated on cancer patients (Brigelius-
Flohe and Kipp, 2009) and expressed in head and neck, lung, ovary, 
bladder, oesophagus, melanoma human cancer cell lines, and healthy 
lymphocytes (Chen et al., 2011a). GPX3-KO mice show increasing H2O2 
in plasma which has a protombotic effect, leading to vascular injury (Jin et 
al., 2011) since GPX3 regulates the bioavailability of nitric oxide from 
platelets and vascular cells (Reeves and Hoffmann, 2009). GPX3 
hypermethylation was associated with chemotherapy response (Chen et 
al., 2011a). However, methylated GPX3 promoter is more frequent in 
oesophageal squamous cell carcinoma and this phenomenon 
downregulates GPX3 which is a proposed carcinogen effect (He et al., 
2011).  
 
Glutathione peroxidase 4 (GPX4) is a monomer (The UniProt, 
2012) with three cellular isoforms, a cytoplasmic, a mitochondrial (The 
UniProt, 2012) and one nuclear (Speckmann et al., 2011). GPX4 is 
involved in regulation of arachidonic acid metabolism (Reeves and 
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Hoffmann, 2009). Cell death by lipid peroxidation is a known result of 
GPX4 silencing (Ueta et al., 2012); and GPX4 has protective effects 
against Alzheimer disease symptoms in mouse brain (Speckmann et al., 
2011). More studies suggest that GPX4 malfunction could lead to 
functional changes in photoreceptors caused by lipid peroxidation and 
compromised cell survival due to inefficient energy supply to the primary 
cilia (Ueta et al., 2012). 
 
SEPHS2 is essential for selenoprotein biosynthesis (Azevedo et 
al., 2010) (see page 39). Mutations in exon 3 of SEPHS2 caused an R10X 
nonsense mutation in a 12 year old girl and this lead to high T4 and low 
T3, reduced levels of Se and GPX3, DIO2 mutations, no expression of 
SELP, developmental coordination disorders, congenital myopathy, 
hypotrophy, respiratory depression and delayed mental development. 
After 30 days of 200 µg/day Se yeast supplementation, GPX3 and T4 
increased but SELP and T3 levels did not change (Azevedo et al., 2010).  
 
Recently, several selenoproteins have been found to be present in 
the endoplasmic reticulum (ER). Selenoprotein S (SELS) has been 
suggested to have a role in brain inflammation by reducing the synthesis 
of proinflammatory cytokines (Fradejas et al., 2011) and regulating 
interleukin 6 release by astrocytes under ER stress (Maraldi et al., 2011). 
Because of its ER localization, it has also been proposed to be involved in 
protein degradation via the unfolded protein response (Maraldi et al., 
2011). In terms of metabolic roles, SELS has also been linked to glucose 
metabolism after studies in participants in western Sweden with coronary 
disease and another group of obese patients showed an increased in 
SELS expression on adipocytes during hyperinsulinemia, leading to the 
suggestion that SELS is a biomarker of chronic diseases (Olsson et al., 
2011). Another endoplasmic reticulum selenoprotein with a wide highly 
expressed in the brain (Hwang et al., 2005; Reeves et al., 2010) is 
Selenoprotein M (SELM). It is thought to reduce toxicity from oxidative 
stress and it also modulates baseline calcium levels (Reeves et al., 2010). 
15kDa selenoprotein 15 (SEP15), another ER selenoprotein is also 
thought to play a role in the protein folded response (Kasaikina et al., 
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2011a). It is expressed in secretory organs (Kasaikina et al., 2011a), and 
has been linked to a reversed cancer phenotype in the intestinal cell lines 
HCT116 and HT29 (Kasaikina et al., 2011a); a recent report suggests that 
there is increased chance of survival on cancer patients when the 
expression of Sep15 in plasma is high (Slattery et al., 2012). 
 
Selenoprotein H (SELH) has been suggested to be responsible for 
the regulation of mitochondrial respiration by upregulating the genes 
involved in mitochondrial biogenesis and oxidation - NRF-1, PGC-1α, and 
Tfam-, and decreasing NF-ΚB, which inhibits the transcription of PGC-1α 
in the nuclear fraction (Mendelev et al., 2011). By inhibiting mitochondrial 
membrane depolarization, SELH has been proposed to protect brain cells 
against mitochondrial induced apoptosis (Mendelev et al., 2011). In the 
hippocampal neuronal cell line HT22, SELH overexpression enhanced 
neuronal cell survival after UVB exposure by stabilizing mitochondrial 
membrane potential, inhibiting p53 and caspades 3 and 9 activation 
(Mendelev et al., 2009). 
 
Finally, SELP (Selenoprotein P), which includes 10 Sec, accounts 
for 50% of the Se in plasma and is responsible for extra hepatic Se 
balance (Burk and Hill, 2009) as an hepatic-tissue Se transporter (Li et al., 
2007). It appears important in Se transport to the brain (Moghadaszadeh 
and Beggs, 2006) and testis where Se levels are maintained by means of 
a receptor mediated uptake of SELP (Burk and Hill, 2009). 
 
1.5.5 Selenium uptake 
Determining Se uptake in vivo is challenging because it is difficult 
to control every condition in the intestine. For this reason, cellular models 
are preferred to explain the absorption of this essential micronutrient 
(Combs et al., 2012).  
 
Zeng et al compared the transport of 500 nmol/L selenite, SeMet, 
methylselenocysteine from the apical to the basolateral side of Caco-2 
monolayers and found that SeMet and methylselenocysteine transport 
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were more efficient than selenite but that transport did not correlate with 
GPx activity, being selenite > SeMSC > L-SeMet (Zeng et al., 2011). 
 
Subsequently, an X-ray absorption spectroscopy approach 
showed that in A549 human lung adenocarcinoma epithelial cells 
treatment with organic Se compounds SelMet was incorporated into 
selenoproteins after 24h while incorporation was slower with Se-
methylselenocysteine (Weekley et al., 2011). 
 
A recent study using,Caco-2 cells, a cell model of human intestinal 
absorption, investigated the uptake of different forms of Se in more detail, 
They found that the best absorptive flux was with SeMet followed by 
semethylselenocysteine and that this occurred through a transcellular 
transport mechanism. In addition they suggested that selenate was 
transported paracellularly and passively across the intestinal monolayer, 
and that selenite reacts with thiol groups of glutathione and cysteine 
reaching the intestinal layer as selenotrisulfides. (Gammelgaard et al., 
2012a). 
1.5.6 Selenoprotein biosynthesis 
 
This essential trace element in proteins is in the form of 
selenocysteine (Sec) metabolized from either organic or inorganic Se 
compounds through different pathways (Papp et al., 2007; Zeng et al., 
2011). Although the organic form of Se, selenomethionine (SeMet) is more 
bioavailable, it does not correspond to the best source of selenoprotein 
biosynthesis (Zeng et al., 2011). 
 
Incorporation of Se as the aminoacid Sec into selenoproteins at 
the UGA codon was first discovered when the TGA codon was found in 
the Open Reading Frame (ORF) of the GPX1 gene (Moghadaszadeh and 
Beggs, 2006; Papp et al., 2007). Sec is coded by UGA (usually a stop 
codon) and incorporated during translation. This requires a special 
structure within the mRNA, the SECIS (selenocysteine insertion 
sequence), to recode the UGA. In eukaryotes the SECIS is located in the 
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3’UTR of the mRNA (Méplan C., 2006; Papp et al., 2007; Hesketh, 2008; 
Mariotti and Guigo, 2010). A specific tRNA, Selenocysteyl-tRNA-Sec (Sec-
tRNASec) (Hubert et al., 1996; Fletcher et al., 2001), is necessary for Sec 
incorporation and this is derived from serine by the reactions of a SEPHS2 
and selenocysteine synthase (Papp et al., 2007). 
 
Figure 4 illustrates how selenoprotein biosynthesis is proposed to 
occur. It starts with the incorporation of serine to tRNASe into Seryl-
tRNASec (Ser-tRNASec) by the enzyme SeryltRNA synthetase (I) (Hubert et 
al., 1996). Either organic (II A) or inorganic sources (II B) are reduced to 
selenide which is then phosphorylated by adenosine triphosphate (ATP) 
(Hoffmann and Berry, 2005) by SEPHS2 (III) to form selenophosphate. 
Selenophosphate and Ser-tRNASec are then incorporated into 
selenocysteyl-tRNASec (Sec-tRNASec) by the action of selenocysteine 
synthase (IV). The SECIS-binding protein 2 (SBP2) then binds the Sec-
tRNASec (Hubert et al., 1996) (V) to form a complex formed with 
selenocysteine-tRNA specific elongation factor (EF-Sec)(VI) (Hubert et al., 
1996). This complex will finally bind the SECIS and lead to Sec UGA 
codon recognition (VII).  
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Figure 4 Selenoprotein biosynthesis. 
(I)The incorporation of Se into selenoproteins requires a specific tRNA that will interact with a highly reactive reduced Se compound (selenophosphate) originated 
from the metabolised organic and inorganic Se compounds. Se from diet is converted into selenocysteine and metabolised into selenide via enzymatic action or 
through gut bacterial action (IIA); selenide can be obtained or from (IIB) oxidation of the inorganic form selenate into selenite and further selenide. (III). The 
metabolised selenide is then catalysed by ATP and SEPHS2 into selenophosphate, which is incorporated into Sec-tRNA
Sec
 (IV). This forms a complex with 
selenocysteine-specific factor (EF-Sec), SBP2 (VI), and the SECIS (VII) to allow translation of selenoproteins at the UGA codon (VIII).  
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1.5.7 Downstream targets of Se 
 
Despite the fact that the main target of Se studies is the effects of 
Se supplementation/depletion on selenoproteins, a group of downstream 
genes has also been identified from microarray experiments when 
assessing the effects of Se. Monitoring changes in expression of such 
targets could help understanding the physiological effects of Se intake.  
 
In a microarray study of normal and cancer prostate cells grown 
with an increasing concentration of Se-methylselenocysteine 16 genes -
other than selenoproteins- were identified as showing altered expression 
(Hurst et al,2008); these included genes with functions in collagen 
transport, cancer and cell proliferation functions (Hurst et al., 2008).  
 
Microarray analysis of RNA from lymphocytes from healthy 
volunteers before and after Se supplementation with sodium selenite 
showed changes in expression of genes within the protein biosynthetic 
pathways, including 61 genes from ribosomal and mitochondrial proteins, 
as well as translation elongation and initiation factors (Pagmantidis et al., 
2008). A similar pathway was identified in the mouse colon in which the 
mice where fed either a Se deficient or Se-sufficient diet and colon 
analysed by gene microarrays (Kipp et al., 2009); a large number of genes 
were either up (1979) or down (2016) regulated under marginal Se 
deficient compared with Se-sufficient conditions.  
 
Other potential targets of selenium like apoptotic regulators (BAX, 
CASP3 and CASP9), tumour suppressors (PTEN) were identified by Se 
supplementation of the human osteosarcoma cell line U2OS (Chen et al., 
2012). BAX, CASP 3 were upregulated at mRNA and protein level. 
Sodium selenite supplementation of the human prostate epithelial cancer 
cell line PC3 was found to inhibit the protein expression of the prostate 
cancer progression regulators TGFβ1 and VEGF, as assessed by ELISA 
(Pei et al., 2010). 
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1.5.8 Selenium and colon 
 
Previous studies have associated increased Se intake with lower 
colorectal cancer risk and improved colorectal cancer survival (Peters and 
Takata, 2008; Meplan and Hesketh, 2012). However, the mechanistic 
basis for such proposed links are not known. It has been hypothesised 
that these effects of Se are due to oxidative stress protection mediated by 
Se-sensitive genes and selenoproteins (Slattery et al., 2012).  
 
SNP in the gene encoding selenoproteins thioredoxin reductase 
(TRX), SELX, and SELN on a case-control study of colon cancer patients 
and controls were related to environmental factors like smoking, aspirin 
and a minimum effect from Se intake, while TRX1, TRX2, and TRX3 SNPs 
were associated with smoking and colorectal cancer (Slattery et al., 2012). 
A similar correlation between SNPs and cancer was found on Korean 
patients with colon and rectal cancer where a SNP on one variant T allele 
of rs34713741 on SELS was associated with a significant risk increase in 
female patients; nevertheless on the same study, SNP on rs5845 or 
rs5859 in SELP15, the risk of rectal cancer was higher in men (Sutherland 
et al., 2010). 
 
Selenium, as sodium selenite, has been linked to tumour reduction 
and therefore proposed for chemopreventive therapy (Thirunavukkarasu et 
al., 2008). Colon adenocarcinoma cells is a cell model commonly used in 
Se experimental models as scientific evidence is been found that Se 
efficiency is linked to gastrointestinal diseases (Peters and Takata, 2008; 
Connelly-Frost et al., 2009; Wu et al., 2010). Once Caco-2 reach 
confluency, their phenotype behaves as the morphology and functionality 
of an intestine (Piana et al., 2008) and the absorption and transport of 
nutrients such as selenium, iron, zinc, calcium, and copper is comparable 
to physiological conditions due to its structure and function is similar to an 
enterocyte (Zeng et al., 2011).  
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More recently, a 6 week supplementation with either 150µg Se/d 
of diary (83% selenomethionine 5% selenocysteine) or yeast (83% 
selenomethionine 5% selenocysteine and 3% selenite) Se of 23 
volunteers (mean age of 64 years) with an initial plasma concentration of 
103µg/l, investigated the effect of Se supplementation on either organic or 
inorganic forms to study the benefits of Se on colon cancer risk 
selenoprotein related. Plasma concentrations of Se increased, finding a 
higher level under Se-yeast supplementation; although women had higher 
plasma Se concentrations, GPx activity in plasma was higher in men. 
Rectal selenoprotein expression had no gender related variations. 
Colorectal biopsies revealed that Se diary supplementation increased GPx 
1 and 2 mRNA levels. Dairy-Se supplementation was enough to maintain 
SELP levels at the 6-week washout period (Hu et al., 2011; Huang et al., 
2011a). 
 
The beneficial effects of Se have also been studied in the rat 1,2-
dimethylhydrazine (DMH) induced tumour model. Treatment with Se as 
sodium selenite resulted in a 60% reduction of the tumour growth after 20 
week of supplementation. Although some nuclear polarity was lost, 
reduced lipid peroxidation, reduced levels of DMH, increased levels of 
glutathione-S-transferase, superoxide dismutase, and glutathione were 
observed after Se treatment (Ghadi et al., 2009 ). In a study in Caco-2 
cells in which cells Se-methylselenocysteine sufficient and deficient media 
was compared, the von Hippel-Lindau tumour suppressor gene was 
downregulated under Se-methylselenocysteine deficient conditions. The 
study hypothesises that Se could provide methyl groups altering 
methylation pathways or by methyl group modification since liver and 
colon from rats has shown a proportional response in the expression of Se 
and DNA methyltransferase (Uthus et al., 2010). 
 
Selenomethionine, methylselenocysteine (SeMSC) and Se 
enriched yeast are 3-fold more effectively transported than selenite (Zeng 
et al., 2011). However, selenite activates the AKT/β-catenin signalling 
inducing apoptosis of colorectal cancer cells (Luo et al., 2012). 
Selenoproteins like SELS have been linked to colorectal cancer; 
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selenoproteins by reducing the impact of ROS by the glutathione 
peroxidases and thioredoxin reductases would protect against cancer 
(Meplan and Hesketh, 2012). 
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1.6 Aims and objectives 
 
Se role in human health has been widely studied in different cell 
models, tissues and biopsies of several organisms, and has pointed out 
the beneficial effects of Se intake in human health with selenoproteins as 
key regulators of metabolic pathways. Apart from these Se-containing 
proteins, Se intake also influences expression of other group of 
genes/proteins by indirect, and largely unknown, mechanisms. The 
purpose of the present study was to investigate possible relationships 
between Se metabolism and recently discovered small RNA species 
(miRNA) with the ability to regulate expression of a protein or group of 
proteins by interacting with its/their mRNA.  
 
To achieve this aim, the following objectives were set: 
 
 To use a bioinformatics approach to identify miRNAs with the 
potential to interact with selenium sensitive genes/pathways. 
 
 To use a custom miRNA microarray to find miRNAs 
expressed in the Caco-2 cell line and detect how their expression changes 
after selenium supplementation/depletion. 
 
 To use transcriptomics to identify transcripts that show 
changes in expression in Caco-2 cells grown under Se 
supplemented/depleted conditions. 
 
 To analyse the datasets from the miRNA microarray and the 
mRNA microarray with bioinformatic tools in order to find possible miRNA-
mRNA interactions that respond to Se supply. 
 
 To test the effect of altered miRNA expression on these 
potential Se-sensitive target genes. 
 
A summary diagram of the aims of my study is shown in Figure 5. 
  
4
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Figure 5 Aims and objectives. 
In order to investigate the effect of Se on miRNAs and their possible targets in Caco-2 cells, RNA from Caco-2 cells grown in cells supplemented with 40.5nM of 
sodium selenite for 72 h was analysed in a total transcriptome experiment and a customised miRNA microarray chip. The chip design was based on 
bioinformatics predictions of miRNAs using genes within a Se-sensitive pathway identified in a human supplementation trial, miRNAs expressed in 
gastrointestinal tissues and cell lines, miRNAs identified on PCR arrays. Microarray results were confirmed by Real Time PCR for both miRNAs and mRNAs. 
The Se-sensitive miRNAs and transcripts were analysed bioinformatically in order to identify potential interactions n and provide a basis for a miRNA functional 
analysis. 
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Chapter 2 Materials and methods 
 
2.1 Materials  
 
2.1.1 Equipment 
 
Jouan High Speed cooling Centrifuge MR 23, Laborgerätebörse 
GmbH  
NanoDrop® ND-1000 Spectrophotometer, Labtech International  
Jouan B4 Centrifuge 
Agilent 2100 bioanalyzer 
Nikon TMS microscope 
LightCycler® 480 Real-Time PCR System 
Applied Biosystems 7900HT Fast Real-Time PCR 
 
2.1.2 Chemicals  
 
Trypan blue Sigma-Aldrich, Germany 
DMEM - Dulbecco's Modified Eagle Medium 
Fetal-calf serum 
Penicillin Streptomycin 
Insulin Bovine with 10mg/mL insulin in 25 mM HEPES, pH8.2 by 
Sigma-Aldrich, Germany 
Transferrin 
DMEM - Dulbecco's Modified Eagle Medium, Invitrogen® 
MEM Non-essential amino acids 100x by GIBCO® 
Sodium selenite Sigma-Aldrich, Germany 
Invitrogen TRIzol® Reagent 
TRIzol® Plus RNA Purification Kit 
Chloroform, minimum 99%, Sigma-Aldrich® 
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Agilent RNA 6000 Nano Kit 
Reverse transcriptase (Roche) 
dNTP by Bioline, UK 
Hyperladder IV, Bioline, UK 
Hyperladder V, Bioline, UK 
Ultrapure agarose, InvitrogenTM 
TAE buffer Tris-Acetate-EDTA, Sigma 
TEB Tris-Borate-EDTA, Fisher 
Diethyl Pyrocarbonate (DEPC) 97% NMR, Sigma ®. 
Ethanol, Analytical reagent grade. Fisher scientific, UK  
Oligo (dT)15 primer for DNA synthesis, Roche, Germany 
Primers Eurofin MWG Operon oligonucleotides, UK 
QIAquick PCR Purification Kit (QIAGEN, UK). 
Transcriptior RT reaction Buffer, 5x, Roche, Germany 
Protector RNase Inhibitor 
LightCycler 480 SYBR Green I Master, Roche, Germany 
Opti-MEM® (Invitrogen, UK) 
Lipofectamine® 2000 Transfection Reagent (Invitrogen, UK) 
Anti-MiR-185 Applied Biosystems, UK 
Anti-MiR negative control Applied Biosystems, UK 
 
2.2 Methods 
 
2.2.1 Cell culture  
 
Human colon adenocarcinoma cells (Caco-2) were used as a 
model of Se effects on the colonic epithelium. Cells were cultured in 75cm 
tissue culture flasks and fed with 15mL of DMEM - Dulbecco's Modified 
Eagle Medium (with 4.5g/L glucose and Glutamax) with 10% Fetal-calf 
serum (FCS) and 1% Penicillin/streptomycin (100 units/mL and 100 
µg/mL, respectively) and grown at 37°C in the presence of 5% CO2. The 
cells were harvested at 80-90% of confluence. 
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For investigation of the effects of Se supply, 5x105 - 10x105 /mL 
cells were seeded into each well of a 6-well plate. Cells were cultured in 
either Se-sufficient or Se-deficient medium comprising 2mL of DMEM (with 
4.5g/L glucose and Glutamax) without added FCS but containing 5µg/mL 
insulin, 100 µg/mL Penicillin/streptomycin, 5µg/mL transferrin, and in for 
Se-sufficient medium 7ng/mL sodium selenite (40.5nM). Cells were fed 
every 2 days and harvested after 72 h in Se sufficient/ depleted media. 
 
To count the number of cells, cells were rinsed with 2mL of 
Phosphate buffered saline (PBS), and incubated with 450 µL of Trypsin at 
37°C for 10 minutes to detach them. After the incubation period, a cell 
pellet was obtained by centrifugation at 1500 RPM from 5 min, the pellet 
was resuspended gently (to avoid lysis) in 10mL of DMEM, diluted 1:2 
dilution in trypan blue and then counted in a haemocytometer a Nikon E 
10 0.25 160 / - Ph 1 DL objective lens. 
 
2.2.2 Sodium selenite 7ng/mL; 40.5nM 
 
Sodium selenite was resuspended to a final concentration of 
10µg/mL in PBS and filtered with a 0.22µm filter, Millipore express PES 
membrane. 
 
2.2.3 RNA isolation for total transcriptome analysis 
 
Total transcriptome isolation was performed to ensure 
conservation of the miRNA population in the final RNA preparation. 
 
Medium from Caco-2 cells was removed and cells were rinsed 
with a volume of PBS equal to that the medium that the flask/well 
contained. 1mL of TRIZOL® Reagent was added per 10cm2 dish area. 
Cells were detached from the bottom with a cell scraper and cell lysate 
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was homogenized by pipetting up and down with an RNase-free filtered 
tip. Cell lysate was collected into a microcentrifuge tube and incubated at 
room temperature for 5 min. 
 
For the separation of aqueous (containing RNA) and organic 
phases, 200µL of chloroform was added to the lysate and the mixture was 
shaken vigorously by hand for 15 sec. After a 3 minute incubation at room 
temperature, the tubes were centrifuged at 12,000 x g for 15 min at 4°C to 
separate the RNA (the upper phase) which was transferred into a fresh 
microcentrifuge tube without disturbing the interphase. Then, in 
accordance with best practice gene expression profiling experiments, a 
second separation phase was performed before ethanol precipitation 
(Naderi et al., 2004). 
 
Then the upper layer was thoroughly mixed with an equal volume 
of ethanol and RNA isolated using a Spin cartridge column. A maximum of 
700 µL added to a Spin Cartridge and centrifuged at ≥12,000 x g for 1 min 
at room temperature. The flow through was discarded and the step was 
repeated with the remaining sample solution. 
 
500 µL of washing buffer II with ethanol were added to the centre 
of the column and centrifuged at ≥12,000 x g for 15 sec at room 
temperature. Flow through was discarded and the washing step was 
repeated a second time. 
 
The membrane of the column was dried by centrifuging at ≥12,000 
x g for 1 min. To obtain 60 µL of purified RNA, 62 µL of 0.05% DEPC-
treated water was added to the centre of the Spin Cartridge and 
centrifuged in a Recovery tube ≥12,000 x g for 2 min at room temperature. 
The RNA was aliquoted 2 or 3 aliquots of RNA were prepared and stored 
at -80°C. 
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2.2.4 Measurement of RNA Concentration 
 
RNA concentration and purity were determined spectroscopically 
using the NanoDrop® ND-1000 Spectrophotometer. The RNA 
concentration was based on 260 nm absorbance. 260/280 ratios between 
1.8-2 indicated low contamination with protein, phenol or other 
contaminants. 260/230 ratios from 1.8-2.2 indicated the nucleic acid purity. 
Such values for both ratios where routinely achieved. 
 
2.2.5 RNA integrity assessment 
 
From each sample, 1µL of 5-500ng/µL total RNA was loaded into 
a RNA Nano chip and analysed by gel filled microcapillary electrophoresis 
using detection through laser-induced fluorescence on an Agilent 2100 
bioanalyzer. 
 
65µL of filtered gel at room temperature was centrifuged after 
vortexing for 10 sec and mixed with 1µL dye. The mixture (Gel-Dye Mix) 
was vortexed and centrifuged in a microcentrifuge at 13,000g for 10 min at 
room temperature. 
 
9µL of the Gel-Dye Mix was loaded into a well marked G from the 
RNA 6000 Nano chip, and compressed for 30sec in the chip priming 
station, 9µL was loaded the wells marked with G; the remaining gel was 
discarded. 5µL of RNA 6000 Nano marker was then loaded into each well. 
Subsequently, 1µL of ladder was loaded into its corresponding well, and 
1µl of RNA previously denatured for 2-3 min at 70°C RNA was loaded into 
the remaining wells. 
The RNA 6000 Nano chip was vortexed for 1 min at 2400 RMP 
and was the sample analysed within 5 min to avoid evaporation of the 
reagents. 
 
 55 
After approximately 30min, the RNA concentration and RNA 
Integrity Number (RIN) were shown for each sample. The RIN is quantified 
from 1 to 10 and indicates the extent of RNA degradation (Schroeder et 
al., 2006). 
 
2.2.6 miRNA target prediction for the protein biosynthetic 
pathway 
 
An earlier study in of human lymphocytes had suggested that the 
protein biosynthetic pathway was sensitive to Se supply. The 61 Se 
sensitive genes within the protein biosynthetic pathway (Pagmantidis et 
al., 2008) were loaded in 3 bioinformatic tools and 1 software for miRNA 
prediction in order to obtain possible miRNA-mRNA interactions that would 
then lead us to build an interactive network. 
 
Microrna.org was chosen because its algorithm has been used in 
target prediction obtained high scores and most of them experimentally 
validated (John et al., 2004) and it offers the flexibility of not relying on the 
seed region completely and because scientific evidence has shown that 
miRNAs interactions occur beyond this region (Brodersen and Voinnet, 
2009), (Grimson et al., 2007) (Lytle et al., 2007), (Mazière and Enright, 
2007), (Stark et al., 2007). 
 
At microrna.org (Betel et al., 2008), each gene symbol was loaded 
into the Target mRNA search tool for Homo sapiens (H. sapiens) in a 
window, as shown in Figure 6. 
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A graphic list of predicted alignment was then visualized. This 
window contains the miRNA sequence and its mRNA alignment site, the 
number of miRNA targets, alignment score, PhastCons score which 
measures the changes in orthology across time and space, and a list of 
miRNA organized by the number of target sites and alignment scores 
hierarchy, where more target sites, a high alignment score, and high 
PhastCons score (higher than 0.57) are the optimal conditions for a 
mRNA-miRNA interaction to occur. 
 
After microRNA.org had scanned the sequences and found 
miRNA-mRNA cleavage sites, the alignments and the scores alignments 
(conservation across species, miRNA energy required, and overall score) 
are displayed along the gene sequence. An example of a protein sensitive 
to Se supply used in this study and its MRE is showed in Figure 7.  
 
Figure 6 Example of data entry for microRNA.org. 
A gene name from the protein biosynthetic pathway is typed into the “Target miRNA” box, 
and by selecting H. sapiens under “Species”, the given mRNA ID will be scanned by 
microRNA.org in order to localize MRE on the gene’s sequence. 
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miRBase from the Sanger Institute, rebranded as Microcosm and 
managed by the European Bioinformatic Institute (EBI) during the course 
of this study, used the miRanda algorithm to find miRNA-mRNA 
complementary base pairing. Differing from microrna.org, perfect seed 
pairing is required. Predicted mRNA targets were obtained by accessing to 
http://microrna.sanger.ac.uk/cgi-bin/targets/v5/search.pl, and by entering 
the gene name selecting H. sapiens as the selected genome as shown in 
Figure 8. 
 
 
 
 
Figure 7 MRE identified by microRNA.org for Mitochondrial Ribosomal Protein S36 
(MRPS36). 
microRNA.org prediction of miRNAs interacting with MRPS36, a protein from the PBP. For 
each miRNA-mRNA alignment, a PhastCons score and the energy needed for the 
interaction are given. These factors set an overall score, the higher the score, the more 
likely for the cleavage to occur. 
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The displayed information now includes miRNA sequences and 
the mRNA binding, p-value, score, total energy required for the cleavage 
and the conservation across species. RPL24 was analysed by the 
miRBase/MicroCosm algorithm and a predicted miRNA interaction, score, 
orthology is represented by Figure 9. 
 
Figure 8 MicroCosm data entry screen.  
A gene sensitive to Se supply in lymphocytes, the Ribosomal Protein Large 24 (RLP24), 
is showed as an example of data entry for miRBase/ MicroCosm using the H. sapiens 
sequence. 
 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 MicroCosm results screen. 
MicroCosm MRE result page showing the alignment, conservation among species, p-
value, energy and overall score of a RLP24. 
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GeneSet2MiRNA miRNA predictions included the miRNA-mRNA 
interactions that have been predicted for at least 4 other algorithms from 
the 9 it compares in order to minimise false positives. Another advantage 
is that a list of gene IDs can be analysed at the same time, so once a file 
in a text or excel format is uploaded into GeneSet2miRNA, a screen like 
the one shown in Figure 10displayed the miRNAs interacting with each 
gene but no further information about energy, score or position of the 
alignment was included. 
 
A Core analysis with the list of genes from the PBP as a 
Reference Set was created in Ingenuity Pathway Analysis (IPA) Figure 23. 
This Network generation tool was used so pathways were created as part 
Figure 10 Screen with the predicted miRNA from GeneSet2miRNA after the 
analysis of the genes within the PBP. 
The miRNAs predicted by 4 or more bioinformatics tools used by GeneSet2miRNA are 
displayed in a chart in which a column containing miRNAs is next to the gene they have 
an alignment with. 
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of the analysis. The data sources for the analysis were the available 
miRNA-mRNA interactions options (miRecords, TarBase, and TargeScan 
Human), and selecting the experimentally observed as confidence feature 
through the human genome and across all tissues and cell lines. 
 
 
 
 
Figure 11 IPA core analysis generator screen. 
The 61 genes from the PBP loaded into IPA in order to obtain miRNAs that have been 
shown to interact with these genes. 
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An image with direct and indirect protein-protein connections was 
created once the analysis was carried out and 9 networks were 
composed. Those networks were merged to produce a visual image of 
miRNA-mRNA interactions and direct and indirect interactions among the 
genes of the PBP. The resulting image was displayed as a sub-cellular 
level and in shown in Figure 23 in Chapter 3. 
 
All the miRNAs from IPA were included because the miRNAs from 
that bioinformatic tool were already experimentally validated. 
 
miRWalk was introduced in 2011 as a new miRNA prediction 
algorithm that also included a dataset of validated targets and uses eight 
other bioinformatic tools (Dweep et al., 2011). microRNA.org started to 
look for mRNA-miRNA complementarity in other gene regions other than 
the 3’UTR since this interaction had been reported previously as also 
functional; for that reason, miRWalk searches for MRE on the 5 and 3’ 
UTRs, ORF and promoter sequences for human, mouse and rat. H. 
sapiens, M musculus and Rattus novergicus.  
 
2.2.7 Primer design 
 
Primers used for RT-PCR or QRT-PCR were designed by 
examining the sequence obtained from NCBI and the accession number of 
each gene in Entrez Nucleotide database. The NCBI Blast website (NCBI) 
was used to assess primer design specificity In silico. A 3’ to 5’ 20-25nt 
long sequence was selected bearing in mind that: the melting temperature 
should be between 55 and 72°C, the 3’ end of the primers should have C 
or G, and the CG% between 45% and 55%. Assessment of CG% content 
of the oligos and annealing temperature of the forward and the reverse 
sequences so the difference is of maximum 1°C was achieved through the 
IDT primer design website (Integrated DNA Technologies, 2009). 
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2.2.8 Primer optimization 
 
Annealing temperature was determined empirically by modifying a 
the predicted annealing temperature by the primer design websites (NCBI; 
Integrated DNA Technologies, 2009) by a series of by 2°C steps. The 
optimal annealing temperature is chosen after visualization on agarose gel 
electrophoresis stained with ethidium bromide after PCR with 29 cycles. 
The assessment of the optimal annealing temperature for SELK, EPHX2, 
and MT1F at 55°C, 57°C, 59°C, and 61°C is shown in Figure 12. After a 
range of temperatures have been tried and if several bands were 
visualised, the primers were designed again, which is the case of SELK. In 
Figure 12; on the same figure, a single band of the predicted size was 
visualized at 61°C for EPHX2 and at 59°C for MT1F. A similar procedure 
is carried out to find the adequate cycle number after the ideal annealing 
temperature had been determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ladder  55°C  57°C  59°C  61°C  - cont. 55°C  57°C  59°C  61°C - cont. 55°C  57°C  59°C  61°C - cont. 
          SELK          EPHX2           MT1F 
 
 
500bp 
 
200bp 
 
100bp 
 75bp 
 
 50bp 
 
 25bp 
Figure 12 Annealing temperature optimization.  
Shows the optimization of the annealing temperature for SELK, EPHX2 and MT1F. 
cDNA was PCR-amplified, at 55, 57, 59 and 61°C after 29 amplification cycles, the PCR 
products were electrophoresed and visualised; the annealing temperature was chosen 
when only one band at the predicted size was visualized. 
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2.2.9 cDNA synthesis 
 
The RNA was synthesized from first-strand cDNA using from 10ng 
to 1µg of RNA template, 0.08A260units of Oligo (dT)15 primer (Roche, 
Germany), and up to 13µL of 0.05% DEPC water. The reaction was 
incubated at 65°C for 10 min and placed on ice. After incubation, the 
following components were added: Transcriptor RT Reaction Buffer 5x 
(Roche, Germany) to a final concentration of 1x, 20U of Protector RNase 
Inhibitor (40 U/ mL)1 (Roche, Germany), 2 mM dNTP-Mix (dNTP; Bioline 
UK), and 10U of Transcriptor Reverse Transcriptase (Roche, Germany) for 
a 20 µL reaction. The mixture was vortexed, incubated for 30 min at 55°C, 
then heated at 85°C for 5 min, and placed on ice.  
 
2.2.10 Polymerase Chain Reaction (PCR) 
 
In order to assess the expression of the genes of interest a semi 
quantitative PCR was performed with a 20µL reaction containing the 
following: 0.5µL of the first strand cDNA, 3nM of MgCl2 (Bioline, UK), 1.2 
µL of MgCl2 solution, 2 µL 10x NH4 buffer, 3µL 100mM 1:10 dNTP Mix, 
1µL of each forward and reverse primers (© Eurofins MWG Operon) in a 
10pmol/µL concentration (SELW, GPX1, GAPDH, SELK, GPX3, PIR, 
SEPHS2, ACBT, and MT1F) and 0.25µL BIOTAQTM DNA polymerase. The 
reaction was amplified under the following conditions: 
 
Denaturing stage  95°C- 3 min 
Amplification stage  
Denaturing    94°C - 1 min 
Annealing   *55°C - 60°C         1 min   26-33 cycles 
Elongation    72°C – 2 min 
Final elongation  72°C – 12 min 
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* Annealing temperature for each primer as well as the number of 
cycles are shown in Table 1. 
  
6
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Primer name Accession number Sequence Length (bp) 
Amplicon 
length (bp) 
Cycles 
*Annealing 
temperature 
SELW_for 
NM_003009.2 
GTTTATTGTGGCGCTTGAGGC 21 
352 26 
60°C 
SELW_rev GAACACAGGGAAAGACCAGG 21 60°C 
GPX1_for 
NM_000581 
TTGGGCATCAGGAGAACGCCA 21 
407 26 
56°C 
GPX1_rev CTGCAACTGCCAAGCAGCCG 20 56°C 
GAPDH_for 
NM_002046.3 
TGAAGGTCGGAGTCAACGGATTTG 23 
112 26 
55°C 
GAPDH_rev 
CATGTAAACCATGTAGTTGAGGTC 25 55°C 
Table 1 Primers and conditions used for RT-PCR. 
Gene name, accession number, sequence, primer length, amplicon size, number of cycles programmed in the thermal cycler and annealing 
temperature used for RT-PCR are shown for the three genes analysed. 
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2.2.11 Agarose gel electrophoresis 
 
The DNA products of the PCR reaction were then separated by 
agarose gel electrophoresis. The gel was prepared by dissolving 1-3% 
agarose (Ultrapure agarose, InvitrogenTM) in 1xTAE buffer (Tris base 
0.04M, Acetate 0.02M, EDTA 0.001M, pH at 25°C 8.25-8.55; Sigma, UK) 
or 1x TEB (Tris-Borate-EDTA, Fisher, UK) buffer at high temperature and 
then adding and mixing 1microlitre of ethidium bromide before gel 
solidification. 8 µL of PCR product mixed with 2 µL of 5x loading dye (50 
nM Tris-HCl pH8.5 nM EDTA, 20% glycerol and 0.1% bromophenol blue) 
were loaded into the gel. 5 µL of DNA marker (Hyperladder IV; Bioline, 
UK) were also loaded to indicate the size of the amplicon. 
Electrophoresis was carried out at 70 V for 40 minutes and the 
RNA bands were visualized under UV light. 
 
To assess the ideal cycle number for the different pair of primers 
PCRs were carried out by testing increasing the cycle number for each 
pair of primers. PCR products were electrophoresed. Figure 13 shows 
GAPDH as an example of cycle number assessment in which once 
visualized in a trans illuminater, the appropriate condition was chosen 
according to the brightest intensity of the band whilst in the linear 
amplification phase before reaching saturation. 
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2.2.12 Polyacrylamide Gel Electrophoresis (PAGE) 
 
To prepare a 6% polyacrylamide gel, 240 g of urea, 50mL of 10x 
Tris/Borate/EDTA buffer (TEB), 75mL of 40% acrylamide and the volume 
of de-ionized H2O required for a final volume of 500mL was warmed at 
37°C; once urea was dissolved, 250 µL of 10% ammonium persulphate 
and 25 µL of tetramethylethylenediamine were added and immediately 
loaded into the appropriate glass plates inserted into the electrophoresis 
apparatus and filled with 0.5X TBE buffer solution.  
 
The samples were denatured at 95°C, loaded into the 6% 
polyacrylamide gel and electrophoresed at 30-40mA 200V for 30 min. The 
gel was stained soaking the gel in a 0.1mg/mL solution of ethidium 
bromide in 1x TBE. The gel was washed for 5 min in 1x TBE and 
visualized with a UV transilluminometer. 
 
 
 
 
 
Figure 13 Experimental assessment for cycle number 
determination in RT-PCR for SELW. 
For each experiment and sets of primers, an assessment of the 
number of cycles was performed in order to determine the right 
conditions (i.e. linear phase before saturation) to quantify the 
expression of a gene by RT-PCR. 
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2.2.13 miRNA microarray design 
 
The human genome V2 Agilent platform is a one colour microarray 
consisting of short probes which hybridize to target miRNAs and which 
contain a hairpin loop that will join the synthesized sequence to the 
miRNA. The platform uses the miRNAs sequences from Sanger 10.1. In 
the work described in this thesis an array was customized using Agilent's 
eArray Design Tool. This allowed experimental confirmation of predicted 
miRNAs.  
 
The design of the customised slide was 8x15K where 737 distinct 
H. sapiens miRNAs were included, distributed according to the following: 
 
 194 miRNAs from a review of the literature -referred to in this 
thesis as the intestinal microRNAome- (Bandres et al., 2006; 
Cummins et al., 2006; Han et al., 2007; Ogier-Denis et al., 2007; 
Monzo et al., 2008; Peng et al., 2009; Sarver et al., 2009). 
 
 292 bioinformatically obtained miRNAs described in section 
2.2.6 by miRNA target prediction (Chapter 3 of this thesis). 
 
 414 miRNAs were taken at random from Illumina human v2 
chip platform miRNA array and PCR arrays. 
 
 10 Mus musculus miRNA as negative control.  
 
miRNA sequence, ID and either literature review, bioinformatic or 
platform origin for each miRNA are shown in Appendix A.  
 
Figure 14 illustrates the distribution of the 754 miRNA IDs listed in 
Appendix A which were loaded into eArray, Agilent’s tool for designing 
miRNA microarray chips. Twenty features per miRNA were chosen which 
were distributed at random across the chips. 
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Figure 14 eArray miRNA microarray chip design summary window. 
Details of the miRNA microarray chip design including the chip format, total of miRNA 
featured, control types, distribution of layout, number of microarrays per slide, and 
name of Microarray. 
 
 
 
 
2.2.14 miRNA microarray hybridization 
 
The miRNA expression profiling was assessed by microarray 
technology and the hybridization was carried out as a service provided 
through Warwick University. 
 
Briefly, the expression of 737 miRNAs (predicted, characterized or 
experimentally validated in intestine tissue/cell lines/ biopsies) was 
investigated in RNA samples obtained as described in section 4.1. 
100ng/ul of total RNA was labelled with Cyanine 3- pCp ligated to the 3’ 
end. Spike ins to assess the labelling and hybridization efficiencies were 
included at both the labelling step and the hybridisation stage. Spike in 
solutions were prepared using the 3rd serial 100:200dilution of Labelling 
Spike-In and the 3rd serial 100:200 dilution of Hyb Spike-In. 
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Two µL Calf Intestine Alkaline Phosphatase (CIP) Master Mix 
prepared with 0.4µL 10X Calf Intestinal Phosphatase Buffer, 1.1 µL 
Labelling Spike-In and 0.5 µL, Calf Intestinal Phosphatase was added to 
each sample. Samples were dephosphorylated by incubation for 30 min at 
37˚C. Samples were denatured with 2.8µL of 100% Dimethyl Sulfoxide 
(DMSO) and incubated for 5-10min at 100˚C. A ligation was carried out 
using 1µL/reaction 10X T4 RNA Ligase Buffer at 37˚C to dissolve 
precipitate, Cyanine3-pCp (3 µL/reaction), and T4 RNA Ligase 
(0.5µL/reaction) to prepare Ligation Master Mix for T4 RNA Ligase and 
subsequently an incubation for 2 h at 16˚C. 
 
The labelled miRNA was purified using separation 2 mL 
microcentrifuge tubes with columns to desalt samples. These columns 
contain a buffer they were separated from the microcentrifuge tube to let 
the buffer drain for 2 min and then the buffer discarded. After 
centrifugation of the column at 1000 x g for 2 min; after which, the column 
was placed back into the microcentrifuge tube 38.7 µL of RNase-Free 
water was added to the labelled sample for a total 50 µL volume that were 
added to the previously drained gel containing spin column. Samples were 
was eluted by centrifugation at 1000 x g for 4 min. Samples were 
translucent and slightly pink after elution and were kept on ice until they 
were vacuumed dry at 50˚C for about an hour and the resulting pellets 
resuspended in 17 µL of RNase Free Water. 4.5 µL of 10X GE Blocking 
Agent and 22.5 µL of 2X Hi-RMP hybridization Buffer were then added to 
each sample to give a final volume of 45 µL that was mixed gently and 
then added to the array slide and incubated at 100˚C for 5 min and 
transferred to an ice water bath. The array slide was then placed into the 
Gasket Slide, and the 60-mer oligo microarray slide into the Chamber 
Base so 490 µL of hybridization solution and samples were dispensed into 
the array slide. The 2 slides were assembled into a chamber that was 
incubated in an oven at 55˚C and continuously mixed at 20 RMP for 20 h. 
After incubation, slides were washed twice with Wash solution 1 and 
separated carefully so the Gasket slide was submerged into a wash 
staining dish (containing Wash Solution 1 and 2mL of 10% Triton C-102). 
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The Oligo microarray slide was submerged into a second wash staining 
dish and washed with rewarmed (37˚C) Wash solution 2 for 5 min.  
 
The array was scanned using an Agilent G2565CA scanner. Data 
were extracted using Agilent’s Feature Extraction, two text files containing 
probe and gene level data from all features as well as array statistics and 
parameters and a list of expressed miRNAs was generated. In spike 
controls within the microarray pointed the obtained signals as biological 
significant rather than the result from processing issues. Because of an 
error message at the moment of the data extraction for one of the Se-2 
sample array (a Se depleted media treated sample), possibly due to a 
leak, this sample was discarded. 
 
2.2.15 miRNA Quantitative Real Time Polymerase Chain 
Reaction (QRT-PCR) 
 
QRT-PCR for miRNA was performed using the TaqMan® 
MicroRNA assay (Applied Biosystems). 
 
TaqMan® Universal PCR Master Mix, No AmpErase® UNG in 
combination with TaqMan miRNA assays was used for the reverse 
transcription of the miRNAs and further PCR amplification were carried out 
and analysed on an Applied Biosystems HT7900 apparatus. The miRNA 
assay uses a FAM labelled probe and there will be ROX within the 
Mastermix as a passive reference dye which might interfere with the 
fluorescent signal from cDNA amplification. 
 
TaqMan® MicroRNA Assays incorporate a target-specific stem–
loop reverse transcription primer to address a fundamental problem in 
miRNA quantitation: the short length of mature miRNAs (~22 nucleotides) 
prohibits conventional design of a random-primed RT step followed by a 
specific real-time assay. The stem–loop structure provides specificity for 
only the mature miRNA target and forms an RT primer/mature miRNA 
chimera that extends the 3’ end of the miRNA. The resulting longer RT 
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product presents a template amenable to standard real-time PCR using 
TaqMan® Assays. 
 
2.2.16 cDNA synthesis of miRNAs 
 
Due to its short length, several approaches for the reverse 
transcription of RNA into its complementary DNA have been developed 
(Raymond et al., 2005; Ro et al., 2006; Sharbati-Tehrani et al., 2008; 
Benes and Castoldi, 2010). The method utilized in this project was the 
reverse transcription of RNA with specific miRNA primers annealed to a 
prime reverse transcription stem-loop which due to its design will 
differentiate from mature to miRNA precursors (Benes and Castoldi, 
2010).  
 
Each miRNA was reverse transcribed with 0.15 µL 100mM dNTPs 
(with dTTP), 1µL MultiScribe™ Reverse Transcriptase, 50 U/μL, 1.5µL 10 
X Reverse Transcription Buffer, 0.19 µL of 20U/µRNase Inhibitor, and 
4.16µL of nuclease-free water for a volume of 7 µL which was mixed and 
placed on ice while 3 μL of 5 X RT primer and 5 μL of 10ng RNA were 
added to the mix. After a 5 min incubation period on ice, the 15 µL final 
volume reaction was transferred to a thermal cycler and reverse 
transcription carried out using the following conditions: 
 
16°C  30 min 
42°C  30 min 
85°C    5 min 
  4°C  Hold 
 
The reaction was placed on ice after cDNA synthesis and kept at -
20°C. 
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2.2.17 miRNAs QRT-PCR 
 
After cDNA synthesis for the specific miRNA of interest, the 
assessment of the expression by Real Time PCR was carried out by 
adding 1 µL of specific miRNA primers corresponding to the miRNA used 
in the first step of cDNA synthesis, 7.76 µL of 0.05% DEPC water, 1.33 µL 
of RT product (from cDNA synthesis), 10 µL of 2 X TaqMan® Universal 
PCR Master Mix No AmpErase® UNG to a final volume of 20µL per well. 
A clear 96 well-plate was centrifuged at 1,500g for 2 min to bring all 
reagents to the bottom and eliminate bubbles that could interfere with the 
correct capture of the fluorescent signal. 
 
Using the Applied Biosystems HT7900, FAM was selected as non-
fluorescent dye detection system and the Default fast run was used with 
the following conditions: 
 
Enzyme activation  95°C  10 min 
Denature   95°C 15 sec 
Anneal   60°C 60 sec 
 
Ct values were extracted with a threshold of 2.0 and a baseline of 
2-3 cycles before the start of the amplification curve. 
 
2.2.18 Reference miRNAs 
A common problem in miRNA RT-PCR analysis is the data 
normalization. There are several approaches described in scientific 
publications; one approach is the development of an algorithm using the 
data from over 400 miRNA RT-PCRs (Mestdagh et al., 2009) and another 
is to carry out data normalization using a miRNA reference such as let-7a 
(Bandres et al., 2006). In this study the reference miRNA approach was 
used.  
 
45 cycles 
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2.2.19 mRNA microarray hybridization 
 
Caco2 cell total mRNA expression profiling was carried by using 
hybridization of total RNA samples to Illumina HumanRef-8 v.3 Expression 
BeadChips. This was carried out commercially by Service XS B.V. 
 
Aliquots of the RNA samples previously analysed by miRNA 
microarray were sent to Service XS B.V. for gene microarray analysis. 
According to Service XS standard operation procedures, quality control 
was determined by Nanodrop ND100 spectrophotometer and Agilent 
Bioanalyzer. 
 
Each RNA sample was reverse transcribed by converting the 
mRNA into a single stranded cDNA with a T7 promoter sequence using T7 
Oligo (dT) Primer, 9 µL Reverse Transcriptase Master Mix and an 
incubation period of 2 h at 42˚C, after which, the plate was placed on ice 
to prepare the synthesis of a second strand; for this purpose, 80 µL 
Second Strand Master Mix was added to each sample (containing 
Nuclease-free water, Second Strand Buffer, dNTP Mix, DNA Polymerase, 
and RNase H) and incubated at 16˚C for 2 h in a thermal cycler previously 
cooled down to 16˚C and with the heat lid off. The resulting cDNA was 
placed on ice and purified with 180 µL cDNA Pure (magnetic beads in 
binding buffer), transferred to an UBottom Plate and shaken for 2 min so 
the cDNA within the samples bind to the magnetic beads. The UBottom 
Plate was then transferred to a magnetic stand to collect the magnetic 
beads and the supernatant was discarded by careful aspiration. The Plate 
was removed from the magnetic stand for the washing step in which 150 
µL of cDNA Wash Buffer was added, shaking the plate at moderate speed 
for 1 min and the wash step repeated one more time. The magnetic beads 
were captured and the supernatant was discarded carefully by aspiration; 
the plate was then shaken vigorously for 2 mins to evaporate residual 
ethanol. cDNA was eluted with 20 µL of 55˚C Nuclease-free Water. 17.5 
µL of the purified reaction was transferred to a PCR plate for further in 
vitro transcription of Biotin-labelled cRNA by adding 7.5 µL of IVT Master 
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Mix (containing Biotin-NTP Mix and an Enzyme Mix) to each sample and 
the reaction was incubated for 14 h at 37˚C. cRNA was purified with 70 µL 
of cRNA Binding Mix and 95 µL of ethanol, RNA Binding Beads were 
removed and cRNA was washed twice with 100 µL cRNA Wash Solution. 
Finally, cRNA was eluted with 40-100 µL 55˚C cRNA Elution Buffer. 
 
After RNA Cy3-labeled and biotinylation into cRNA, 750ng cDNA 
was hybridized an overnight to Illumina HumanRef-8 v.3 Expression 
BeadChip containing the complementary gene-specific sequences 
according to Whole-Genome Gene Expression Direct Hybridization Assay 
protocol. A Beadchip image was produced by iScan that scans at two 
wavelengths simultaneously creating two images per array. after the 
BeadChip scan by the Illumina iScan array scanner, fluorescence signal 
intensity from the laser excited fluor of the hybridized single stranded 
products of the beads was measured for each bead location. Finally, the 
signals were converted into a TIFF file for transcript quantitation. 
 
From the high resolution images, raw signals were normalized with 
no background adjustment using the Illuminas’s Genomestudio v.2010.1 
software. Internal controls (spiked-in controls and sample dependant 
controls) complied with specifications, gene signals were strong enough 
and all highly expressed genes were present and therefore signal 
generation was considered “passed” for analysis. Data exported from 
Illumina Bead Studio in a GeneSpring compatible format was loaded into 
GeneSpring GX 11 for analysis and analysed using the 
Illumina.SingleColor.HumanRef-8_V3_0_R1_11282963_A technology 
annotation package. 
 
2.2.20 mRNA QRT-PCR 
 
Primers were designed using with a 45-55% CG content, forward 
and anti-sense sequences should have no more than 2°C Tm difference; 
and an amplicon size of less than 150 bp to ensure the closest efficiency 
to 2.0 (see section 2.2.7) Gene name and accession numbers, primer 
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sequences, amplicon length, and annealing temperatures used for QRT-
PCR are summarized in Table 2. 
 
  
 
7
8
 
Primer name Accession Number Sequence 
Primer 
length 
(bp) 
Amplicon 
length 
(bp) 
Start Stop 
Annealing 
temperature 
GPX1_for NM_000581.2 
NM_201397.1 
ACGAGGGAGGAACACCTGATCTTA 24 
102 
780 803 
57°C 
GPX1_rev TTAGTGGGGAAACTCGCCTTGG 22 881 860 
GPX2_for 
Nm_002083.2 
AGCTCTGGGCCTTCACAGAATGAT 24 
117 
871 895 
57°C 
GPX2_rev TCCACACCTGCCCTTTATTGGTC 24 960 984 
GPX3_for 
NM_002084.3 
CAGCCTGGCACAAATGGATGC 21 
163 
1018 1038 
57°C 
GPX3_rev GTACACATTCCCAGAAAGACAC 22 1180 1159 
SELK_for 
NM_021237.3 
GACAACCGGACATGCGCATTC 21 
116 
479 499 
63°C 
SELK_rev TGTGAGGACACAGAGCAGTCCT 22 594 573 
SEPHS2_for 
NM_012248.2 
ACGTCTCTCCCTCTAAACCCCA 22 
111 
2103 2124 
57°C 
SEPHS2_rev TCACCAGGAATCTGCCGCAA 20 2213 2194 
ACBT_for 
NM_001101.3 
TGTTACAGGAAGTCCCTTGCCATC 24 
90 
1481 1504 
60°C 
ACBT_rev CTCCCCTGTGTGGACTTGGG 20 1570 1551 
GAPDH_for 
NM_002046.3 
TGAAGGTCGGAGTCAACGGATTTG 24 
128 
113 136 
57°C 
GAPDH_rev CATGTAAACCATGTAGTTGAGGTC 24 240 217 
MT1F_for 
NM_005949.3 
ACCTTTCTCCCAGATGTAAACAGAGAGA 28 
82 
313 340 
60°C 
MT1F_rev GAATGTAGCAAATGGGTCAAGGTGG 25 394 370 
 
  
 
7
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Primer name Accession Number Sequence 
Primer 
length 
(bp) 
Amplicon 
length 
(bp) 
Start Stop 
Annealing 
temperature 
PIR_for NM_001018109.2 
NM_003662.3 
CGGAAGAGCAGGTCTTGATGTG 22 108 
V1_1332 
V2_1366 
V1_1353 
V2_1387 
60°C 
PIR_rev GGAATTCTTTAGAAGCACCGGCT 23  
V1_1439 
V2_1473 
V1_1417 
V2_1451 
Table 2 Sequences, amplicon length, and conditions for primers used for QRT-PCR. 
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Optimal amplification temperatures were determined empirically by 
performing a semi quantitative PCR and visualized on a PAGE as 
described in section 2.2.8. 
 
2.2.21 Reference genes in Caco-2 cell line 
 
A relative quantification analysis was performed to compare the 
different targets normalized to an endogenous reference gene after the 
concentration from the samples had been determined according to the 
crossing point of the sample in the standard curve. 
 
Beta actin (ACTB), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), beta-2-microglobulin (B2M), hypoxanthine phosphoribosyl-
transferase I (HPRT1), succinate dehydrogenase complex, subunit A 
(SDHA), and tyrosine 3-monooxygenase/tryptophane 5-monooxygenase 
activation protein, zeta polypeptide (YWHAZ) are six of the most common 
reference genes used when normalizing genomic data from Caco-2 cells 
(Piana et al., 2008). The best expression stability was found in ACTB, 
GAPDH, HPRT1, the stability decreased on YWAHZ, B2M, and SDHA, 
hence of GAPDH and ACBT were used in this study in order to normalize 
the expression of the genes assessed by RT-PCR and QRT-PCR. 
 
2.2.22 PCR product purification 
 
In order to produce a standard curve RNA was reverse transcribed 
into cDNA, a series of ten 10-fold dilutions of the concentrated DNA 
carried out and then the diluted DNA amplified by PCR with the specific 
set of primers intended to be used for the standard curves. The PCR 
product was the purified with QIAquick PCR Purification Kit (QIAGEN, 
UK). After PCR amplification, 1 volume of PCR product was mixed with 5 
volumes of Buffer PB and placed into a spin column and centrifuged at 
13,000 RPM for 30-60 sec. After the flow-through was discarded, the 
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column was washed with 750 µL Buffer PE and centrifuged at 13,000 
RPM for 30-60 sec. The columns were dried at 13,000 RPM. PCR product 
was then eluted with 50µL of Buffer EB applied to the centre of the 
membrane and collected in a microcentrifuge tube by a 1 min 
centrifugation at 13,000 RPM. Purified DNA was then stored at -20°C and 
used within 3 months. PCR of the purified products was used to produce a 
standard curve was produced for each gene of interest. 
 
2.2.23 cDNA amplification 
 
1:40 dilution of cDNA and 1:40 of each serial dilution was pipetted 
into a 96 well plate plus forward and reverse primers 1 pmol each, 2x 
LightCycler 480 SYBR Green I Master and 0.05% DEPC water to a final 
volume of 20µL.  
 
QRT-PCR for mRNA assessment was run in a Light Cycler 480 
Roche with the following programme: 
 
Pre-Incubation 95°C  5min 
Amplification  Denature 95°C 10sec 
   Annealing *°C 15sec 
   Elongation 72°C  5sec 
Melting curve  95°C 5sec 
   65°C 1min 
   95°C continuous 
 
And a final cooling step at 40°C for 30sec 
 
* Refer to Table 2 for annealing temperature. 
 
The quantification was programmed at the end of every 
amplification cycle. 
 
 
45 cycles 
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2.2.24 QRT-PCR quality control 
 
Since SYBR Green I will bind to any double stranded structures 
included primer dimers, the accurate detection of the gene of interest 
needs to be assed. For that purpose, the Light Cycler 480 software 
performs a melting curve analysis which will generate a peak according to 
the detected amplified products produced by the fluorescent dye at 65°C-
95°C. The melting temperature of cDNA is monitored at the end of each 
cycle by raising the temperature by a fraction of a degree while the 
fluorescence is monitored; because SYBR Green does binds to any 
double stranded structure, in case there is presence of primer dimers or 
contamination, these different strands will denature and produce a 
different peak. As shown in Appendix B, the melting peaks for each gene 
of interest as well as the house keeping genes used to normalized the 
data showed a similar melting point represented by a single peak across 
all samples and standard curves. Standard curves showing the efficiency, 
error and slope are also presented on Appendix B as means of quality 
control for QRT-PCR. 
 
2.2.25 miRNA silencing 
 
miRNA silencing was performed with an antisense technology. A 
perfect complementary oligonucleotide (anti-miR) can bind to the 
endogenous miRNA to prevent RISC formation (Figure 15) and this will 
silence miR function and lead to down-regulation of its expression. 
 
 
Figure 15 Anti-miR-185 sequence.  
Perfect complementary cleavage of Anti-miR-185 oligonucleotide 
sequence to the mature miR-185.  
3’ UGGAGAGAAAGGCAGUUCCUG 5’
RISC
miR-185
Anti-miR
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Anti-miR-185 and a negative control were purchased from Applied 
Biosystems, UK and transiently transfected using cationic lipid-mediated 
gene delivery which reacts with the negatively charged phosphate groups 
of nucleic acids to then be easily adhered to the membrane (Karra and 
Dahm, 2010). This approach has been used previously to achieve anti-
miR delivery and miRNA silencing. 
 
Prior to transfection, 3.5x105 Caco-2 cells were seeded and grown 
for 24 h. Caco-2 cells were then treated with a transfection media 
containing either Anti-miR-185 or Negative control. The concentrations 
tested were 30, 50 and 70nM for Anti-miR and Negative control. For each 
6 well plate, 5 µL of Lipofectamine® 2000 Transfection Reagent 
(Invitrogen, UK) was added to 250 µL of Opti-MEM® (Invitrogen, UK) and 
incubated for 5 min (“A”); at the same time, 30, 50, and/or 70 nM (“B”) of 
Anti-miR-185 and negative control (“C”) with corresponding concentrations 
was added to 250 µL of Opti-MEM® and incubated for 5 min. After 
incubation, “A” and “B”; and “A” and “C” were mixed together, incubated 
for 20 min, and transfected into the cells. Media was changed 24 h after 
transfection. 
 
2.2.26 hsa-miR-185 knockdown 
 
Gene silencing using anti-miR often requires empirical 
assessment of the culture conditions required to achieve optimal knock-
down of miRNA expression, and such assessment includes modifying the 
following conditions (Song et al., 2009; Tsang et al., 2010; Wang et al., 
2010a): oligonucleotide concentration, cell density at the time of 
transfection, and length of exposure. To determine the optimal conditions 
for miR-185 knock-down, a screen of cell density, anti-miR concentration 
and exposure time was carried out. The experimental set-up for this 
screen is illustrated in Figure 16, Figure 17, and Figure 18; The period of 
anti-miR treatment was varied but the total period that the cells were 
grown in Se-supplemented transfection medium (DMEM with 4.5 g/L 
glucose and Glutamax, Insulin 5 µg/mL, transferrin 5 µg/mL and Sodium 
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selenite 7ng/mL; 40nM) was kept constant at 72h since this period of 
supplementation has been used throughout the experiments described in 
Chapters 4 and 5.  
 
As shown in Figure 16, to achieve anti-miR treatment for 24 h, 
cells were grown in 2mL of Se-supplemented transfection media for 48 h 
prior to transfection with the anti-miR. No penicillin was used in the 
medium since cell membrane permeability is increased during transfection 
which compromises cell survival. To achieve anti-miR treatment for 48h, 
cells were seeded in Se-supplemented transfection media 24 h before 
transfection (as shown on Figure 17). Finally, to achieve anti-miR 
treatment for 72 h cells were transferred into Se-supplemented 
transfection media and transfected at the same time, 24h after seeding 
(see Figure 18). In all cases the medium was changed 24 h after 
transfection and every 24h subsequently. 
 
Expression of anti-miR knockdown was assessed by QRT-PCR 
using Taqman assays. For miRNA QRT-PCR, absolute quantification of Ct 
values were normalised to hsa-let-7a and RNU6B. However, miRNA-185 
knockdown was found to affect the expression of hsa-let-7a but not 
RNU6B, and therefore in the knockdown experiments miR-185 expression 
was normalised to expression of RNU6B. 
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Figure 17 Anti-miR transfection optimization model at 48 h. 
48h of miRNA silencing experiment, cells were seeded and Se supplemented; 
transfected 24 h later for RNA to be isolated 48 h after oligonucleotide treatment. Cells 
were fed with Se supplemented medium 24h after transfection. 
 
Figure 16 Experimental design of miR-185 silencing for 24 h.  
The experiment was designed in order to maintain the cells under 72h of Se 
supplementation. Therefore, for miRNA inhibition at 24 h, cells were Se supplemented 
24hrs prior seeding, transfected with 70nM of either Anti-miR-185 or negative control; RNA 
was isolated 24 h after transfection. 
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Figure 18 Anti-miR transfection optimization model at 72 h. 
For the 72 h Anti-miR treatment, cells were Se supplemented and transfected 24 h after 
being planted; Se supplemented medium was replaced every 24 h after transfection and 
RNA was extracted 72 h after transfection. 
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As shown in Figure 19, treatment with the anti-miR for 24 h led to 
lower mean miR-185 expression at the 3 tested concentrations, 30, 50 and 
70nM. Unexpectedly, the highest knockdown (~80%) was achieved with 
an anti-miR concentration of 30nM. The pattern of knockdown after 48h 
was different (Figure 20) with a similar knockdown of approximately 40% 
at anti-miR concentrations of 50 and 70nM. For anti-miR treatment for 72 
h, only a concentration of 70nM experiment was used. As shown in Figure 
21 with an anti-miR concentration of 70nM the extent of miR-185 
knockdown fell as the length of treatment time increased from 24h to 72h. 
Overall, the data in Figure 19-Figure 21 suggest that the extent of 
knockdown fell as the length of incubation with the miR increased and 
treatment with 70nM ant-miRNA produced consistent knockdown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 miR-185 silencing at 24h.  
48h h after seeding, Caco-2 cells transfected with 30nM, 50nM, and 
70nM of anti-miR-185 and after a further 24 h RNA was extracted 24h 
and the expression of miR-185 was assessed by QRT-PCR. miR-185 
expression was and normalized to RNU6B levels and the data 
expressed relative to the expression in cells treated with the negative 
control anti-miR. Data shown are means =/- s.e.m, n=9. 
 
 
 
*** * ** 
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Figure 20 miR-185 knockdown at 48h.  
miR-185 expression in which cells were Se-supplemented for 72h 
while 48h of anti-sense transfection to achieve miR-185 knockdown. 
RNA was extracted at 72h and the expression of miR-185 was 
assessed by QRT-PCR. miR-185 expression was and normalized to 
RNU6B levels and the data expressed relative to the expression in 
cells treated with the negative control anti-miR. Data shown are means 
=/- s.e.m, n=9. 
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Figure 21 Expression of miR-185 after 24, 36, and 72 h of 
Anti-miR-185 exposure.  
Caco-2 cells were treated with 70nM of either Anti-miR-185 or 
negative control, RNA was isolated, reverse transcribed and 
QRT-PCR revealed a knockdown of miR-185 normalized to 
RNU6B n=9. 
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Chapter 3 miRNA target prediction and miRNA 
microarray chip design 
 
3.1 Introduction 
 
Previous work has found changes in Se intake in vivo to alter 
expression of a number of genes e.g.(Kipp et al., 2009). The work 
presented in this thesis was proceeded by a transcriptomic analysis in 16 
healthy human volunteers who took a daily 100µg supplement of sodium 
selenite over 6 weeks followed by hybridization of lymphocyte RNA to 
DNA microarrays from 32 samples representing before and after 
supplementation (Pagmantidis et al., 2008). The data generated from this 
assay was analysed by Metacore, and this software generated a biological 
network of 61 differentially expressed genes and the most significant 
network was a Protein Biosynthetic Pathway (PBP). 
 
The transcriptomic data showed a rather small increase in 
expression of some genes and these were then analysed by Metacore, a 
pathway analysis tool, and integrated them into a protein coding network. 
This group of proteins included cytoplasmic ribosomal proteins of subunits 
40S and 60S, mitochondrial ribosomal proteins and initiation and 
elongation factors. Pathway analysis pointed to ribosomal proteins and a 
PBP as being responsive to Se supplementation (Pagmantidis et al., 
2008). Another study in mouse colon investigated the mRNA expression of 
selenoproteins and other genes (Kipp et al., 2009). For this study, 
GenMAPP was used for pathway analysis, finding translation factors, 
ribosomal protein, mRNA processing/binding, and regulation of elongation 
factors as well as mTOR signalling pathway to be ranked the highest. 
Although a different Se compound, species and tissue of interest were 
used for this second in vivo study, a protein biosynthetic pathway was also 
identified as affected by Se. 
 
 91 
Although these transcriptome-level studies showed that a change in 
dietary Se alters expression of a range of genes, there has been no study 
to date of whether Se supply alters expression of miRNAs. It is possible 
that regulation of pathways, such as the PBP that are affected by alters Se 
supply may involve miRNAs. The nature of the miRNA mechanisms of 
action, a miRNA or miRNA cluster could regulate a group of proteins. 
 
Many miRNAs are computationally predicted but not all are 
validated as being expressed in any particular cell line or tissue. Indeed, 
finding functional miRNAs and their targets represents a challenging task 
due their multiple complementarity and tissue specificity. Although many 
miRNA genes have been identified in the human genome search for the 
expression of the corresponding miRNA in a particular cell line is often the 
first step in understanding their role. The profile of miRNA expression in 
Caco-2 cells is not known. Because Caco-2 was the selected experimental 
model in which the investigation of Se regulated gene expression through 
miRNAs, it was necessary to investigate the miRNA profile of this 
particular cell line. The approach was to design a miRNA chip including 
miRNAs likely to be expressed in gastrointestinal cell lines or tissues 
and/or of a particular relevance of Se-regulated gene expression rather 
than attempt to use a genome wide miRNA array. This chapter describes 
the process by which a customised miRNA microarray chip was designed 
using a combination of 4 bioinformatic tools, a review of the relevant 
literature to identify miRNAs which are known to be expressed in biopsies 
and colonic cell lines, as well as the miRNAs for which sequences have 
been validated and which therefore have been previously included on 
PCR arrays or microarray platforms (Figure 22). 
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Figure 22 miRNA microarray chip design. 
A customised miRNA microarray chip was designed using the most abundantly 
expressed miRNAs used on PCR arrays and microarrays, miRNAs predicted to target the 
genes from the protein biosynthetic pathway (PBP) and miRNAs expressed in intestinal 
tissue or cell lines identified from previous research. 
 
For this project I used GeneSet2MiRNA (which collects information 
from 11 bioinformatic tools), microrna.org, MicroCosm (which are based 
on complementary and conserved binding predictions) and Ingenuity 
Pathways Analysis (which searches for protein-protein and protein-miRNA 
interactions) to predict miRNAs. As these miRNAs are only predicted, 
there is no published information about their interactions. Since metazoan 
miRNA cleavage does not need perfect Watson-Crick base pairing; 
hundreds or even thousands of targets are often the outcome of 
bioinformatic predictions (Jackson and Standart, 2007; Brodersen and 
Voinnet, 2009; Schnall-Levin et al., 2011; Subramanyam and Blelloch, 
2011). Therefore, by comparing the results from these tools that employ 
different algorithms and finding an overlap for mRNA-miRNA interactions, 
the aim was to increase the likelihood of finding miRNA targets to validate 
experimentally. 
 
3.2 Bioinformatics tools 
The design of the customized miRNA array chip was based on 
prediction of appropriate miRNAs that could regulate Se biological 
pathways using a bioinformatics tools, most of them based on the 
miRanda algorithm, which is designed by the Computational Biology 
Center of Memorial Sloan-Kettering Cancer Center. This algorithm has 
been used to generate many bioinformatics tools since the algorithm was 
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made freely available and it is flexible so that parameters can be adjusted 
according to requirements. Target prediction is based on complementarity 
between the target sequence and the mature miRNA, energy needed for 
the miRNA-mRNA duplex formation and orthology, focusing mainly in the 
3’UTR (John et al., 2004). 
 
3.2.1 MicroCosm Targets 
 
MicroCosm Targets is a bioinformatics tool developed by the 
Enright Lab (Grocock et al.). miRNA and genomic sequences are obtained 
from miRBase and EnsEMBL respectively. microCosm contains mature 
miRNA and miRNA* sequences gathered from 58 species; ~60% of the 
mature miRNAs within microCosm are experimentally validated (Griffiths-
Jones et al., 2008). Seed region complementarity, interactions within the 
3’UTR, orthology alignment with at least two species and thermodynamic 
interactions are measured by Vienna RNA folding routines (Griffiths-Jones 
et al., 2008) and are the criteria of miRNA-target prediction. 
 
3.2.2 microrna.org 
 
This bioinformatics tool is based on a modification of the miRanda 
algorithm, and focuses on almost perfect 3’UTRmRNA-5’miRNA 
complementary sites, which are analysed thermodynamically (Mazière and 
Enright, 2007). The microRNA library is based on small RNA sequence 
data collected from human and rodent tissues and cell lines (Landgraf et 
al., 2007). The genome library from Homo sapiens (172), Mus musculus 
(64), and Rattus norvegiocus (16) was downloaded from the University of 
California Santa Cruz (UCSC) genome browser (Kuhn et al., 2007). 
 
microrna.org gives a score to the potential alignment by allowing 
mismatches in the seed region, but seeks complementary binding in the 
gene for mature miRNAs and it will give different scores to multiple 
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alignments of the same miRNA on the same sequence. For a miRNA to be 
considered in the library it must be conserved among species; the 
orthology is filtered by PhastCons, a conservation score that measures the 
probability of genome changes across time and space using Phylogenetic 
Hidden Markov Models (Betel et al., 2008) with a cut off of 0.57. It scans 
the possible miRNA-gene interactions from two files, one containing 
miRNA sequences (file1) and the other containing RNA/DNA sequence 
(file2), in two stages. The first stage includes reading sequences from files 
1 and 2 to find A:U and G:C complementary sites (alignment score). The 
second stage will then score the alignment by its thermodynamical 
parameters. More recently, seed site pairing, orthology, and 
thermodinamical stability of the miRNA-mRNA interaction were called 
mirSVR. 
 
3.2.3 GeneSet2MiRNA 
 
At the time of the analysis, this web-tool predicted miRNAs from a 
list of genes (entered by accession number or gene name) and looked for 
miRNA-target interactions with miRecords, an algorithm that contains 
documented validated and predicted targets from 9 species; these 
predicted targets are collected from 11 algorithms of miRNA target 
prediction. The GeneSet2MiRNA score is based on the number of 
commonly predicted miRNA hits. Unlike the previous bioinformatic tools, a 
complete set of genes can be uploaded into GeneSet2MiRNA, and 
selecting Homo sapiens as organism, the list of mapped genes with their 
correspondent predicted miRNAs or miRNA clusters is displayed. 
However, no orthology or alignment details are displayed. The score given 
corresponds to the number of algorithms that the miRNAs were predicted 
by at least 4 of these tools. 
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3.2.4 Ingenuity Pathways Analysis (IPA) 
 
IPA is a biological pathway analysis software that provides a visual 
analysis of gene interactions building networks in health and disease. 
Biological and molecular scientific publications on Homo sapiens, Mus 
musculus and Rattus novergicus; it also supports 9 other species. IPA 
pathways include information from scientific articles and the chemical and 
physiological behaviour of other interacting components as well as 
miRNAs (Ingenuity, 2008) which represented a bioinformatics tool with 
experimentally validated. 
 
A core analysis was created using direct and indirect relationships 
using the experimentally observed confidence option, species-human, and 
all cells and tissues, all data sources available to IPA. 
 
3.3 Intestinal microRNA 
 
Due to their role in different cell processes, it is not surprising that 
miRNAs would have tissue specificity. Since the discovery of miRNAs in 
1992 and the discovery of their role in cancer 10 years later (Nugent et al., 
2011), there have been several reports of studies of miRNA expression 
using high throughput approaches. At the time of the chip design, only IPA 
considered miRNA tissue specificity. To include miRNAs thought to be 
expressed in intestinal cells, a number of publications involving the 
presence of endogenous miRNAs across cell lines, tissues and biopsies 
from healthy or metastatic intestine and even embryonic intestinal cells 
were also considered in the array design. 
 
The first attempt to investigate the miRNA expression in colon was 
a study in which miRNA serial analysis of gene expression (miRAGE) 
based on cloning and a serial analysis gene expression (SAGE) was used 
to ligate 18- 26-nucleotide-long isolated RNA molecules by specialized 
linkers which were then cleaved to allow binding to streptavidin-coated 
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magnetic beads so that cloning and sequencing of tags enabled miRNA 
sequence comparison using colorectal cancer tissues. The novel miRNAs 
were then confirmed as Dicer dependant processing in HCT116 (Cummins 
et al., 2006). QRT-PCR with TaqMan MicroRNA Assay kit (Applied 
Biosystems) on RNA from 16 colorectal cancer cell lines (using the human 
normal colon cell line CCD-18Co as means of comparison) and normal 
compared to non-tumorous colorectal tissues form USA identified 13 
differentially expressed miRNAs. Their data correlated to miRNAs already 
identified by SAGE (Bandres et al., 2006). 
 
Later, epigenetic mechanisms of miRNA action were investigated 
with a focus on tissue specificity and using HCT116 and DKO cells with 
microarray Combimatrix and further confirmation by miRNA detection kit 
and QRT-PCR primers from Ambion (Han et al., 2007). Ogier-Denis and 
Fasseu (Ogier-Denis et al., 2007) reviewed the relations between 
intestinal pathologies and miRNAs. miRNAs were investigated in cancer 
cell lines as tumour suppressors or oncogenes, and in colorectal 
inflammatory diseases where they increase the mRNA instability of pro-
inflammatory cytokines, or enhancing resistance to bacteria. 
 
Sarver et al (Sarver et al., 2009) compared the expression of 
miRNA in tumour samples against normal colon tissues from biopsies from 
an American population. RNA samples were analysed by Illumina miRNA 
BeadArray, a PCR based system which polyadenylates RNA to then 
reverse transcribe it to its 5’-end with a universal biotinylated oligo-dT 
primer sequence. 
 
miRNAs from stem cells were considered from Monzo and 
Navarro’s work who investigated if miRNA expression would be present in 
embryonic, normal and cancer tissue and assessed the relationship 
between the function and morphology of stem and cancer cells by 
analysing embryos and normal-tumour paired colorectal human samples 
by QRT-PCR TaqMan MicroRNA Assay. (Monzo et al., 2008).  
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Finally, a study comparing mRNA and miRNA expression profiling 
efficiency to classify cancer types (Peng et al., 2009) was also included 
into the chip design. 
3.4 miRNAs from PCR arrays and assays 
Since the discovery of miRNAs, several approaches have been 
developed for the identification of these new small RNA species. However 
some of these contain probes that are mis-assigned (Sales et al., 2010) 
which leads to incorrect annotations in public databases. Often, snoRNA, 
snRNA and tRNA sequences are included in miRBase (Langenberger et 
al., 2011); examples of such an incorrect annotation are miR-1274a and 
1274b that share identical stretches with tRNA such as tRNA (Lys5) and 
tRNA (Lys3); (Schopman et al., 2010). 
 
In order to minimise the inclusion of mis-assigned miRNAs, I 
decided to include miRNAs from miRNA PCR arrays and microarrays 
because these sequences represent the most abundantly expressed and 
previously characterized miRNAs used by Illumina and Invitrogen. 
 
3.5 Results 
 
The protein biosynthetic pathway was loaded into MicroCosm 
Targets, selecting the genome H. sapiens. An interactive map with the 
alignment throughout the species was displayed as well as the score that 
represented the complementarity (the closer to 100 the more Watson-
Crick base pair bound), energy required for cleavage and the sequence 
location of the miRNA. For microrna.org, the 61 Se-sensitive proteins were 
uploaded into the website as target mRNA, with search options H. sapiens 
as species. Alignment details, orthology and score were displayed. 
miRNAs that were predicted to target the genes of the PBP were extracted 
from MicroCosm, microrna.org and GeneSet2miRNA. A large number of 
entities were obtained from the bioinformatics tools, so the miRNAs were 
selected by taking the miRNAs that had the most number of interactions 
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with the same mRNA sequence. Examples of the readout of the analyses 
are shown in Figure 23 and Figure 24, and the summary of these data 
presented in Appendix A. 
 
miRNA from IPA were obtained from a network image in which 
miRNA-mRNA direct interactions were obtained using the grow tool. The 
general settings used are previously described in Chapter 2 section 2.2.6 
miRNA target prediction for the protein biosynthetic pathway; which briefly 
comprises: growing out all molecules from experimentally observed direct 
interactions in all human tissues and cells. The analysis as subcellular 
layout is shown in Figure 23 where direct and indirect protein-protein 
interactions as well as the direct miRNA interactions with these proteins 
are visualised. Direct interactions are represented by a continuous arrow 
whereas the indirect interactions have a dotted arrow. GeneSet2miRNA 
predicted 225 miRNAs, MicroCosm 83, microRNA.org 31, IPA 43; 
because several miRNAs were predicted by these tools more than once, 
the results from the various bioinformatic tools described above were 
merged to give a final number of 292 miRNAs.
  
9
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 miRNA identification by IPA 
Merged networks from a core analysis of the protein biosynthetic pathway showing experimentally validated direct 
miRNA interactions and protein-protein interactions as well as cellular protein localization. 
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Since IPA offers experimentally validated miRNAs and 
GeneSet2miRNA had already a filter of at least 4 bioinformatic tools for 
miRNA to be considered all the miRNAs from IPA and GeneSet2miRNA 
were included in the design. The fact that a miRNA targeted the same 
gene sequence a minimum of 5 times was the inclusion factor for miRNAs 
predicted from Microcosm and microrna.org. Lastly, mature miRNAs as 
well as mRNAs* were included. 
 
In summary, and as shown in Figure 24, 61 genes were uploaded 
into each bioinformatics tool to predict miRNAs that may target them. 
microRNA.org predicted 1845, 1583 emerged form from MicroCosm, 446 
from GeneSet2miRNA and 54 from IPA. miRNAs predicted from 
microRNA.org and MicroCosm were filtered according to the number of 
interactions each miRNA had with the same mRNA sequence (for 5 times 
or more) to give a total of 31 miRNAs from microRNA.org and 83 from 
Microcosm. miRNAs from IPA and GeneSet2miRNA were not filtered in 
this instance because IPA miRNA-mRNA interactions and 
GeneSet2miRNA miRNAs were both previously validated. 
 
Because some miRNAs had more than one target and the cleavage 
with the same mRNA sequence occurred more than 5 times, some 
miRNAs were listed more than once after the first filter. So the resulting 
miRNA list was to eliminate the repeats from the 4 lists generates on the 
previous step which the numbers had been reduced to 18 miRNAs from 
microRNa.org, 52 miRNAs from MicroCosm, 43 from IPA, and 228 from 
GeneSet2miRNA. Finally, these miRNAs overlapped and when this 
overlap was removed there was a total of 292 miRNAs that had passed 
the filters from the bioinformatics tools and the software; these were 
included on the miRNA microarray chip. 
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Figure 24 Bioinformatically predicted miRNAs. 
61 genes from the protein biosynthetic pathway (PBP) were used to predict miRNA-
mRNA interactions using 4 bioinfomartic tools: microRNA.org, Microcosm, 
GeneSet2miRNA, and IPA. miRNAs extracted from each bioinfomartic tool were filtered 
according to the number of times the same miRNA interacted with the same mRNA 
sequence at least 5 times (except for IPA from which all the miRNAs were included. On 
the second filter, miRNAs that had several targets within the PBP were counted as 1. 
 
 
As shown on Figure 25, the number of miRNAs included on the chip 
that had been extracted from literature review are: 152 miRNAs from 
miRAGE technology (Cummins et al., 2006); real time PCR that lead to the 
identification of 13 miRNA differentially expressed in cancer tissues 
(Bandres et al., 2006), 21 miRNAs from the effects of methylation and 
miRNA expression research using real time PCR and microarray (Han et 
al., 2007), finally both microarray and real time PCR studies that identified 
101 miRNAs expressed in colon from embryonic and cancer tissues 
(Monzo et al., 2008). In addition, 17 miRNAs were included from a (Ogier-
Denis et al., 2007) a review of functional miRNAs in intestine inflammatory 
processes (Ogier-Denis, Fasseu et al. 2007).27 miRNAs were included 
from an investigation of the relationship between epigenetics, miRNAs and 
their effects on tumour development (Sarver et al., 2009), and 23 miRNAs 
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found associated with oncogenes (Peng et al., 2009); both these studies 
had used a microarray approach. 
 
 
Figure 25 miRNAs from literature review. 
A flow chart of the publications available up to the moment of the chip design and the 
technologies such as real time PCR, microarray, PCR array and miRAGE, used identify 
the expression of new miRNAs in colorectal cancer (CRC) samples, normal colon tissue, 
embryonic colon tissues, and colon cancer cell lines. These 7 lists were combined and an 
overlap of miRNAs from the 7 sources reduced the number to a total of 194 miRNAs 
which constituted the intestinal miRNAome and were included on the Agilent microRNA 
microarray chip. 
 
 
Tools to identify miRNAs have been developed increasingly since 
2002. To identify miRNA expression in 2009, microarrays and PCR 
platforms contained the best-characterized and experimentally validated 
miRNAs. A number of miRNAs from the Illumina human v2 chip platform 
and commercially available PCR arrays were selected and included in the 
chip design. These corresponded to the miRNA sequences which were 
best characterized and some of which were experimentally validated. In 
addition, 414 miRNAs were taken randomly from Illumina human v2 chip 
platform miRNA array and PCR arrays from. 
 
Finally, as internal negative control 10 miRNA from Mus musculus 
(M. musculus) were also included in the design, these were not expected 
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to be expressed in Caco-2 cells and so were used to monitor false 
positives. 
 
Note from Venn diagram on Figure 26, that there is an overlap in 
the miRNAs identified from the different sources, where 81 miRNAs are 
common to those on the intestinal miRNAome and those originated by 
bioinformatic analysis (53 miRNAs from commercially available platforms, 
the Intestinal miRNAome, and bioinformatically predicted; and 28 from 
Bioinformatical predictions and the intestinal miRNAome. These two sets 
of miRNAs could be likely to be expressed on Caco-2 cells and may have 
a link with the functions of Se.  
 
 
 
Figure 26 Venn diagram illustrating the miRNAs within the miRNA microarray 
design. 
miRNAs were obtained from research articles in which the expression of miRNAs was 
identified across several intestine biopsies, tissues, and cell lines (Intestinal miRNAome); 
Bioinformatic predictions on Se downstream targets (Bioinformatically predicted miRNAs); 
finally, the best characterized mature miRNA sequences in 2010 (miRNAs from 
commercially available arrays). 
 
A comprehensive list of predicted miRNAs through microrna.org, 
Ingenuity Pathway Analysis, GenSet2miRNA and MicroCosm, as well as 
the miRNAs expressed in the intestine, those obtained from commercial 
assays; and finally, the M. muluscus miRNAs used as negative control are 
in Appendix 1. 
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From a more detailed analysis of the group of 81 miRNAs common 
to the bioinformatically and literature review obtained, the le-7 family, miR-
200 and its isoforms and the miRNAs miR-141 and miR-16 were present. 
Let-7 family is a widely expressed miRNA family across several organisms 
that is involved in various cell processes, acts as a tumour suppressor and 
even miRNA processing. 
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3.6 Discussion  
 
Due to its flexibility to target mRNA through an imperfect 
complementary base pair match, miRNAs can have thousands of mRNA 
targets. In order to narrow down the possible mRNA-miRNAs interactions, 
bioinformatics tools are often used as the first step in miRNA research 
(Huang et al., 2011b). Algorithms give the researcher the flexibility to 
choose the parameters of the search, as 5’UTR, 3’UTR or ORF search, 
and they rank the likelihood of mRNA-miRNAs interaction through a series 
of thermodynamics and orthology. However, mature miRNAs sequences 
are not necessarily conserved across species and these miRNA target 
prediction tools do not consider miRNA tissue specificity; finally, false 
positives on predictions are also common. 
 
In order to address some of these issues, in this study we decided 
to scan mRNA sequences to find miRNAs that would target them with 
several bioinformatics tools were used with either by using the 3’UTR or 
the mRNA as a starting point for miRNA predictions, including all the 
experimentally validated miRNAs from IPA and narrowing down the 
miRNAs that will target the same gene several times. GeneSet2miRNA 
(bioinformatic tools that uses 11 other tools as filters and to support its 
predictions) has the largest output over the other miRNA prediction tools, 
and since it already takes into account at least 4 of its filters, all the 
predictions were included. All these measurements were taken to minimise 
the amount of data generated bioinformatically as well as reduce false 
positives. 
 
Tissue specificity is not considered as a predicting factor because 
miRNA roles in cellular processes are not well understood and the 
expression of these genes is slightly different across cell lines which is 
why the expression of miRNAs in a given tissue cell line cannot be 
predicted easily. Thus, for this study, experimentally validated endogenous 
intestine miRNAs, regardless of any changes in expression, were part of 
the miRNA array. This way, miRNAs lost during miRNA prediction due to 
 106 
lack of orthology are not being strong candidate for mRNA targeting but 
could be expressed in Caco-2 cells were investigated. 
 
Because the aim of the study was to investigate the role of Se on 
Caco-2 cells, miRNA predictions have not been the focus of the miRNA 
microarray chip design, but rather the focus was miRNAs for which their 
mature sequence from microarray or PCR array experiments have been 
defined, as well as miRNAs expressed on intestinal samples. A detailed 
list of the miRNA chip design as well as the origin of those miRNAs 
(bioinformatical, literature searched, or mature miRNA characterized 
sequences) is presented in Appendix A. 
 
Interestingly, a total of 81 miRNAs were found to be 
bioinformatically predicted and part of the intestinal microRNAome. The 
miRNA microarray would confirm whether those miRNAs are present on 
the experimental model Caco-2 cell line. Some of these miRNAs have 
been studied previously: for example, previous work on colorectal 
microdissections from German patients suggested that miR-143 and miR-
145 (among others) might have a role on metastasis progression (Kahlert 
et al., 2011); miR-200 is associated with epithelial cancer progression and 
cancer stem-like cells proliferation; miR-200 family is a tumour suppressor 
miRNA (Bao et al., 2011). Homologous of miR-200 (Dykxhoorn, 2010), 
miR-200a, miR200b, miR-200c, and miR-141 (except miR-429), are 
miRNAs from the cluster 17-92, an oncogene promoter family (Tsuchida et 
al., 2011) were bioinformatically generated and part of the literature review 
lists included in the miRNA microarray chip design. Colorectal 
microdissections from German patients suggested that the miRNAs miR-
19b, miR-194, let-7b, miR-1275, miR-143, miR-145, and miR-638 might 
have a role on metastasis progression (Kahlert et al., 2011). 
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Chapter 4 Experimental validation of predicted 
miRNAs and the effects on Se supplementation on 
Caco-2 cells 
 
4.1 Introduction 
 
Prediction of miRNA-mRNA interactions using a range of 
algorithms, databases (Kuhn et al., 2008; Huang et al., 2011b) or 
previously published data (Nugent et al., 2011) often is the initial approach 
to studies on miRNAs, and was the approach also adopted for this work as 
described in Chapter 3. Using the list of possible miRNAs expressed in the 
intestine generated in Chapter 3, a high-throughput microarray-based 
assay to examine the expression of miRNAs in Caco-2 cells was carried 
out. An additional aim was to determine the effect of Se supply on their 
expression. There was little experimental data available to assess whether 
or not predicted through the bioinformatic analysis miRNAs were 
expressed in gut epithelial cells, and in particular the Caco-2 cell line. This 
chapter presents the results of microarray hybridization of 100ng/µl of total 
RNA from Caco-2 cells to detect expression of the predicted small RNA 
species, and by using RNA from Caco-2 cells cultured under both replete 
and deficient Se, to determine the effect of Se on their expression. 
 
Since the discovery of miRNAs almost 20 years ago (Lee et al., 
1993) several techniques have been developed to assess miRNA 
expression; among them northern blot, QRT- PCR, Next Generation 
Sequencing (NGS), and miRNA microarray profiling. According to 
experimental design, some of these approaches are more suitable than 
others. 
 
Northern blot is a widely used technique for miRNA detection; it 
provides high sensitivity but requires high input of RNA sample (Ro et al., 
2006; Sharbati-Tehrani et al., 2008). The approach also requires individual 
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detection arrays, so they can be very costly, particularly because Lock 
Nucleic Acid (LNA) technology is often used. 
 
An alternative is to use miRNA QRT-PCR, which involves 
amplification using specific probes. Both northern blot and miRNA QRT-
PCR are highly sensitive and they are designed for individual miRNA 
investigation rather than investigation of groups of multiple miRNA 
simultaneously. 
 
miRNA PCR arrays are based on QRT-PCR technology and will 
assess the expression of multiple miRNAs at the same time. miRNA 
probes are produced in 96-well plates or 384-well format; miRNA in the 
test sample are converted into cDNA by reverse transcription, which can 
be achieved by poly A tailing or LNA. In addition to the plate, a thermal 
cycling signal is generated in wells containing primers for a miRNA derived 
in the sample. This approach was not appropriate for the present study 
because the miRNAs had not been experimentally validated and available 
PCR arrays contained miRNA sequences only for characterized miRNA. 
 
Assessing several miRNAs in a single assay, both to monitor the 
expression of miRNA and to discover novel miRNAs can be achieved 
through microarray technology or NGS. Like the alternative techniques 
already mentioned, these approaches also have their challenges and 
limitations. Examples of limitations of NGS are sequencing errors (Git et 
al., 2010), high requirement for concentration of RNA than for microarrays, 
and poorer sensitivity than the microarrays. On the other hand, 
sequencing can be more reliable when detecting miRNA families that may 
vary by a single nucleotide in a short sequence moreover, NGS has been 
found to have better reproducibility (Willenbrock et al., 2009) and a high 
ability to discover novel miRNAs because, it does not rely on use of 
predetermined probes (Buermans et al., 2010). To achieved stable melting 
temperature, microarray platforms have been developed with LNA bases, 
the use of pre-miRNA sequences (which only gives an understanding of 
the miRNA processing rather than monitoring their expression) or the 
addition of a stem loop (Git et al., 2010). 
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miRNA microarrays can be analysed using different platforms. It 
was reported that the Ambion platform was better in distinguishing signals 
from the background that the Agilent platform; Agilent however, included 
mature specific miRNA sequences and it is among the platforms with the 
highest scores in terms of accuracy (Git et al., 2010). For analysis of two 
tissues containing either a small miRNA population (human liver) and a 
large miRNA population (human prostate), the Agilent platform showed the 
best reproducibility compared with QRT-PCR assays and with other 
microarray platforms. The reproducibility of the data was attributed to the 
technology used for the Agilent platform dynamic hybridization (Sato et al., 
2009).  
 
As illustrated in Figure 27, this chapter describes the investigation 
of the effect of Se supply on miRNAs via miRNA profiling by means of 
miRNA microarray and the results were validated using QRT-PCR. Agilent 
was chosen as the microarray platform because as noted above, 
comparison platforms revealed it to have the highest sensitivity (Sato et 
al., 2009) and because it offered flexibility for array design through eArray, 
allowing specific miRNAs of interest to be included on the chip. 
 
For a group of miRNAs identified by this microarray analysis the 
confirmed as Se-regulated by QRT-PCR; bioinformatic analysis was 
carried out to identify their mRNA targets.  
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Figure 27 Chapter 4 workflow. 
Caco-2 cells were treated with 40.5 nM sodium selenite and RNA was isolated after 72 h. 
RNA passed the quality assessment with RIN values >9.1, 260/280 ratio >1.8 and 
260/230 ratio >2.0. The expression of selenoproteins is highly dependent on the Se 
available to the cells and the cells’ responsiveness to sodium selenite was checked by 
measurement of expression of GPX1 or SELW. After RNA passed quality assessment, 
and difference in Se status confirmed by GPX1 and SELW expression samples were sent 
for miRNA microarray analysis where Se-sensitive miRNAs were identified. These 
miRNAs were analysed with a bioinformatics tools to predict the biological processes that 
the Se-sensitive miRNAs might be interacting with using miRWalk and IPA. 
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4.1 Results 
 
miRNA microarray analysis of RNA from Se 
supplemented/deprived Caco-2 cells requires good quality RNA in order to 
achieve reliable expression data for these experiments, so the quality of 
RNA was analysed by gel electrophoresis, RNA Integrity as measurement 
on a Bioanalyzer, and nucleic acid purity assessed by absorbance using a 
Nanodrop. 
 
As described in materials and methods, Caco-2 cells were seeded 
into 6-well plates. Briefly, 5x105 cells were seeded into each well; 24 h 
later, cells were fed with either Se sufficient or deficient media, medium 
was changed every 2 days, and after 72h, total RNA was isolated. Either 3 
or 4 biological replicas per treatment per experiment were included. 
 
4.1.1 Quality control of RNA used for microarray analysis 
RNA was extracted using the PureLink RNA kit QIAGEN, UK 
according to manufacturer’s instructions to achieve total transcriptome 
extraction, including a high yield of miRNAs. This method uses a spin 
column technology based on RNA binding properties in the presence of 
high salt concentrations (Rump et al., 2010). In order to check that the 
total transcriptome RNA isolated contained small RNA species such as 
miRNA, RNA was denatured and subjected to electrophoresis on a 6% 
acrylamide gel. The ethidium-bromide stained RNA fragments were 
visualized using an UV transilluminator. Specific miRNAs cannot be 
identified without specific probes therefore small RNA populations were 
assessed by visualization of the tRNA and the 5S and 3.5S fractions. 
 
As shown in Figure 28, results from the electrophoresis of the 
RNA samples showed that all eight samples prepared for microarray 
analysis exhibited three clear bands, one at 175nt and two of ~300nt; 
these correspond to the expected sizes of 5S and 3.5S rRNA. The 4 lanes 
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of the left show the RNA samples from cells treated with Se whereas the 4 
lanes on the right are samples from cells grown without Se. Bands 
corresponding to tRNA (100nt), and a small RNA population (75nt) were 
also observed in all eight samples. The presence of these bands implies 
the presence of miRNAs. 
 
 
Figure 28 polyacrylamide gel of small RNA species.  
RNA samples from Se depleted (right lanes) Se supplemented (left lanes) 
Caco-2 cells resolved by electrophoresis through a 6% polyacrylamide get. The presence 
of the 5S and 3.5S rRNA and tRNA population revealed the presence of low molecular 
weight RNA species. 
 
RNA is susceptible to RNases that could digest it into short 
fragments, so reducing its integrity and potentially interfering with 
downstream applications by producing a difference in gene expression 
proportional to the level of degradation. In order to assess the RNA 
integrity, samples were analysed with Agilent 2100 Bioanalyzer which 
separated the RNA by microcapillary electrophoresis according to their 
molecular weight. The 28S and 18S ribosomal RNA can be visualized 
using fluorescent detection. 
 
As shown Figure 29A, two major bands corresponding to 28S and 
18S ribosomal RNA were observed.  
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Figure 29B shows a graphical representation of the 18S and 28S 
rRNA peaks, from which early stages of RNA degradation can be 
monitored. The early stages of RNA degradation can be detected when 
the 28S peak is lower than the 18S rRNA peak. The RNA Integrity Number 
(RIN) is calculated from the peak of absorbance values and is a measure 
of RNA integrity (Schroeder et al., 2006). The analysis of these samples 
showed no evidence of the 28S peak being lower than the 18S rRNA and 
it was concluded that integrity was not compromised. The lowest RIN 
value measured was 9.1. Microarray quality control requirements have 
stated a minimum RIN of 7 (Kiewe et al., 2009). 
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Figure 29 Assessment of RNA integrity using the Agilent Bioanalyzer. 
RIN values of RNA isolated on the 10 of February 2010 sent for miRNA 
microarray analysis and further transcriptomic analysis. A) Computer 
generated gel electrophoresis image; B). RIN is calculated based on the 
18S and 28S ribosomal ratio with an Agilent designed algorithm; C) A 28S 
peak lower than the 18S peak indicates degradation of RNA. 
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4.1.2 Assessment of cell response to Se supply 
 
RNA isolated from either Se-supplemented or Se-depleted Caco-2 
cells was reverse transcribed and subjected to RT- PCR, as described in 
Chapter 2, to assess the level of expression of selenoprotein mRNAs 
known to be affected by Se depletion (Pagmantidis et al., 2005). 
Amplification was carried out with primers specific for GPX1 and SELW, 
selenoproteins low in the selenoprotein hierarchy and therefore expected 
to decrease dramatically under marginal levels of Se, and the 
housekeeping gene GAPDH. Separation of the PCR products by agarose 
gel electrophoresis showed single bands of 407, 352, and 128 bp 
respectively, sizes consistent with the expected products. As shown in 
Figure 30 and Figure 31, SELW and GPX1 mRNA levels were lower in 
cells grown in Se-depleted medium whereas the reference gene GAPDH 
was unaffected. 
 
 
 
Figure 30 Semi-quantitative PCR for GPX1 to assess Caco-2 cell response 
to Se supplementation/depletion.  
Caco-2 cells were treated with/without 7ng of sodium selenite for 72 h after 
which total RNA was isolated, reverse transcribed and amplified over 28 cycles at an 
annealing temperature of 60˚C with specific primers to detect GPX1. DNA fragments 
were stained with ethidium bromide after electrophoresis through a 2% agarose gel at 
70V for 45 min. 
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Figure 31 Semi-quantitative PCR for SELW to assess Caco-2 cell response 
to Se supplementation/depletion.  
Caco-2 cells were treated with/without 7ng of sodium selenite for 72 h after 
which total RNA was isolated, reverse transcribed and amplified over 29 cycles at an 
annealing temperature of 60˚C with specific primers to detect SELW. DNA fragments 
were separated by electrophoresis in an ethidium bromide-stained 2% agarose gel at 70V 
for 45 min. 
 
 
 
Figure 32 Semi-quantitative PCR for GAPDH in Caco-2 cells during Se 
supplementation/depletion.  
Caco-2 cells were treated with/without 7ng of sodium selenite for 72 h after 
which, total RNA was isolated, reverse transcribed and amplified over 29 cycles at an 
annealing temperature of 55˚C with specific primers to detect GAPDH for normalization of 
SELW and GPX1. DNA fragments were stained with ethidium bromide after 
electrophoresis through a 2% agarose gel at 70V for 45 min. 
 
 
HyperLadder IV 
 Se-1     Se-2       Se-3            Se+1             Se+2              Se+3       Neg. Cont 1000bp 
700pb 
 
500bp 
 
 
400bp 
 
 
300bp 
 
 
 
 
 
 
 
200bp 
 
 
 
 
 
100bp 
352bp 
HyperLadder IV 
 Se-1             Se-2             Se-3              Se+1            Se+2           Se+3       Neg. Cont 
    128bp 
1000bp 
 
 
 
 
 
 
 
 
600pb 
500bp 
 
 
 
 
400bp 
 
 
 
 
 
 
300bp 
 
 
 
 
 
 
 
 
 
 
 
200bp 
 
 
 
 
 
 
 
 
100bp 
 117 
SELW and GPX1 expression was quantified by band 
densitometry, and normalized to that of GAPDH as a reference gene. As 
shown in Figure 33 there was a statistically significant (n=9, P<0.005) 
reduction of approximately 50% in both SELW and GPX1 expression in 
cells grown in Se-depleted medium compared with cells grown in Se-
supplemented medium. 
 
 
 
4.1.3 miRNA microarray design and analysis 
 
The human genome V2 Agilent platform is a one-colour microarray 
consisting of a short probe that hybridizes to the target miRNA and 
contains a hairpin loop that will join the synthesized sequence to the 
miRNA. In the present work, a platform of customized miRNAs was 
designed to investigate the global changes in miRNA expression under 
different Se concentrations. Human genome V2 Agilent miRNA microarray 
was hybridization to miRNA sequences from Sanger miRBase10.1, the 
Figure 33 Assessment of Se status of Caco-2 cells at mRNA level by semi-
quantitative PCR. 
Gene specific bands generated by semi-quantitative PCR were quantified by 
densitometry of corresponding bands and data was normalized to GAPDH. Knockdown 
to 49% of basal GPX1 level and 46% of basal SELW level. 
*** *** 
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miRNA database with sequences and annotation, performed by Warwick 
University who also performed a second round of RNA quality control of 
the samples by measuring 260/280 ratios, determining RIN using a 
Eukaryote Total RNA Nanochip and by measuring the presence of small 
RNA species using a Small RNA detected on Bioanalyzer. 
 
The array was customized using Agilent's eArray Design Tool so 
that predicted miRNAs could be confirmed. eArray, Agilent’s microarray 
chip design tool, was used to introduce miRNAs of interest using the 
miRNA’s name as identifier and an accession number was assigned to 
each miRNA. 20 features were selected per miRNA i.e. each miRNA was 
represented on the array by a total of 20 on the chip. 
 
The design of the customised slide was 8x15K where 737 distinct 
H. sapiens miRNAs and 10 negative control miRNAs were included. The 
miRNA accession numbers are stated in Appendix A. Using bioinformatics 
analysis, which predicted miRNAs that could be interacting with the PBP, 
miRNAs from literature review, and miRNAs with probes already designed 
were included in the miRNA microarray design. The miRNAs included 
were the following and summarized on Figure 34: 
 
 194 miRNAs identified as present in colon tissue or colon cell 
lines (Bandres et al., 2006; Cummins et al., 2006; Han et al., 2007; Ogier-
Denis et al., 2007; Monzo et al., 2008; Peng et al., 2009; Sarver et al., 
2009).  
 
 A total of 292 miRNAs bioinformatically identified by 
microrna.org, Microcosm, GeneSet2MiRNA, and IPA (miRNAs predicted 
to target the genes within the PBP, as described in Chapter 3). 
 
 414 miRNAs taken from the Illumina human v2 chip platform 
miRNA array and PCR arrays which mature sequences were best 
characterized, and some even experimentally validated. 
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 10 miRNAs from Mus musculus as an internal negative 
control, not expected to be expressed in Caco-2 cells and on the array to 
monitor false positives. 
 
miRNA data files were loaded into GeneSpring GX 11 using the 
Agilent.miRNA.27924-06-Apr-2010-00-00 technology annotations. In 
accordance with the Agilent guided workflow expression values <1 were 
threshold to 1.0 and expression values were transformed to log base 2. 
Normalisation was performed using a 75th percentile shift and no baseline 
transformations were applied to the data. Control probes were removed 
from the dataset, prior to applying flag based filtering to remove probes 
where 'absent' flags were present across all the arrays. As a result, 139 
miRNAs were identified as being expressed in Caco-2 cells and these are 
listed in Table 3; for each miRNA ID, the average of the four samples 
treated with Se sufficient media is represented by the column intensity 
Se+; and the average of the fold change of the 3 samples treated with 
depleted media is represented by the intensity Se-. Standard Error of the 
Mean (SEM) for intensity Se+ and intensity Se- are on the left of its 
corresponding column. 
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miRNA ID 
 
Intensity 
Se+ 
 
SEM 
 
Intensity 
Se- 
 
SEM 
hsa-let-7a 9.022078 0.048636 8.820162 0.153127 
hsa-let-7b 5.570349 0.13509 5.241132 0.145011 
hsa-let-7c 4.15079 0.069962 3.908818 0.156409 
hsa-let-7d 5.438476 0.069183 5.043078 0.183156 
hsa-let-7e 7.447854 0.061173 7.22813 0.08258 
hsa-let-7f 8.443757 0.051569 8.183253 0.150259 
hsa-let-7g 6.899875 0.047792 6.548454 0.146985 
hsa-let-7i 4.435931 0.054651 2.917846 1.459711 
hsa-miR-1 1.539187 0.889478 ND 0 
hsa-miR-103 8.740459 0.056656 8.150362 0.284686 
hsa-miR-106b 6.87748 0.06488 6.114391 0.142393 
hsa-miR-107 8.947761 0.035605 8.316946 0.248256 
hsa-miR-10a 6.717397 0.019686 5.922079 0.192433 
hsa-miR-10b 5.256574 0.036311 3.961272 0.191949 
hsa-miR-122 7.705111 0.0753 7.200214 0.256444 
hsa-miR-1225-3p 0.761272 0.761272 ND 0 
hsa-miR-1246 8.404661 0.045084 8.007711 0.100357 
hsa-miR-125a-5p 4.9337 0.211012 4.583426 0.384583 
hsa-miR-126 0.807424 0.807424 ND 0 
hsa-miR-1260 6.241816 0.204559 5.623343 0.072961 
hsa-miR-1268 5.168417 0.107281 4.466561 0.437194 
hsa-miR-1274a 3.947706 0.104513 3.395757 0.106161 
hsa-miR-1275 6.546358 0.067031 6.164011 0.105459 
hsa-miR-128 4.845628 0.155514 3.772382 0.283495 
hsa-miR-1290 4.961497 0.088476 4.45236 0.089803 
hsa-miR-1308 7.489403 0.135294 6.495912 0.075958 
hsa-miR-130a 7.271505 0.024923 6.463021 0.253988 
hsa-miR-130b 7.686863 0.029542 7.052551 0.197461 
hsa-miR-133b 4.153336 0.123501 1.211295 1.211295 
hsa-miR-135a* 0.513313 0.513313 ND 0 
hsa-miR-139-3p 1.596573 0.922267 ND 0 
hsa-miR-140-3p 3.274347 0.080247 1.04089 1.04089 
hsa-miR-141 2.656021 0.889822 1.06891 1.06891 
hsa-miR-146b-5p 2.429291 0.8112 ND 0 
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miRNA ID 
 
Intensity 
Se+ 
 
SEM 
 
Intensity 
Se- 
 
SEM 
hsa-miR-148a 6.309481 0.088048 5.64309 0.116346 
hsa-miR-148b 4.296767 0.082223 3.888899 0.208164 
hsa-miR-149 4.214053 0.098441 2.479133 1.24343 
hsa-miR-151-3p 4.82627 0.092285 4.15908 0.228345 
hsa-miR-151-5p 7.646506 0.025719 7.187045 0.147258 
hsa-miR-155 1.586798 0.916139 ND 0 
hsa-miR-15a 6.497092 0.131338 5.896285 0.07258 
hsa-miR-15b 9.523644 0.055495 9.227596 0.193577 
hsa-miR-16 9.031421 0.047499 8.401617 0.211289 
hsa-miR-16-2* 2.302734 0.017126 0.72783 0.72783 
hsa-miR-17 8.7281 0.029747 7.973865 0.254897 
hsa-miR-181a 3.662432 0.065618 1.228198 1.228198 
hsa-miR-181b 0.766178 0.766178 ND 0 
hsa-miR-181d 0.759912 0.759912 ND 0 
hsa-miR-182 1.607439 0.538577 0.738159 0.738159 
hsa-miR-1826 3.805342 0.119984 2.253012 1.127791 
hsa-miR-183 5.463388 0.040492 5.293923 0.169285 
hsa-miR-185 3.249075 0.047917 ND 0 
hsa-miR-18a 5.46938 0.051774 4.166729 0.335517 
hsa-miR-18b 3.892383 0.079531 2.945387 0.214296 
hsa-miR-192 8.81948 0.073175 8.362597 0.165423 
hsa-miR-192* 3.739343 0.072182 1.161362 1.161362 
hsa-miR-193a-5p 3.267643 0.128876 1.085885 1.085885 
hsa-miR-193b 5.722821 0.116303 5.086825 0.246936 
hsa-miR-194 7.951715 0.073849 7.11759 0.21224 
hsa-miR-196a 5.874406 0.039025 5.675287 0.210436 
hsa-miR-197 1.487843 0.859075 ND 0 
hsa-miR-19a 4.036184 0.224467 2.521994 1.261043 
hsa-miR-19b 6.729723 0.116472 5.937374 0.209224 
hsa-miR-200a 4.823103 0.125039 4.142203 0.169459 
hsa-miR-200b 8.784505 0.027983 8.311356 0.150306 
hsa-miR-200b* 2.433924 0.057725 0.770812 0.770812 
hsa-miR-200c 9.509499 0.035174 9.105114 0.194941 
hsa-miR-203 3.312888 0.148644 ND 0 
hsa-miR-205 7.623943 0.070904 6.851522 0.349415 
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miRNA ID 
 
Intensity 
Se+ 
 
SEM 
 
Intensity 
Se- 
 
SEM 
hsa-miR-20a 8.515029 0.058233 7.855546 0.206871 
hsa-miR-20b 5.779429 0.08682 4.955113 0.256972 
hsa-miR-21 8.687183 0.17167 8.33308 0.146673 
hsa-miR-210 5.429186 0.072436 4.313433 0.414999 
hsa-miR-215 7.415388 0.103265 6.707484 0.124641 
hsa-miR-22 7.041272 0.103703 5.99773 0.09331 
hsa-miR-221 7.320775 0.047578 6.834014 0.207322 
hsa-miR-224 6.21015 0.066881 5.718695 0.174656 
hsa-miR-23a 8.76048 0.035599 8.254145 0.156926 
hsa-miR-23b 8.887954 0.045638 8.427639 0.180123 
hsa-miR-24 7.706882 0.015514 6.938614 0.208507 
hsa-miR-25 8.730531 0.035503 8.267186 0.200301 
hsa-miR-26a 6.553495 0.078728 5.604189 0.342955 
hsa-miR-26b 6.903256 0.078364 6.392556 0.153007 
hsa-miR-27a 5.136983 0.178805 4.290397 0.15054 
hsa-miR-27b 7.367695 0.075607 6.752449 0.175431 
hsa-miR-28-5p 5.326918 0.040254 4.192954 0.071334 
hsa-miR-29a 6.434781 0.086205 5.962504 0.246721 
hsa-miR-29c 2.315162 0.772385 ND 0 
hsa-miR-30b 6.428092 0.10009 5.50396 0.153747 
hsa-miR-30c 3.719069 0.0498 2.389714 1.197941 
hsa-miR-30d 5.130328 0.035981 3.762747 0.499089 
hsa-miR-31 4.573383 0.067303 3.784522 0.253689 
hsa-miR-320a 7.162013 0.068845 6.686425 0.2042 
hsa-miR-320b 8.736092 0.083738 8.282818 0.160009 
hsa-miR-320d 9.186129 0.07521 8.800443 0.16449 
hsa-miR-324-3p 4.25236 0.292101 3.462472 0.196601 
hsa-miR-331-3p 6.223843 0.064975 5.621734 0.208552 
hsa-miR-338-3p 5.707143 0.081372 5.171111 0.248368 
hsa-miR-34a 5.688154 0.059739 5.300952 0.234408 
hsa-miR-361-5p 6.328471 0.008713 5.725645 0.174457 
hsa-miR-362-5p 5.122375 0.06553 4.560436 0.168691 
hsa-miR-365 7.648694 0.033593 6.920944 0.199908 
hsa-miR-371-3p 10.44318 0.013523 9.91175 0.156585 
hsa-miR-371-5p 8.533873 0.071373 7.629844 0.210436 
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miRNA ID 
 
Intensity 
Se+ 
 
SEM 
 
Intensity 
Se- 
 
SEM 
hsa-miR-372 10.70369 0.064067 9.980973 0.186918 
hsa-miR-373 9.382831 0.025974 8.733498 0.358062 
hsa-miR-373* 4.371428 0.036219 3.900571 0.043516 
hsa-miR-374b 2.313436 0.772538 ND 0 
hsa-miR-375 3.706311 0.115586 2.25997 1.134564 
hsa-miR-378 3.629943 0.043706 1.14892 1.14892 
hsa-miR-378* 1.496086 0.863842 ND 0 
hsa-miR-423-5p 5.341558 0.133256 4.69064 0.179493 
hsa-miR-425 5.725467 0.031887 4.726552 0.390949 
hsa-miR-429 4.201887 0.354806 ND 0 
hsa-miR-455-3p 6.987688 0.058694 6.451077 0.176121 
hsa-miR-483-3p 7.462019 0.105371 6.712069 0.209494 
hsa-miR-483-5p 6.673096 0.064219 6.299194 0.167861 
hsa-miR-494 8.721159 0.082309 8.044923 0.081757 
hsa-miR-500* 4.20676 0.108002 3.495719 0.174715 
hsa-miR-501-3p 0.514599 0.514599 ND 0 
hsa-miR-501-5p 3.012151 0.09318 1.947929 0.978837 
hsa-miR-502-3p 3.283707 0.129955 1.034 1.034 
hsa-miR-517a 3.537956 0.045974 1.07354 1.07354 
hsa-miR-517c 3.686805 0.05355 1.145054 1.145054 
hsa-miR-518e* 3.698566 0.182194 0.844874 0.844874 
hsa-miR-522 6.290417 0.038312 5.761151 0.190301 
hsa-miR-532-5p 5.081926 0.04608 4.099361 0.188114 
hsa-miR-572 3.61681 0.09918 2.441185 1.220714 
hsa-miR-574-3p 1.647611 0.951357 ND 0 
hsa-miR-574-5p 4.164115 0.296571 1.176549 1.176549 
hsa-miR-623 0.499574 0.499574 ND 0 
hsa-miR-625 3.371898 0.066472 ND 0 
hsa-miR-629 0.55128 0.55128 ND 0 
hsa-miR-638 6.01501 0.078613 5.688327 0.203988 
hsa-miR-652 3.864843 0.059972 1.191884 1.191884 
hsa-miR-660 4.083408 0.093736 2.250578 1.128048 
hsa-miR-663 3.857931 0.10928 2.36189 1.180957 
hsa-miR-671-5p 4.464573 0.071565 1.065811 1.065811 
hsa-miR-7 4.440113 0.075812 4.108745 0.077011 
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miRNA ID 
 
Intensity 
Se+ 
 
SEM 
 
Intensity 
Se- 
 
SEM 
hsa-miR-720 10.40175 0.091499 9.843947 0.198153 
hsa-miR-92a 9.791742 0.047591 9.312716 0.224071 
hsa-miR-93 8.199486 0.070915 7.72554 0.299353 
hsa-miR-940 5.483562 0.114589 5.330604 0.108044 
hsa-miR-96 5.229107 0.140879 4.821802 0.116776 
hsa-miR-99b 4.160071 0.081881 3.686793 0.217586 
Table 3 miRNAs expressed in Caco-2 cells 
RNA from Caco-2 cells was examined by hybridization to human genome V2 
Agilent microarray and analysed by GeneSpring GX11. 145 positive signals were 
identified. intensity Se+ column shows the fold change of a particular miRNA 
under Se supplementation; while intensity Se- represents the intensity response 
of a miRNA to Se depleted conditions. 
 
In Chapter 3, the use of bioinformatics tools IPA, MicroCosm, 
microRNA.org, and GeneSet2mRNA to predict miRNAs that targeted the 
genes in the PBP is described. The resulting miRNAs were included in the 
microarray chip design. The ratio of miRNAs predicted over the miRNAs 
expressed on the microarray was: IPA ratio 0.3, MicroCosm ratio 0.26, 
GeneSet2miRNA -ratio 0.25 and microrna.org -ratio 0.16. 
 
194 miRNAs included on the chip design were extracted from 
literature as a group of miRNAs expressed in intestinal tissues, biopsies, 
and cell lines and I refer to them here as the intestinal microRNAome. 
From this intestinal microRNAome, 71 miRNAs signals were detected in 
Caco-2 cells; this number corresponds to about 37% of the intestinal 
miRNAome, relatively low number of miRNAs that would be expected to 
be expressed in this particular cell line; however, many isoforms of the 
miRNAs from the intestinal miRNAome were expressed. On the other 
hand, 74 miRNAs that were not part of that miRNAome were detected on 
our array. Some miRNAs detected under Se-supplementation conditions 
were not detected under Se deficient conditions. Perhaps rather 
surprisingly, the converse was not observed. This observation suggests 
that Caco-2 cells do not include any pathways for increased expression of 
miRNA that are activated by Se depletion but pathways are activated by 
the presence of Se or repressed by Se deficiency. 
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Differential miRNA expression analysis was performed using t-
tests in GeneSpring (Benjamini-Hochberg False Discovery Rate (FDR) 
multiple testing correction applied) where probes had a corrected p-value 
of <0.05. Thirteen miRNAs passed the flag filter and were considered as 
differentially expressed, showing an upregulation in the presence of Se. 
The greatest changes in expression were shown by miR-185, miR-625, 
miR-203, and miR-429, where no signal was detected with Se-depleted 
RNA samples, and a FC 3.85, 3.37, 3.31, and 4.20 respectively for Se 
supplemented RNA samples. In addition to these dramatic changes, the 
difference in expression for the remainder of Se sensitive miRNAs was 
~20% (Table 4). 
 
 
miRNA ID 
 
Intensity 
Se- 
 
Intensity 
Se+ 
 
p-value 
hsa-miR-185 ND 3.2490754 3.06E-08 
hsa-miR-625 ND 3.3718982 1.30E-07 
hsa-miR-203 ND 3.3128884 7.77E-06 
hsa-miR-28-5p 4.1929545 5.326918 2.50E-05 
hsa-miR-429 ND 4.201887 1.70E-04 
hsa-miR-373* 3.9005706 4.3714275 3.98E-04 
hsa-miR-10b 3.9612722 5.2565746 5.58E-04 
hsa-miR-22 5.9977303 7.041272 8.18E-04 
hsa-miR-532-5p 4.099361 5.0819263 0.00199156 
hsa-miR-1308 6.495912 7.489403 0.00220046 
hsa-miR-494 8.044923 8.721159 0.00235208 
hsa-miR-106b 6.1143913 6.8774805 0.00298004 
hsa-miR-30b 5.50396 6.428092 0.00323074 
Table 4 Microarray expression of differentially expressed 
miRNAs.  
Expression of miRNAs from RNA from Caco-2 cells after 72h of 
either Se supplementation or depletion analysed by miRNA 
microarray using the Human genome V2 Agilent platform. Data 
were analysed by student t-test and Benjamini-Hochberg multiple 
testing correction. 
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In summary, Figure 34 shows that from the 737 miRNAs obtained 
from the literature review, bioinformatic predictions or software search, and 
other expression platforms, 139 miRNAs were expressed in Caco-2 cells 
(Table 3), from which 13 were differentially expressed (Table 4).  
 
Figure 34 miRNA microarray chip design summary and miRNA expression. 
737 miRNAs (purple box) from predicted from 3 bioinformatic tools and a software using 
the PBP as target genes (red box); miRNAs expressed in intestinal tissues and cell 
lines(yellow box); and miRNAs from miRNA PCR assays and microarrays (blue box) were 
used to investigate the effects of Se on miRNA expression. 10 M. musculus miRNAs 
(grey box) were also included on the miRNA chip design as internal negative control. The 
145 positive signals were detected on the miRNA microarray were control probes and 
those described on the yellow, blue and red boxes of the same diagram, none of the M. 
musculus miRNAs were expressed. Table 3 shows the 139 out of 737 miRNAs that were 
expressed on Caco-2 cells. Finally, these 139 miRNA were flag filtered by Gene Spring 
detecting 13 differentially expressed miRNAs presented in Table 4. 
 
During the course of this study, hsa-miR-1308 was erased from 
the Sanger database because it had been identified as a tRNA fragment 
rather than a miRNA, and Agilent discovered a missing G between the 
 127 
hybridization sequence and the hairpin loop of the miRNA probes, which 
could have affected the intensity of the signal. 
 
4.1.4 Further experimental confirmation of miRNA microarray 
data. 
 
In order to validate the results from the microarray experiment, a 
second technique was used to confirm the miRNAs susceptible to Se 
supply/depletion performed with biological replicates. QRT-PCR is 
considered as the gold standard in gene expression quantitation (Git et al., 
2010), so was the approach used for validation. 
 
 
Figure 35 miRNAs with no significant change when comparing Caco-2 cells 
grown under Se depleted /supplemented conditions 
Flag filter analysis (GeneSpring GX) was used for the identification of control miRNAs 
in RNA samples (n=4) isolated from Caco-2 cells grown for 72h under either Se-
depleted conditions or with the addition of 7ng/ mL Se as sodium selenite and 
hybridized to a V2 Agilent 8x15k miRNA microarray.  
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In order to amplify miRNA by PCR, poly-A tailing, hairpin loop 
extension and LNA are some of the methods developed to reverse 
transcribe and amplify miRNAs. Among scientific work involving colonic 
epithelium tissues/cells/biopsies published in 2010, the Taqman PCR 
assay was the most frequent used method for miRNA QRT-PCR (Sato et 
al., 2009) and was adopted for the current study. For the present analysis, 
miRNAs were prioritised according to changes in the microarray data such 
as the smallest p-value (<0.001), the biggest change in expression (Se 
supplemented/Se depleted), and scientific evidence of being present in 
epithelium or colon tissues. On the basis of low p-value, and large 
changes in expression between cells grown under Se sufficient or deficient 
medium, hsa-miR-185, hsa-miR-28-5p, hsa-miR-10b, and hsa-miR-106b 
were chosen for validation by q-miRNA-PCR. In order to normalise the 
data, two control miRNAs were also chosen for analysis: RNU6B and hsa-
let-7a. Of a panel of miRNAs commonly used as reference (hsa-let-7a, 
hsa-miR-16, hsa-miR-15a, hsa-miR-103, hsa-miR-423-5p, hsa-miR-21, 
hsa-let-7f, and hsa-miR-200b), hsa-let-7a was chosen as it showed the 
smallest change in expression between the Se treatments (Figure 35) and 
it has also been reported as a reference/endogenous miRNA in colon 
tissues (Bandres et al., 2006); finally, scientific evidence has suggested 
that the let-7 family is involved in miRNA processing (Jakymiw et al., 2010) 
and has been reported as a stable miRNA in colorectal cancer (Chang et 
al., 2010). RNU6B is a small nuclear RNA widely used to normalize q-
miRNA-PCR data for gastric tissues, biopsies and cell lines (Tchernitsa et 
al., 2010a; Wang et al., 2010b) because it has fewer associations with 
physiopathological factors than the rest of the snoRNAs commonly used 
as housekeeping miRNAs and therefore the most stable (Gee et al., 
2011). 
 
cDNA is synthesized in the Taqman assays by tailing the mature 
miRNA with a common sequence and using a universal primer as a 
template to reverse transcribe it. This universal primer is a hairpin loop 
designed with a single strand sequence on its 5’ end that will bind to the 3’ 
end of the miRNA followed by a double stranded segment with the 
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universal primer binding sequence contained in the loop as shown in 
Figure 36. 
 
Dual-labelled hydrolysis probes that will produce a fluorescent 
signal corresponding to the number of amplified DNA copies are used for 
QRT-PCR detection.  
 
 
 
 
 
 
 
 
The first step of the miRNA reverse transcription is specific to each 
miRNA sequence to be amplified. This means that normalization will not 
be as accurate as using the same cDNA to amplify test and reference 
 
Figure 36 cDNA synthesis and QRT-PCR of miRNAs using the Taqman 
Assays. 
Step 1 shows cDNA synthesis using a looped primer. The 3’end is 
complementary to the mature miRNAs sequence to extend the ~22nt sequence, 
where as the 5’ end encodes a universal primer in step two, PRC products are 
amplified from cDNA synthesised from step 1 and the universal primer. 
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genes, as for conventional QRT-PCR sample generated from a single 
RNA sample.  
 
Master mixes contained: 0.075mM dDNTP mix with dTTP; 3.8 U of 
RNase inhibitor, 3µL of RT primers; and 5 µL of 10ng RNA concentration 
for a 15 µL final cDNA volume. To control such likely variation, the same 
sample was reverse transcribed with 8 different primers at the same time. 
A separate master mix, each containing the relevant miRNA primer was 
prepared for each of the 8 arrays.  
 
Real-time amplification was carried out as described in Chapter 2, 
and Cycle threshold (Ct) values were extracted from the Applied 
Biosystems 7900HT Fast Real-Time PCR System using the FAM Non 
Fluorescent as the dye detection system. For data extraction, a 2.0 
threshold and a baseline set 2-3 cycles before the amplification curve 
were used. Relative quantification was calculated by ΔΔ Ct formula using 
the Ct values of the miRNAs of interest minus the miRNAs of reference.  
 
After normalization against both reference miRNAs (hsa-let-7a and 
RNU6B), the relative expression of all the studied miRNAs appeared 
increased in cells grown in Se supplemented medium compared with cells 
grown in Se-depleted medium. This finding is consistent with the 
microarray data. However, absolute differences in levels of expression 
were different when comparing Se treatments with the two different 
techniques. For example; miR-185, miR-429, and miR-625 were not 
detected in cells grown in Se depleted medium when the RNA was 
analysed by the microarray chip, but produced detectable signals after 28-
30 cycles of QRT-PCR. 
 
Figure 37 shows the relative expression of the miRNAs as 
measured by QRT-PCR when normalized to RNU6B. Compared to Se 
depleted conditions, RNA from cells grown in Se-supplemented medium 
showed a 67% increase in miR-625 expression, a 55% increase of miR-
10b, 52% in miR-106b, 48% in miR-185, and 36% in miR-149. 
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Figure 37 Relative expression of miRNAs measured by QRT-PCR and 
normalized to RNU6B for confirmation of selected Se sensitivity of 
miRNAs.  
Samples sent for the analysis by miRNA microarray analysis plus two biological 
replicas were reverse transcribed using a specific stem loop primer and amplified 
by hydrolysis probes. Absolute expression was normalized to the snoRNA 
RNU6B and relative expression was expressed as a percentage. According to 
the microarray data, the expression of miR-625, miR10b, miR-106b, miR-28-5p, 
miR-185, and miR-429 were up-regulated in the presence of Se, which was 
confirmed by QRT-PCR. 
 
 
** * * *** *** *** 
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Figure 38 Relative expression of miRNAs measured by QRT-PCR and 
normalized to let-7a for confirmation of selected Se sensitivity of miRNAs 
detected.  
Samples sent for the analysis by miRNA microarray analysis plus two biological 
replicas were reverse transcribed using a specific stem loop primer and amplified 
by hydrolysis probes. Absolute expression was normalized to let-7a and relative 
expression was expressed as a percentage. According to the microarray data, 
the expression of miR-625, miR10b, miR-106b, miR-28-5p, miR-185, and miR-
429 were up-regulated in the presence of Se, which was confirmed by QRT-
PCR. 
 
Relative quantification was also calculated using let-7a as a 
second reference. As shown in Figure 38, normalization of miRNA 
expression relative to let-7a as the reference indicated an up-regulation of 
all the miRNAs I response to Se supplementation, in agreement with both 
the analysis of the expression data normalized to RNU6B and the 
microarray results. However, the level of upregulation in the presence of 
Se was slightly different from that after normalization with RNU6B, with a 
28% increase in miR-185, 18% increase in miR-106b, 26% increase in 
miR-10b, 37% increase in miR-149, and 27% increase in miR-625.  
 
** ** ** ** * * 
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4.1.5 Bioinformatic analysis to predict effects of Se through 
miRNAs. 
 
After the expression of the Se-sensitive miRNAs was confirmed by 
QRT-PCR, a bioinformatics analysis was carried out to predict the targets 
of these 13 miRNAs. 
 
As shown schematically in Figure 39, miRWalk was used to 
predict miRNA-mRNA interactions in 3 different ways: targeted predicted 
by 5 bioinformatic tools, predicting using experimentally validated miRNA- 
3’UTR interactions and predicting using interactions of the 13 miRNAs on 
5’ and 3’UTR sequences. 
 
 
Figure 39 Se-sensitive miRNA target prediction using miRWalk. 
miR-10b, miR-22, miR-28-5p, miR-30b, miR-106b, miR-185, miR-203, miR-373*, miR-
429, miR-494, miR-532-5p, miR-625, and miR-1308 targets were predicted by miRWalk 
in three different ways: A) miRNA target prediction in selected areas (5’ and 3’UTR) B) 
miRNA target prediction using 5 bioinformatic tools, and C) miRNA-mRNA experimentally 
validated interactions from the literature. Step A predicted 7092, B 874, and 597 from C, 
after repeated records were extracted from each list, each one of the 3 lists of miRNA 
targets were analysed independently and pathway analysis produced the data shown in 
Figure 41, Figure 42, and Figure 40 respectively. 
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Approximately 7,000 genes were found to be predicted targets of 
the 13 Se sensitive miRNAs identified in in this study, because of the 
promiscuity in miRNA-mRNA target pairing; typically a single miRNA could 
regulate 100 possible targets. 
 
These genes were identified using a new algorithm for miRNA-
gene interaction prediction developed in 2011, miRWalk. miRWalk, is 
similar to GeneSet2miRNA in the sense that a group of genes can be 
uploaded for miRNA prediction and 8 already established algorithms are 
used to identify possible targets. In the case of miRWalk, 4 of the 8 
independent bioinformatic tools must predict the same miRNA-gene 
interaction in order for it to be considered a plausible result. miRWalk 
includes experimentally validated data from EntrezGene PubMed and 
predictions occur at the promoter region, ORF,3’and/or 5’ UTR as long as 
the miRNA seed region binds to the sequence of interest (Dweep et al., 
2011); and it assigns a p-value according to the number of miRNA base 
pairs that would bind to an mRNA sequence. 
 
The bioinformatic analysis with the 13 Se-sensitive miRNAs using 
miRWalk, described in Chapter 2 section 2.2.6, resulted in 8878 targets. 
These data were then analysed by IPA to predict physiological functions of 
this group of miRNAs and thus of Se activity through miRNAs. Three lists 
of genes were generated from miRWalk, using 1) miRWalk and the 
comparison of 5 bioinformatic tools; using 2) miRWalk validated targets 
and 3) miRNA target prediction on the 3’UTR.  
 
For each analysis, a graph showing the most significant pathways 
of the data set and a table showing the numerical value of the significance 
of the association between the data set and the canonical pathway 
measured in 2 ways: 1) The p‐value calculated using Fisher’s exact test 
determining the probability that the association between the genes in the 
dataset and the canonical pathway is explained by chance alone. 2) A 
ratio of the number of molecules from the data set that map to the pathway 
divided by the total number of molecules that map to the canonical 
pathway is displayed. 
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The top 5 canonical pathways from each of the three lists are as 
below: 
 
1. Predictions on the 5’ and 3’ UTR: 
 
 
Figure 40 Pathways generated from of the 13 Se-sensitive miRNA targets  
Semaphorin signalling in neurons, AMPK signalling, axonal guidance signalling, cardiac 
hypertrophy signalling, and HMGB1 signalling were the IPA generated networks using the 
predicted targets from the 13 Se-sensitive miRNAs interacting with the 5’ and 3’UTR.  
 
 
 
 
Pathway 
 
p-value 
 
Ratio 
Semaphorin signalling in neurons 1.37E-04 29/52 (0.558) 
AMPK signalling 1.5E-04 59/137 (0.431) 
Axonal guidance signalling 6.14E-04 140/395 (0.354) 
Cardiac hypertrophy signalling 1.47E-03 88/227 (0.388) 
HMGB1 signalling 1.61E-03 42/96 (0.438) 
Table 5 p-value and ratios of the pathways generated from of the 13 Se-sensitive 
miRNA targets shown on Figure 40. 
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2. Comparison of 5 target prediction tools 
 
 
Figure 41 Comparison the pathways generated from the 13 Se-sensitive miRNAs 
targets predicted by 5 bioinformatic tools. 
Integrin signalling, Semaphorin signalling in neurons, ERK/MAPK signalling, cardiac b-
adrenergic signalling, and regulation of actin-based motility by Rho are the top 5 
canonical pathways predicted by miRWalk and 4 other bioinformatic tools. 
 
 
 
Pathway 
 
p-value Ratio 
Integrin signalling 7.46E-04  21/198 (0.106) 
Semaphorin signalling in neurons 1.32E-03 9/52 (0.173) 
ERK/MAPK signalling 1.94E-03 19/188 (0.101) 
Cardiac b-adrenergic signalling 3.82E-03 14/126 (0.111) 
Regulation of actin-based motility by Rho 4.1E-03 11/88 (0.125) 
Table 6 p-values and ratios of the pathways generated by the comparison the 
pathways generated from the 13 Se-sensitive miRNAs targets predicted by 5 
bioinformatic tools shown on Figure 41. 
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3. miRWalk validated targets in the 3’UTR 
 
 
Figure 42 Pathways generated from the validated targets of the 13 Se-sensitive 
miRNAs. 
Molecular mechanisms of cancer, aryl hydrocarbon receptor signalling p53, pancreatic 
adenocarcinoma signalling, p53 signalling, and glioblastoma multiform signalling were 
IPA generated networks from the 13 Se-sensitive miRNA validated targets interacting 
with the 3’UTR according to miRWalk.  
 
 
 
Pathway 
 
p-value 
 
Ratio 
Molecular mechanisms of cancer  5.31E-17 50/358 (0.14) 
Aryl hydrocarbon receptor signalling  1.11E-13 28/150 (0.187) 
Pancreatic adenocarcinoma signalling  3.78E-12  23/110 (0.209) 
p53 signalling 6.5E-11  20/87 (0.23) 
Glioblastoma multiform signalling 1.1E-09  24/155 (0.155) 
Table 7 p-values and ratios of the pathways generated from the validated targets of 
the 13 Se-sensitive miRNAs shown on Figure 42. 
 
 
Because these networks were the result of the pathway analysis of 
the predicted mRNA targets from the Se-sensitive miRNAs, it was 
expected that some pathways would be directly involved with Se biological 
roles. This was not observed, however an alternative interpretation of 
these pathways is addressed in the discussion of the present chapter.  
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4.2 Discussion 
The first step in miRNA research is generally target prediction, and 
it is followed by experimental validation. High-throughput analysis of 
miRNA expression in the Caco-2 cell line and the effect on the expression 
of Se was tested using a miRNA transcriptomic approach. The microarray 
comprised probes and predicted target genes involved in the PBP, which 
was identified as regulated by Se in previous studies (Pagmantidis et al., 
2008), miRNAs previously identified as expressed in human intestinal cells 
or tissues and therefore with “tissue specificity”. Because these miRNAs 
have been experimentally validated elsewhere, most of them were 
expected to be expressed; however, only about 37% of them were 
detected in the Caco-2 cell line in this study. This is not an unusual 
phenomenon; authors of other studies have reported that mature miRNAs 
already validated experimentally in the same or a similar cell line have not 
been detected; for example the hsa-miR-145 (Bandres et al., 2006) was 
not expressed neither in Banderas, Cubedo et al, nor in the present study. 
Also, only 101 miRNAs were found to be bioinformatically predicted out of 
the 292; and 90 out of the141 from PCR and microarrays platforms. 
 
Mature miRNA and miRNA* sequences were included and 
analysed. Interestingly, of the two corresponding miRNA mature and * 
sequences, hsa-miR 375 and hsa-miR 375*, the latter was up-regulated in 
the presence of Se, whereas hsa-miR 375 was expressed but no Se-
dependant changes in expression were detected suggesting than for this 
particular case, has-miR-375* responsiveness to Se must be mediated by 
the miRNA* rather than the mature mRNA species. 
 
In terms of bioinformatic tools, from the detected miRNAs in Caco-
2 cells, a higher number of miRNAs from IPA were expressed compared 
with the miRNAs predicted by GeneSte2miRNA, microRNA.org, or 
MicroCosm. This is not surprising since it is a tool with experimentally 
validated mRNA-miRNA interaction information. The association between 
the predicted miRNAs and the miRNAs expressed in Caco-2 was 
Microcosm > GeneSet2miRNA > microrna.org.  
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Appendix A shows, from the 145 expressed miRNAs, 71 
correspond to those obtained through literature review, and 69 of them 
were the result of bioinformatic prediction tools.  
 
One of the aims of this chapter was to investigate how Se 
supplementation and depletion affect the miRNA expression, the model for 
the present experiment was taken from (Pagmantidis et al., 2005) who 
aimed to investigate the effects of Se on selenoprotein expression. In this 
model, Caco-2 cells are grown in medium without serum with or without 
Se. the level of GPX1 expression in the Se deficient cells is very low and 
comparable to that found in cell grown in normal medium (Gautrey et al., 
2011) this reflects the low Se content of normal media (Leist et al., 1996) 
and the sensitivity of GPX1 expression Se supply. 
 
In future work a more complete picture of the miRNA profile might 
be obtained by also analysing miRNAs in cells grown in normal medium. 
However, using the Se deficient and supplemented media, I was able to 
identify miRNA potentially sensitive to Se supply. 
 
Interestingly, the Se sensitive miRNAs identified by the array were 
all up-regulated, and in some instances “on-off” effect between Se 
supplemented and depleted cells was indicated by QRT-PCR. Widely 
used miRNAs as reference species were examined within the data 
obtained to identify which were the most stable miRNAs for the for the 
purposes of use in normalizing QRT-PCR data to validate the microarray 
data, from which has-let-7a emerged as a candidate. Literature review 
identified the 44nt long snoRNA, RNU6B, as a suitable external second 
reference miRNA for data normalization. QRT-PCR data generated from 
the original samples analysed by miRNA microarray hybridization plus 2 
biological replicas generated were normalized to these two reference 
miRNAs. Results of these analyses were very similar for both reference 
miRNAs, indicating that they were suitable controls for normalization. 
According to a study in which small nucleolar RNAs –but not RNU6B- and 
several miRNAs including let-7a and miR-16, two reference miRNA 
candidates for this study, miR-16 were explored as potential reference 
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miRNA candidates, let-7a was chosen over miR-16 according to the study 
on the role of miRNAs in colorectal cancer and miR-16 is a tumour 
suppressor (Chang et al., 2010). The miRNAs that were not detected by 
microarray hybridization of sample obtained from cells grown under Se-
depleted conditions were detected by QRT-PCR probably reflecting 
greater sensitivity of QRT-PCR compared to microarray. Nevertheless, the 
direction of change in miRNA expression measured between samples 
from Se-supplemented to Se-depleted cells was consistent between the 
two techniques.  
 
A study using QRT-PCR and miRNA chip found down regulation 
of miR-373* in a study on bone marrow from children with B-cell precursor 
acute lymphoblastic leukaemia (Ju et al., 2009); on the other hand, miR-
373* was overexpressed in retinoblastoma detected by microarray and 
northern blot (Zhao et al., 2009). And finally reported as expressed in a 
QRT-PCR analysis where no significant difference of the expression of 
miR-373* was reported between melanoma cells and primary human 
melanocyte (Satzger et al., 2010). 
 
mir-429 is a member of the miR-200 family, together with miR-141, 
200a, 200b, and 200c, it has been suggested to prevent the transition of 
the normal stratified squamous epithelium to metaplastic columnar 
epithelium target ZEB1 and ZEB2 in order to maintain the oesophagus 
phenotype (Smith et al., 2011; Stratmann et al., 2011). It was reported as 
down-regulated in colon cell lines and tissues (Stratmann et al., 2011; Sun 
et al., 2011b; Zhang et al., 2011b). Its role was studied by overexpressing 
with a mimic miR-429 in colon cancer biopsy and cell viability was found to 
be decreased as well as cell attachment; both which were inversely 
proportional to the concentration of mimic miR, suggesting that miR429 
could play a role in cancer proliferation and progression. Also, 
downregulation of c-myc by a reporter assay targeting c-myc 3’UTR, gene 
responsible for cell cycle progression, apoptosis and cellular 
transformation (Sun et al., 2011b). Overexpression of miR-429 is 
suggested to be linked to cancer on cells expressing CD133 which is a 
well-known colorectal cancer biomarker (Zhang et al., 2011b). 
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Microarray data from colorectal adenocarcinoma samples linked a 
high rate in mortality with miR-185 overexpression despite cancer stage, 
gender and age of colorectal cancer Swedish patients. A correlation 
between the downreguation of miR-133b while miR-185 is up-regulated 
seemed to facilitate colorectal cancer progression (Akcakaya et al., 2011). 
miR-185’s role in cell proliferation in the colon cell line SW1116 mimicked 
RhoA/Cdc42 downregulation which could be translated into cancer 
survival due to a regulation of cell cycle and facilitating malignant cell 
apoptosis, reducing cancer progression (Liu et al., 2011b). Limited 
research on miRNA-185 in colorectal cancer suggested to be an 
oncogene and tumour suppressor, the expression of this miRNA on 
kidney, ovarian and breast cancer models associated miR-185 
downregulation with inhibition of cancer proliferation regulated by the a 
reduction of expression of a sine oculis homeobox, Six1, that acts as cell 
cycle regulator (Imam et al., 2010)  
 
A study of colorectal cancer samples from 58 Irish patients found 
that the expression of miR-10b is implicated in cancer progression after a 
QRT-PCR analysis related the increasing expression level of miR-10b to 
the depth of invasion progressing from Tumour (T)1 T1 to T4, where the 
most significant change was from stage T2 to T3 (Chang et al., 2011). In 
silico hypermethylated CpG sites were found upstream miR-10b which 
were then observed in a methylation array, linking this miRNA with 
epigenetic changes and reducing colony formation of cancer cells by 
targeting and downregulating MAPRE1 (Kim et al., 2011b). 
 
miR-106b is part of the miR-106b-25 oncogene cluster (Nishida et 
al., 2012) and it was the most studied miRNA at the time that the miRNA 
microarray in this present work was performed. Experiments on 
gastrointestinal samples are limited, but they include the microarray data 
from a large number of gastric cancer tissues from Germany comparing 
healthy against cancer tissues; miR-106b was overexpressed 9/10 times 
in patients where the cancer had invaded the lymph-nodes (Tchernitsa et 
al., 2010b); and there was a similar pattern in biopsies of colon cancer and 
 142 
its surrounding areas (Wang et al., 2010b). In neoplastic gastric cancer, 
the expression on human peripheral blood of miR-106b is up-regulated; 
and after resection of the cancerous tissue, miR-106b expression dropped 
(Tsujiura et al., 2010). Transfection of miR-106b into colon cell lines 
inactivates the Cyclin-dependent kinases (CDK) inhibitors, responsible for 
cell cycle activation (Cicenas and Valius, 2011) facilitating cancer 
progression (Kim et al., 2009b). 
 
There is no previous evidence of the gastrointestinal expression of 
miR-30b; it has been reported as differentially expressed in invasive 
urothelial carcinoma of the bladder detected by microarray; and its 
upregulation is associated with low survival when miR-30b together with 2 
other miRNAs are overexpressed (Wszolek et al., 2011). Targets of miR-
30b are CELSR3, GALNT1, GALNT7, SEMA3, and TWF (in melanoma 
cells), genes promoting immunosuppression and tumour progression and 
transmembrane modifications in favour of cancer progression (Gaziel-
Sovran et al., 2011); another oncogene role of miR-30b was found in 
medulloblastoma (Lu et al., 2009). However, it inhibits epithelial to 
mesenchymal transition in hepatocytes decreasing cell apoptosis and 
invasion by targeting TGF-β1 (Zhang et al., 2012).  
 
miR-203 promotes tumour suppression by targeting and degrading 
Akt2 mRNA on the human colon adenocarcinoma cell line HT29 with a 
p53 mutation but not with the wild type (Li et al., 2011). This is supported 
by a study on gastric or colorectal cancer as well as colonic cell lines in 
which the downregulation of this miRNA directly correlated with the tumour 
growth. (Chiang et al., 2011). 
 
miR-28-5p expression in colorectal samples was down-regulated 
on the tumorous samples after pairing 24 biopsies from normal and 
cancerous biopsies from Italian patients. Following the assessment of 
miR-28-5p expression, transfection of miR-28-5p in HCT116 and RKO 
human colorectal adenocarcinoma cell lines decreased cell proliferation 
due to a 2.2 (HCT116) and 1.8 (RKO) fold increase in the apoptosis 
promoter protein poly(adenosine diphosphate-ribose) polymerase 1. 
 143 
Controversially, miR-28-5p reduced cell invasion while its isoform miR-28-
3p had the opposite effect. This could be explained by the target genes of 
miR-28-5p being CCND1 and HOX83 with cell cycle and proliferation 
functions as opposed to the miR-28-3p target NM23-H1 having a 
metastatic role miR-28-3p target (Almeida et al., 2012). 
 
The abundantly expressed miR-22 was detected by northern blot 
in several tissues and recently its expression was assessed by QRT-PCR 
in HCT116, HCT116 p53 KO and HT29 colon cancer cell lines. HIF-1α 
was identified as a miR-22 target, its translation but not transcription being 
affected. The protein level of the hypoxia regulator HIF-1α changed 
inversely to miR22 expression (Yamakuchi et al., 2010; Yamakuchi et al., 
2011). Cell viability was reduced in HT-29 after miR-22 vector transfection, 
with a ~30% increased in apoptotic nucleis and a 95% decrease in cell 
survival (Zhang et al., 2011a). 
 
miR-532-5p had no references when the thesis was being written. 
 
The role of miR-184 in the gastrointestinal system has been 
suggested to be as a regulator of apoptosis and inhibitor of cancer 
proliferation under miR-494 overexpression according to studies on 
gastrointestinal stromal tumours (GIST) cells with a KIT mutation (Kim et 
al., 2011c) -a transmembrane protein inhibits apoptosis when mutated 
(Casar-Borota et al., 2012)- and a target of miR-494 verified by luciferase 
reporter assays. 
 
miR-494 transfection resulted in a decreased expression of KIT 
protein expression and a slightly lower effect on mRNA expression, 
suppression of cell proliferation and a 25% increase in apoptosis assessed 
by flow cytometry (Kim et al., 2011c).  
 
In 2011, miR-625 overexpression was found in human oocytes (Xu 
et al., 2011); more recently, the expression of miR-625 was identified in 
neoplastic and healthy pancreatic biopsies with overexpression in the 
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former detected by a PCR assay (Yu et al., 2012) but with no further 
correlation to the progression of the disease or functional analysis.  
 
From the initial bioinformatic analysis in which the targets from the 
13 Se-sensitive miRNAs were predicted by miRWalk and the networks 
identified by IPA function of these group of miRNAs could be elucidated. 
Some of these pathways such as the semaphorins were related to 
neuronal function; these are a membrane-associated secreted proteins 
associated with axon guidance and nervous system development 
(Pasterkamp, 2012). Semaphoring signalling mechanisms have been 
suggested to play important roles in neural injuries and diseases, and 
proposed to be able to regenerate central nervous system failure 
(Pasterkamp, 2012). Another function of the semaphorin system is the 
guidance of neuronal molecules. They may have a similar function in the 
immune system, (Schmidt and Rathjen, 2010) which they have been 
identified as being expressed in T and B cells, increasing antibody 
production and acting on macrophages to produce cytokines (Mizui et al., 
2009). A possible function of miRNA regulation of selenoproteins in human 
intestine might be linked to enhancement of the immune system observed 
under Se supplementation.  
 
Cardiac electrophysiology, adaptability and heart failure are 
determined by the cardiac β-adrenergic signalling, another pathway 
identified by IPA as being Se-sensitive. β-adrenergic receptors are also 
responsible for calcium transport and glycogen catabolism to generate 
strong cardiac contractions and provide glucose; when these systems fail, 
the cardiac muscle loses contractibility and congestive heart failure occurs 
(Saucerman and McCulloch 2006); Keshan disease is a well known 
cardiomyopathy observed under low Se intake; and more recently, an 
increased expression of calcium channels genes observed in Se 
deficiency has been reported to induce cardiomyocyte injury (Cui et al., 
2012). 
 
The identification of ERK/MAPK signalling pathway as being Se-
sensitive miRNA regulated suggests that miRNAs could also regulate 
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extracellular communication by activation of intracellular responses for an 
adequate biological response achieved due to extracellular signal-
reductase kinase (ERK) and mitogen-activated kinase (MAPK) balance in 
plasma and intracellular compartments (McKay and Morrison, 2007). 
 
Most pathways identified by IPA were related to cancer 
proliferation and invasiveness. This includes integrin signalling which has 
an identified role in cancer proliferation and invasiveness by cell cycle 
control. It is regulated by the expression of integrin adaptors the regulation 
of which is known to contribute to cancer development and metastasis 
(Cas proteins). In epithelial-rich tissues, tumour aggressiveness is 
modified by Crk proteins and, tumour progression by the IPP complex, 
expressed and tumour growth, cell-cell adhesion and cancer progression 
and invasiveness facilitated by the Cap family (p140CAP). Interestingly, 
high levels of p140CAP and NEDD9 lead to resistance to cancer 
therapy.(Cabodi et al., 2010). 
 
A crosstalk signalling model has been proposed (Gong et al., 
2010) between HMGB1 and cancer pathways since overexpression of 
HMGB1 protein is associated with cancer proliferation and activates 
pathways like MAPK and AKT (Gong et al., 2010) which were identified by 
the present analysis. HMGB1 overexpression is associated with tumour 
growth, inflammation and apoptosis regulators (Jia et al., 2013). HMGB1 
in Caco-2 cells might be regulated by the G1-S phase transition cell cycle 
regulator CyclinE rather than by p53. 
Aryl hydrocarbons activate metabolic and detoxification pathways, 
cellular proliferation and migration; and regulate immune and neuronal 
systems (Barouki et al., 2012).  
 
p53 is a crucial DNA damage response mediator (Reinhardt and 
Schumacher, 2012). Despite the fact that Caco-2 cells lack the p17 
chromosome where the p53 gene is located (Yu et al., 2010), DNA 
damage response pathways were predicted to be affected by the Se-
sensitive miRNAs. p53 regulates more than 2,500 tumorigenesis and 
tumour invasion genes (Mao et al., 2012). Loss of heterozygosity is the 
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main cause of TP53 impaired activity triggering cancer (Bellini et al., 
2012), a loss of p53 function has pro-apoptotic effects through 
mitochondria outer membrane permeabilization (Stegh, 2012), possibly by 
caspase 8 (Liu et al., 2011a).  
 
There is evidence for DNA damage response genes being targets 
of miRNAs; for example SFN2H and miR-99 family in MCF7 cells (Mueller 
et al., 2012) and p53 dependent upregulation of miR-192, miR-194, and 
miR-215 in U2OS, SJSA, HT29, and A549 cells In addition, p53 promoting 
pri-miRNA to pre-miRNA processing (Wan et al., 2011) has linked miRNAs 
and p53 signalling pathways.  
 
The pancreatic signalling pathways, predicted to be miRNA-
sensitive is also related to p53. This pathway affects the epithelial cell 
compartment and the stromal cell compartment (transforming growth 
factor-β), cell apoptosis triggered by inadequate DNA damage response 
(TP53) activation of cell cycle progression and apoptosis, high production 
of undifferentiated cells (McCleary-Wheeler et al., 2012). In addition, IPA 
identified glioblastoma multiform as another miRNA-sensitive pathway. 
This pathways is expressed in aggressive brain tumours characterized by 
vascular proliferation, tumour chemoresistance and cell death and with a 
general genomic instability that leads to a common mutation of the p53 
pathway, cancer cycle progression by inactivation of the pRB signalling 
pathway, cancer development by PTEN, proliferation, invasion and 
apoptosis by transcription target activation from plasma membrane to the 
nucleus via STAT protein complexes (Mao et al., 2012). 
 
Interestingly, another classification of the p53 and cardiac 
signalling pathways identified by IPA could also be as metabolic pathways; 
recently p53 has been suggested to regulate metabolic functions like 
oxidative stress and glucose and fatty acid metabolism by glycolysis, 
activation of ᵝ-oxidation or mitochondrial oxygen consumption (Zhang et 
al., 2010). Similarly, the cardiac hypertrophy signalling is regulated in the 
event of heart contractibility failure where phenotypic cardiomyocytes 
exhibit metabolic changes like utilization of free fatty acids which 
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decreases ATP availability in cardiomyopathy; in later stages of heart 
disease, this shifts back to glucose to produce energy. Another metabolic 
related change observed in the pathways analysis is Akt signalling, which 
responds to cardiac failure and helps maintain the homeostasis through 
protein synthesis, inhibition of apoptosis and metabolism also occurs in 
colon. An increased apoptosis and fibrosis is observed when the heart 
cannot adapt and activation of the apoptotic pathways, caspase activities, 
ᵦ-adrenergic, mitochondria cytochrome C occurs (Harvey and Leinwand, 
2011). This could then link the APMK signalling pathway normalising the 
energetic balance ATP generation and consumption, cell growth under low 
nutrient availability, as well as regulating glucose metabolism. It also 
triggers ULK-1 dependent mytophagy of defective mitochondria controlling 
mitochondrial homeostasis (Mihaylova and Shaw, 2011). 
 
Overall, it is possible that the p53, cardiac hypertrophy signalling 
Akt signalling pathway that are predicted to be targets of Se-sensitive 
miRNAs may have metabolic regulatory functions in Caco-2 cells. 
 
In summary, results from QRT-PCR thus validated the miRNA 
microarray data and so detection of the expression of miRNAs in Caco-2 
cells and more specifically, measurement of changes in expression under 
difference Se availability was accomplished. Finally, a newly developed 
algorithm was used as a guide towards prediction of effects of the miRNAs 
found to be Se regulated. The large number of gene targets predicted 
made possible the identification of several pathways using IPA, some of 
which include cancer signalling pathways and biological functions 
representative of other organs other than in the intestine. In order to find 
closer biological functions between these Se-sensitive miRNAs in Caco-2 
cells and since these findings of Se were identified based on studies in 
different experimental models or species, we reasoned that a role for Se 
regulated miRNAs may be identified more robustly by examining effects of 
Se on gene expression pathways in the same cell lines as used for the 
miRNA microarray analysis; thus the response of the Caco-2 cell 
transcriptome was determined by microarray analysis as described in 
Chapter 5. 
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Chapter 5 Transcriptomic array characterisation of 
selenium sensitive genes on Caco-2 cells 
 
5.1 Introduction 
 
Several microarray experiments to address gene expression 
changes after alterations in Se status have been done using samples from 
rats, humans and mice, from different tissues and with varying dose and 
time of exposure. Overall, the response of selenoproteins has been 
similar, but the response to downstream targets to Se supplementation 
has varied when organic or inorganic forms of Se were compared (Bosse 
et al., 2009; Liao et al., 2011). Because the available microarray data from 
Se supplementation do not match the conditions of the present study and 
in order to link the miRNA results with the mRNA, a transcriptomic 
experiment was performed with the same RNA as was used for the 
previous miRNA microarray experiment.  
 
In order to analyse the data generated by microarrays or other 
large sets of data, different approaches have be taken, for example the 
use of statistics and hypergeometric probabilities algorithms when the data 
to be compared have not been generated under the same conditions 
(Falcon and Gentleman, 2007) or the use of software that integrates 
molecules into networks for example Ingenuity Pathway Analysis from 
Ingenuity systems.  
 
In Chapter 4, 13 miRNAs were identified as altered by Se-supply 
using a miRNA microarray, and these changes were confirmed by QRT-
PCR. This chapter describes a global transcriptomic array experiment was 
carried out to investigate genes which shared expression changes under 
the same conditions under which the miRNAs were found earlier to show 
altered expression in Chapter 4 so a “match” between these two data sets 
could be done. 
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The expression at mRNA level of downstream targets of Se, as 
well as the expression of selenoproteins, after Se supplementation or Se 
deprivation has been investigated previously in several tissues and 
organisms. This was of particular importance because miRNA data are 
limited especially in gut cells. These studies have shown similarities and 
differences among the data sets. Nevertheless, these data were not 
suitable for the present study because the conditions of each experiment 
are different, such as tissue or cell line, organisms or gender in which the 
experiments have been conducted, time and dose of exposure/deficiency 
and finally the use of either organic or inorganic form of Se (or a 
combination of both). And since the study started from a group of targets 
from an experiment carried out under different circumstances to the one 
the miRNA microarray described in Chapter 4. Therefore to achieve the 
aim of finding a relationship between the miRNAs identified as being 
sensitive to Se supply and expressed mRNAs in Caco-2 cells, the same 
RNA was sent for a total transcriptomic experiment. 
 
Prior to the work described in this thesis, no published data were 
available describing whether miRNA expression changes in response to 
altered Se supply. However, during the course of this work, although 
nothing has been published on miRNA expression responses to Se in 
Caco-2 cells a few reports indicate possible relationships between Se or 
selenoproteins and expression of specific miRNA. The first study linking 
Se with miRNA expression was an investigation which showed that the 
expression of the miR34 and its isoforms in prostate cancer cells was 
sensitive to Se concentration in the culture medium (Sarveswaran et al., 
2010). Furthermore, due to previous evidence linking Se deficiency and 
bone disorders (Sun et al., 2011a), an investigation in patients suffering 
from Kashin-Beck disease showed that Se partially protected against 
chondrocyte cell death caused by T-2 toxin and also found changes in 
expression of a group of miRNAs that have been suggested to regulate 
differentiation targeting genes that encode fibril-forming collagen (Li et al., 
2008; Chen et al., 2011b). Another study of adipose tissue–derived stem 
cells (ATSCs) showed that silencing of miR-10b and miR-23b increased 
the mRNA expression of the selenoprotein SENP1, and in a 
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complementary way, after SENP1 knockdown, an upregulation of miR10b 
and miR323b was observed (Kim, Jung et al. 2011); the same study found 
that miR-10b and miR-23b knockdown reduced cell death (Kim et al., 
2011a). Finally, in human lung adenocarcinoma cells TRX1 expression 
was silenced by a specific miRNA resulting in cell toxicity, ROS 
production, and decreased in cell viability (Poerschke and Moos, 2011).  
 
Overall, the above studies indicate that selenoprotein gene 
expression can be regulated by miRNA and that changes in Se supply can 
alter miR expression. Work described in Chapter 4 and this chapter of this 
thesis has identified a number of miRNA for which expression is altered in 
Caco-2 cells by Se supply in the culture medium. The aim of the 
experiments described in the present chapter was to investigate the 
possible functional significance of the observed changes. To achieve this, 
the samples from which the 13 Se-sensitive miRNAs were identified were 
sent hybridized to a HumanRef-8 Expression Illumina BeadChip to 
investigate the transcripts sensitive to Se supply. I also carried out a two-
stage analysis. Initially, since data were also available describing those 
mRNA in Caco-2 sensitive to exactly the same changes in Se supply, a 
bioinformatic approach was used to link the two datasets by using the 
target prediction tools previously described (Chapter 2) to look for MRE in 
the Se-sensitive transcripts. Second, having identified miRNA that were 
predicted to have target sequences in Se-sensitive genes, effects of 
silencing one specific miRNA was investigated using anti-miR. Antisense 
and miRNA mimics are the used as means of understanding miRNA role 
in gene expression regulation, disease diagnosis and therapy (Gambari et 
al., 2011). 
 
The aims and objectives of this chapter are to identify the mRNAs 
changing upon 40.5nM sodium selenite supplementation on Caco-2 cells 
for 72 h, for which the same samples that triggered the upregulation of the 
13 Se-sensitive miRNAs described in Chapter 4 were sent for a total 
transcriptomic experiment in order investigate if there is a link between the 
Se-sensitive miRNAs and the Se-sensitive mRNAs through a target 
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prediction between the two data sets, to find candidate miRNA(s) and /or 
mRNA(s) for a functional analysis. 
 
A summary of the work carried out in this chapter is illustrated in 
Figure 43. 
 
 
Figure 43 Chapter 5 workflow 
RNA samples were sent for a total transcriptome experiment in order to identify changes 
in expression of mRNAs under the same conditions the Se-sensitive miRNAs were 
identified. 53 transcripts were differentially expressed after 72 h of 40.5 nM sodium 
selenite treatment. After similar levels of expression were obtained by QRT-PCR, a 
pathway analysis by IPA generated metabolic related pathways and mitochondrial 
respiration related toxicological lists. On the other hand, a miRNA target prediction 
analysis between the miRNA and the mRNA microarrays revealed matches between 
these two data sets; one of them was miR-185. After miR-185 knockdown, the levels of 
expression of two of its predicted targets (GPX2 and SEPHS2) changed. 
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5.2 Results 
 
5.2.1 Transcriptomic analysis of gene experiment on Caco-2 
cells 
 
As described in Chapter 4, RNA quality was assessed before 
samples were sent for total transcriptomic analysis. Only those samples of 
sufficient quality for hybridization and for which the Se supplementation 
had been proved to be effective by looking at the expression of GPX1 and 
SELW were analysed. The RNA was subjected to Service XS’ quality 
control assessment that is carried out as part of a regular procedure prior 
to sample hybridization to ensure reliable data is obtained. 
 
Aliquots of the RNA samples previously analysed by miRNA 
microarray were sent to Service XS. Prior to gene microarray analysis, and 
according to Service XS standard operation procedures, quality control 
was determined by Nanodrop ND100 spectrophotometry and capillarity 
electrophoresis on the Agilent Bioanalyzer. Hybridization was carried out 
as previously described using a Human genome V2 Agilent chip in 
Chapter 2 section 2.2.16 microarray hybridization. 
 
BeadChips were scanned using the Illumina iScan array scanner, 
where the fluorescent signal intensity from the single stranded fluor 
excited products of the beads was located and quantified from TIFF files 
corresponding to each assay in order to obtain a raw signal from a high 
resolution image which were then normalized with no background 
adjustment using Illuminas’s Genomestudio v.2010.1 software. Internal 
controls (spiked-in controls and sample dependent controls) complied with 
specifications, gene signals were strong enough and all highly expressed 
genes were present and therefore signal generation was considered 
“passed” for analysis. 
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Data exported from Illumina Bead Studio in a GeneSpring 
compatible format was loaded into GeneSpring GX 11 for analysis and 
analysed using the Illumina.SingleColor.HumanRef-
8_V3_0_R1_11282963_A technology annotation package. Expression 
values below 1 were thresholded to 1.0 on import and transformed to log 
base 2 prior to analysis. Quantile normalisation was applied across the 
samples with a baseline transformation to the median of all samples. To 
support flag based filtering, detection p-values <0.6 were marked as 
'absent' and p-values >0.8 marked as 'present'. Detection p-values >0.6 
but <0.8 were marked as 'marginal'. 
 
Of 23206 entities, 13670 remained after filtering on flags so that 
100% of the samples in any given group (treated or untreated) had 
'present' or 'marginal' flags associated with each probe. Hierarchical 
clustering was used to assess the similarity of samples using a Euclidian 
distance metric with a centroid linkage rule. Samples from cells 
supplemented with selenium clustered as a separate group to those 
without selenium supplementation. 
 
Differential gene expression analysis was performed using t-tests 
in GeneSpring (Benjamini-Hochberg FDR multiple testing correction 
applied) where probes had a corrected p-value of <0.05 and 
supplemented with RankProducts analysis using the RankProd package in 
BioConductor (probes with a pfp<0.05). 
 
A cut-off of 1.0 was decided in order to obtain all the entities that 
changed under Se supplementation/ deprivation and because a 
bioinformatic pathway analysis was planned with gene lists; a higher 
number of genes for pathway analysis on IPA is preferred. This resulted in 
a quality controlled probe list of 53 significantly differentially expressed 
entities as shown in Table 8. 
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Symbol Entrez Gene Name Accession 
Fold 
change 
Regulation 
(Se+ vs Se-) 
GPX1 Glutathione peroxidase 1 NM_201397.1 3.321 ↑ 
SELW1 Selenoprotein W, 1 NM_003009.2 2.651 ↑ 
MT1E Metallothionein 1E NM_175617.3 1.823 ↑ 
MT1G Metallothionein 1G NM_005950.1 1.804 ↑ 
MT1F Metallothionein 1F NM_005949.2 1.777 ↑ 
GPX3 Glutathione peroxidase 3  NM_002084.3 1.716 ↑ 
SELN1 Selenoprotein N, 1 NM_206926.1 1.58 ↑ 
MT1X Metallothionein 1X NM_005952.2 1.527 ↑ 
MT1A Metallothionein 1A NM_005946.2 1.522 ↑ 
MT1H Metallothionein 1H NM_005951.2 1.509 ↑ 
LOC728643  NR_003277.1 1.428 ↑ 
SEPHS2 
Selenophosphate 
synthetase 2 
NM_012248.2 1.392 ↓ 
CMIP c-Maf-inducing protein NM_030629.1 1.378 ↑ 
GPX2 
Glutathione peroxidase 2 
(gastrointestinal) 
NM_002083.2 1.375 ↓ 
PIR 
Pirin (iron-binding nuclear 
protein) 
NM_001018109.
1 
1.37 ↓ 
MT2A Metallothionein 2A NM_005953.2 1.357 ↑ 
FABP7 
Fatty acid binding protein 
7, brain 
NM_001446.3 1.324 ↑ 
CGB5 
Chorionic gonadotropin, 
beta polypeptide 5 
NM_033043.1 1.323 ↑ 
DCUN1D4 
DCN1, defective in cullin 
neddylation 1, domain 
containing 4  
NM_015115.1 1.306 ↓ 
EPHX2 
Epoxide hydrolase 2, 
cytoplasmic 
NM_001979.4 1.305 ↑ 
ME1 
Malic enzyme 1, 
NADP(+)-dependent, 
cytosolic 
NM_002395.3 1.301 ↓ 
PIR 
Pirin (iron-binding nuclear 
protein) 
NM_001018109.
1 
1.298 ↓ 
C7ORF59 
Chromosome 7 open 
reading frame 59 
NM_001008395.
2 
1.294 ↑ 
CD63 CD63 molecule 
NM_001040034.
1 
1.292 ↑ 
HTATIP2 
HIV-1 Tat interactive 
protein 2, 30kDa 
NM_006410.3 1.286 ↓ 
IFI6 
Interferon, alpha-
inducible protein 6 
NM_022872.2 1.284 ↑ 
ORM1 Orosomucoid 1 NM_000607.1 1.283 ↑ 
GNG10 
Guanine nucleotide 
binding protein (G 
protein), gamma 10 
NM_001017998.
2 
1.282 ↑ 
KLF5 
Kruppel-like factor 5 
(intestinal) 
NM_001730.3 1.28 ↓ 
GCNT3 
Glucosaminyl (N-acetyl) 
transferase 3, mucin type 
NM_004751.1 1.276 ↓ 
HAND1 
Heart and neural crest 
derivatives expressed 1 
NM_004821.1 1.272 ↑ 
C6ORF192 
Chromosome 6 open 
reading frame 192 
NM_002483.3 1.27 ↓ 
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Symbol Entrez Gene Name Accession 
Fold 
change 
Regulation 
(Se+ vs Se-) 
CEACAM6 
Carcinoembryonic 
antigen-related cell 
adhesion molecule 6 
(non-specific cross 
reacting antigen) 
NM_052831.2 1.27 ↓ 
SELK Selenoprotein K NM_021237.3 1.269 ↑ 
GPX4 
Glutathione peroxidase 4 
(phospholipid 
hydroperoxidase) 
NM_001039847.
1 
1.255 ↑ 
GGH 
Gamma-glutamyl 
hydrolase (conjugase, 
folylpolygammaglutamyl 
hydrolase) 
NM_003878.1 1.25 ↓ 
GAB2 
GRB2-associated binding 
protein 2 
NM_080491.1 1.245 ↑ 
LAMB1 Laminin, beta 1 NM_002291.1 1.245 ↓ 
ATP6V1B1 
ATPase, H+ transporting, 
lysosomal 56/58kDa, V1 
subunit B1 
NM_001692.3 1.242 ↑ 
FGG Fibrinogen gamma chain NM_000509.4 1.239 ↑ 
OIP5 Opa interacting protein 5 NM_007280.1 1.235 ↓ 
IFITM3 
Interferon induced 
transmembrane protein 3 
(1-8U) 
NM_021034.2 1.227 ↑ 
CACYBP Calcyclin binding protein NM_014412.2 1.225 ↑ 
SULT1A1 
Sulfotransferase family, 
cytosolic, 1A, phenol-
preferring, member 1 
NM_177530.1 1.22 ↑ 
OSTC 
Oligosaccharyltransferas
e complex subunit 
NM_021227.2 1.217 ↓ 
SLC1A3 
Solute carrier family 1 
(glial high affinity 
glutamate transporter), 
member 3 
NM_004172.3 1.217 ↓ 
IFITM2 
Interferon induced 
transmembrane protein 2 
(1-8D) 
NM_006435.2 1.211 ↑ 
LY6E 
Lymphocyte antigen 6 
complex, locus E 
NM_002346.1 1.208 ↑ 
ATP1B3  XM_001133534.1 1.205 ↓ 
GPT2 
Glutamic pyruvate 
transaminase (alanine 
aminotransferase) 2 
NM_133443.1 1.204 ↓ 
PAGE4 
P antigen family, member 
4 (prostate associated) 
NM_007003.2 1.197 ↑ 
GSDMB Gasdermin B NM_018530.2 1.179 ↑ 
MAT2B 
Methionine 
adenosyltransferase II, ᵝ 
NM_013283.3 1.135 ↑ 
Table 8 Differentially expressed genes in Caco-2 cells grown under Se 
supplemented/depleted conditions.  
List of genes differentially expressed from RNA extracted from Caco-2 cells grown in Se 
supplemented/depleted media. Transcriptomic experiment was carried out using Illumina 
HumanRef-8 v.3 Expression BeadChip as platform. Expression values and normalization 
were obtained using GeneSpring with a cut-off of 1.0 to investigate change in expression. 
The mRNA levels of selenoproteins GPX1, SELW, GPX3, SEPN1, SELK, and GPX4 
were up-regulated under Se supplementation conditions; whereas SEPHS2 and GPX2 
were down-regulated under the same conditions. 
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Selenoproteins GPX1, SELW, GPX3, SEPN1, SELK, and GPX4 
were up-regulated when cells were cultured under Se supplemented 
conditions, across species and tissues.  
 
The most affected selenoproteins were GPX1 and SELW. This is 
consistent with the hierarchy for selenoprotein protection against Se 
deficiency (Crane et al., 2009; McCann and Ames, 2011), these are low 
hierarchy selenoproteins and therefore more susceptible to changes in 
dietary Se (Bellinger et al., 2009; Kasaikina et al., 2011b). 
 
5.2.2 Bioinformatic analysis of network building on selenium 
sensitive genes 
 
The 53 Se sensitive genes were analysed by IPA both to identify 
the major altered pathways and to provide a graphic representation of 
gene-gene interactions and a representation of regulatory processes 
within the cell that could identify the roles of the up or down regulated 
genes changed upon Se supplementation. IPA aims to group a large 
number of molecules and compares the number of molecules within our 
experiment in relationship to a specific pathway to calculate the threshold 
and test the statistical significance. However, pathway analysis with the 
short list of 53 genes resulted in the identification of a small number of 
networks with a score above the threshold.  
 
Canonical pathways identified as Se-sensitive were arachidonic 
acid metabolism, glutathione metabolism, and selenoamino acid 
metabolism. The P value is calculated according to Fisher’s exact test to 
associate the number of genes that could be associated to that network by 
chance Figure 44; the generated networks are ranked according to their 
significance.  
Toxicity list analysis in IPA identified oxidative stress, positive 
acute phase response proteins, and decrease respiration of mitochondria 
as being Se-sensitive pathways (Figure 45). 
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As described in Chapter 4, a graph showing the most significant 
canonical pathways (Figure 44) and toxicity lists (Figure 45) of the 
microarray and a table showing the p-value and ratios as a measurement 
of the significance of the association between the data set and the 
canonical pathways (Table 9) or toxicology lists (Table 10Table 10 p-value 
and ratio from toxicity list from IPA on the Se-sensitive genes from Figure 
45.). 
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Figure 44 Canonical pathways from IPA on the Se-sensitive genes. 
Dataset of canonical pathways from IPA using 53 Se sensitive genes identified by 
microarray from Caco-2 cells. This figure shows a histogram ordered according to the p-
value which is calculated by dividing the number of genes from the differentially 
expressed genes from Caco-2 cells grown under Se depleted/supplemented conditions 
listed on Table 8 by the number of genes that forms each pathway. The ratio of Se-
sensitive genes/genes from a pathway represented by the orange line that connects one 
rectangle with another. Ratios above the threshold line are significant pathways for the set 
of genes analysed in IPA. 
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Figure 45 Toxicity list from IPA on the Se-sensitive genes. 
Ingenuity Pathway Analysis showing the mechanisms of toxicity from the 53 Se sensitive 
genes after Se supplemented/ depleted treatment in Caco-2 cells. The toxicity list 
histogram, follows the same rules as the Canonical Pathways on Figure 44, the p-value 
is used to rank the order of the pathways and the orange line that connects the orange 
rectangles is calculated by dividing the number of genes from the differentially expressed 
genes from Caco-2 cells cultured under Se depleted/supplemented conditions listed on 
Table 8 by the number of genes that forms each pathway. 
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Pathway 
 
p-value 
 
Ratio 
Arachidonic Acid Metabolism 3.6E-06 5/54 (0.093) 
Glutathione Metabolism 1.59E-05 4/35 (0.114) 
Selenoamino Acid Metabolism 7.28E-03 2/29 (0.069) 
Sulfur Metabolism 4.37E-02 1/10 (0.1) 
Folate Biosynthesis 4.37E-02 1/10 (0.1) 
Table 9 p-values and ratios of the top 5 canonical pathways from IPA on the Se-
sensitive genes from Figure 44. 
 
 
 
Toxicity list 
 
p-value 
 
Ratio 
Oxidative Stress 5.24E-07 5/37 (0.135) 
Cardiac Fibrosis 2.82E-02 2/59 (0.034) 
Decreases Respiration of Mitochondria 3.51E-02 1/8 (0.125) 
CAR/RXR Activation 6.91E-02 1/16 (0.062) 
Liver Necrosis/Cell Death 8.87E-02 2/112 (0.018) 
Table 10 p-value and ratio from toxicity list from IPA on the Se-sensitive genes 
from Figure 45. 
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5.2.3 Microarray validation by QRT-PCR  
 
For verification of the microarray data, 8 genes were chosen to be 
amplified by QRT-PCR. PCR primers used for this purpose were designed 
using the accession numbers of the genes of interest and NCBI 
sequences. NCBI BLAST software was used to ensure specificity.  
 
RNA from 6 samples (3 Se depleted and 3 Se supplemented) in 3 
biological replicates was isolated and reverse transcribed as previously 
described in chapter 2. 
 
Because SYBR Green from Roche was used as the fluorescent 
dye, quality control of the amplification primers was carried out by of 
measuring melting temperature of each sample. For each set of primers, a 
melting temperature analysis was done and they all displayed one peak at 
the melting peak chart which shows that the fluorescent signal read by the 
LightCycler originated from only one amplified product.  
 
A summary of the efficiency, error and slope for every gene 
amplified with SYBR green on the Light cycler is shown on Table 11. In 
Appendix B, the standard curve their slope, amplification curves as well as 
the melting temperature analysis as means of quality control assessment 
for QRT-PCR (Bustin et al., 2009) analysis from LightCycler480 Software 
Version 1.5 are displayed for the genes used for microarray confirmation 
by QRT-PCR. As shown in Table 11 the genes of interest had an error of 
less than 0.1 which is less than the minimum required according to the 
LightCycler 480 Operator’s manual for Software Version 1.5. In addition, 
the efficiency coefficient was close to 2, a good indicator that the 
amplification efficiency is close to 100%. 
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Gene of interest 
 
Error 
 
Efficiency 
ACBT 0.0345 2.057 
GAPDH 0.0418 1.972 
GPX1 0.0192 1.953 
GPX2 0.0305 2.002 
GPX3 0.0416 1.968 
SELK 0.0366 1.968 
SEPHS2 0.0385 1.965 
PIR 0.0992 1.763 
Table 11 Summary of QRT-PCR amplification conditions for the Standard curves of 
each of the amplified genes by QRT-PCR using SYBR green as a fluorescent dye 
and Light Cycler as PCR system. 
PCR efficiency was assessed by the LightCycler480 software using serial dilutions of 10 
from a concentrated PCR product. QRT-PCR should be carried out conditions that give 
an efficiency close to 2 and a minimal error (<0.2). These criteria were achieved for all 
transcripts. 
 
 
The expression of the six selected target genes normalized either 
to the expression of either ACBT or GAPDH is shown in Figure 46 and 
Figure 47. Using either reference gene, expression of GPX1, GPX3, and 
SELK are found to be increased in Se supplemented cells compared to 
cells from Se deficient medium, whereas expression of SEPHS2, and PIR 
were decreased. Relative expression of the targets showed similar change 
to those observed in the transcriptomic experiment although the difference 
in expression of SELK and PIR between the Se treatments was not 
statistically significant, but showed a similar trend to the microarray data. 
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Figure 46 Expression of selected target genes by QRT-PCR using normalization to 
ACBT. 
GPX1, GPX3, SEPHS2, SELK, and PIR primers were designed and specificity was 
assessed empirically by melting curve analysis in which a single melting peak was 
produced. Efficiency for each gene was close to 2 and error was <0.2. Cp values were 
extracted from the LightCycler and data was normalized to ACBT. GPX1, GPX3, and 
SELK were found to be up-regulated in cells grown under Se sufficient media, whereas 
SEPHS2 and PIR were down-regulated in cells cultured under the same conditions.  
*** 
*** 
*** 
NS 
NS 
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5.2.1 Bioinformatic association of microarray results 
 
To assess potential MRE within the Se-sensitive genes identified 
in the transcriptomic experiment (Chapter 5), the target prediction tools 
previously described (Chapter 2) were used. Because miRNA-mRNA 
cleavage occurs not only within the 3’ or 5’UTR but also in the ORF, no 
restrictions on the MRE localization were made when this was allowed by 
the database (e.g. microCosm and miRWalk). When using databases such 
as GenSet2miRNA the search of the mRNA sequence was within the 
3’UTR. Thus, essentially the search for MRE in the Se sensitive genes 
Figure 47 Assessment of relative expression of genes normalized to GAPDH for 
microarray confirmation expressed as percentage. 
GPX1, GPX3, SEPHS2, SELK, and PIR primers were designed and specificity was 
assessed empirically by melting curve analysis in which a single melting peak was 
produced. Efficiency for each gene was close to 2 and error was <0.2. Cp values were 
extracted from the LightCycler and data was normalized to ACBT. GPX1, GPX3, and 
SELK were found to be up-regulated in cells grown under Se sufficient media, whereas 
SEPHS2 and PIR were down-regulated in cells cultured under the same conditions. 
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was carried out as described in Chapter 2 but without restriction of the 
regions of the nucleotide sequences. Briefly each HUGO ID 
(microRNA.org and microCosm) or group of HUGO IDs (miRWalk and 
GeneSet2miRNA) of the genes were loaded into the bioinformatics tools, 
in this case, the default setting were changed in order to allow the scan of 
the gene throughout the entire sequence; thermodynamics, seed region 
and orthology parameters were the same as for the rest of the 
bioinformatics predictions described in this thesis. However, during the 
course of this study, because some of the bioinformatics tools were 
upgraded (microRNA.org and GeneSet2miRNA) some parameters were 
modified. The miRNA target genes identified are listed in Table 12 as well 
as the bioinformatics tool which predicted them. As shown in Table 12 
miR-185, miR-625, miR429, miR373*, miR22, miR-532-5p, miR106b, and 
miR-30b were predicted to recognise target sequences in mRNAs showing 
differential expression in Caco-2 cells following altered Se supply. Thus, of 
the 13 Se-sensitive miRNA identified by miRNA-microarray analysis 
(Chapter 4), 8 were predicted to have targets in Se-sensitive mRNAs. 
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miRNA 
 
miRNA target 
 
Bioinformatic tool 
hsa-miR-185 
GPX3 
miRWalk  
microRNA.org 
microCosm 
GPX2 microRNA.org 
SEPHS2 microRNA.org 
hsa-miR-625 
ME1 
CACYBP 
miRWalk 
GeneSet2miRNA 
ATP6V1B1 
CMIP 
miRWalk 
GPX1 microCosm 
hsa-miR-429 SELK 
miRWalk 
microRNA.org 
hsa-miR-373* 
HTATIP2 
GPT2 
miRWalk 
hsa-miR-22 GTP2 miRWalk 
hsa-miR-532-5p EPHX2 miRWalk 
hsa-miR-106b 
GPX2 microCosm 
MT1F microRNA.org 
hsa-miR-30b GPX3 microCosm 
Table 12 Bioinformatic correlation of Se sensitive miRNA-mRNA interaction.  
MRE from the Se sensitive genes identified in Chapter 4 were matched with the 
miRNAs from Chapter 4 by microRNA.org, miRWalk, microCosm and 
GeneSet2miRNA.  
 
 
 
Prior to my work, only limited research had been published about 
any of these miRNAs. The most studied miRNA was miR-106b although 
there are few data available in gastrointestinal models and more 
specifically, colorectal models. This miRNA has been identified as an 
oncogene with the potential to develop metastasis (Tchernitsa et al., 
2010a; Wang et al., 2010b; Nishida et al., 2012). With regards to the rest 
of the Se-sensitive miRNA function in the colon, had been proposed to 
have a role in miR-10b with cancer progression (Chang et al., 2011), but 
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the opposite effect was reported in human gastric cancer cells(Kim et al., 
2011b; Kim et al., 2011c). miR-373* has been found to be expressed in 
bone marrow (Ju et al., 2009), melanoma cells, primary human 
melanocyte (Satzger et al., 2010) and retinoblastoma (Zhao et al., 2009). 
So far, some Se-sensitive miRNAs have been only been found to be 
tumour suppressors on colorectal tissues or cell lines when they are up-
regulated; this is the case of miR-429 (Sun et al., 2011b) miR-203 (Chiang 
et al., 2011; Li et al., 2011), and miR-28-5p which has been reported to 
reduce invasion of tumour cells (Almeida et al., 2012). miR-22 
overexpression by transfection (Zhang et al., 2011a) and miR-494 
upregulation (Kim et al., 2011c) have been categorized as oncogenes. 
 
Neither miR-30b nor miR-625 have been studied in the 
gastrointestinal epithelium and there is no evidence for expression miR-
532-5p at all. However, miR-30 expression has been reported as an 
oncogene in bladder carcinoma (Gaziel-Sovran et al., 2011; Wszolek et 
al., 2011) and medulloblastoma (Lu et al., 2009), and controversially it 
suppresses of tumour progression in hepatocytes (Zhang et al., 2012). 
miR-625 is overexpressed human oocytes (Xu et al., 2011) and pancreatic 
biopsies (Yu et al., 2012) but no further hypothesis of its function has been 
proposed. 
 
miR-185 has been found to be expressed in colorectal 
adenocarcinoma samples (Akcakaya et al., 2011). In addition mi185 has 
been suggested to have a pro-apoptotic effect on cancer cells, and a 
tumour suppressor effect (Liu et al., 2011b), although oncogenic effects 
have been reported in kidney, ovarian and breast tumours (Imam et al., 
2010).  
 
In the literature, only a few targets had previously been identified 
for the Se-sensitive miRNAs: miR-30b targets in melanoma cells are 
CELSR3, GALNT1, GALNT7, SEMA3, and TWF (Gaziel-Sovran et al., 
2011); HIF-1α was identified as a miR-22 target (Yamakuchi et al., 2011); 
finally, Six1, a tumour progression regulator, was indicated to be a target 
for miR-185 in kidney, breast, and ovaries (Imam et al., 2010). As shown 
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in Table 12, bioinformatic analysis with microRNA.org, MicroCosm, 
miRWalk and GeneSet2miRNA identified MRE for miR-185, miR-625, 
miR429, miR373*, miR22, miR-532-5p, miR106b and miR-30b within Se-
sensitive mRNAs GPX1, GPX2, GPX3, SEPHS2, ME1, CACYBP, 
ATP6V1B1, CMIP, SELK, HTATIP2, GPT2, EPHX2 and MT1F. According 
to the network analysis from Chapter 5, GPX1, 2, 3, and SEPHS2 which is 
necessary for the synthesis of selenophosphate synthase, were part of the 
Glutathione metabolism pathway. 
 
miR-185 was chosen as the focus for subsequent functional 
analysis using anti-miR silencing. This choice was based on its previously 
reported expression in colorectal tissue (Akcakaya et al., 2011; Liu et al., 
2011b) and the prediction that it has MRE targets in the three 
selenoprotein mRNAs GPX2, GPX3 and SEPHS2. In addition to miRNA 
target prediction, the SECIS element was also predicted in the above 
mentioned selenoproteins sequences using SECISearch 2.19 (Kryukov et 
al., 2003). Table 13 shows the MRE start sites of miR-185 and 
complementary information showing where SECIS element is predicted. 
For GPX3 and SEPHS2, two miR-185 recognition elements were 
predicted, whereas GPX2 had only one; one of these predictions was of 
particular interest since SEPHS2 MRE for miR-185 started at the 
nucleotide 570, which is within the predicted SECIS element (550-647). 
Since Se supplementation led to increased expression of miR-185, the 
aim of the miR silencing experiments was to investigate if knock-down of 
miR-185 under Se supplementation conditions led to an effect on its 
predicted targets similar to at observed during Se depletion. 
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miR-185 target 
 
MRE start 
 
SECIS 
 
Bioinformatic tool 
GPX2 145 861-955 microRNA.org 
GPX3 
314 
1533-1625 
microCosm 
microRNA.org 
1234 miRWalk 
SEPHS2 
570 
550-647 
microRNA.org 
2112 miRWalk 
Table 13 miR-185 predicted MRE in the selenoproteins genes.  
Targets for miR-185 were identified by microRNA.org, microcosm, and miRWalk 
bioinformatics tools. SECIS site was identified using SECISearch 2.19 on GPX2, 
GPX3 and SEPSH2 sequences, and then related to the MRE with miR-185 cleavage 
site. 
 
5.2.1 Expression of mRNAs identified as miR-185 targets in 
silico 
 
The bioinformatic analysis described in section 5.2.1 indicated that 
the transcripts for, GPX3 GPX2 and SEPHS2 had MRE for miR-185. 
Having determined conditions for miR-185 silencing, RNA from cells that 
had been treated with the anti-miR-for 48 was reverse transcribed and the 
level of expression of miR-185 targets assessed by QRT-QPCR. After 48h 
treatment with the ant-miR, the expression of the potential miR-185 targets 
GPX2 and SEPHS2 was significantly increased by approximately 60% 
(Figure 48) compared with negative control; in contrast there was no 
significant effect on GPX3 expression. 
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Figure 48 mRNA levels of miR-185 target genes after 48h of anti-miR 
exposure. 
Cells Se-supplemented for 72h and transfection was performed 24h after planted 
with 70nM of anti-miR185. The expression of the miR-185 was assessed by QRT-
PCR and normalized to GAPDH. The expression of GPX3 and SEPHS2 changed 
significantly at 48h of anti-miR185 exposure; the effects on GPX2 were no 
significant. 
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5.3 Discussion 
 
This chapter describes a microarray analysis on the same RNA 
from Caco-2 cells analysed for miRNA. None of the transcripts from the 
PBP that were used for the bioinfomatic analysis to predict miRNAs 
described in chapter 3, were found to form altered expression. Despite the 
fact that the PBP was previously identified in two tissues from different 
organisms, changes in gene expression can be triggered differently. 
 
The expression at mRNA level of downstream targets of Se as 
well as the expression of selenoproteins after Se supplementation or Se 
deprivation has been investigated previously in several tissues and 
organisms finding similarities and differences among the data sets. When 
comparing these data, we have to take into account the fact that the 
conditions of each experiment are different such as; tissue or cell line 
organisms and gender in which the experiments have been conducted, 
time and dose of exposure/deficiency and finally the use of either organic 
or inorganic form of Se (or a combination of both). 
 
In this chapter, pathway analysis shows a significant effect on the 
arachidonic acid pathway (Figure 44). Previously it has been suggested 
that the overall effect of Se supplementation on the arachidonic acid 
metabolism is the decreased oxidation of arachidonic acid in 15-HpETE, a 
lipo hydroperoxidase activity metabolite. (Rock and Moos, 2010); from the 
list of Se sensitive genes listed in Table 8. GPX1, GPX2, GPX3, GPX4 
and EPXH2 were part of the inflammatory pathway and arachidonic acid 
metabolism pathway according to IPA. However, inhibition of Trx in the 
human umbilical vein cell line, EA.hy926, released arachidonic acid 
inducing cell toxicity (Crane et al., 2009); this effect was also found in 
normal subcutaneous areolar and adipose mouse tissue L929 (Kurosawa 
et al., 2009). The enrichment of a selenoprotein, SELP, as well as Se 
supplementation of human embryonic kidney cells (HEK-293) prevented 
oxidation of arachidonic acid metabolism by reducing lipid 
hydroperoxidases (Rock and Moos, 2010). Another gene from IPA’s 
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arachidonic acid metabolism list, EPHX2, which encodes for the enzyme 
soluble epoxide hydrolase, was identified as one of the 36 genes of 
arachidonic acid metabolism from a bioinformatics analysis on prostate 
cancer databases and up-regulated in prostate cancer samples, its 
function is to degrade the epoxides formed from the arachidonic acid 
metabolism (Vainio et al., 2011; Morisseau et al., 2012). 
 
The production of γ-glutamylcysteine from cysteine and glutamate 
by glutamate cysteine ligase is the first step in glutathione metabolism; 
after the addition of a glycine by glutathione synthetase, γ-
glutamylcysteinylglycine is formed and transported outside the cell and 
can act as an extra source of cysteine for the cells (Forman et al., 2009). 
The function of glutathione peroxidases is as a redox regulator but activity 
of glutamate cysteine ligase and glutathione synthetase also determine 
the levels of GPX (Bentley et al., 2008). Nevertheless, IPA listed GPX1, 
GPX2, GPX 3, and GPX 4 on the glutathione metabolism pathway. 
 
Selenophosphate synthetase 2 (SEPHS2) and Methionine 
adenosyltransferase II β (MAT2B) were identified by IPA as part of the 
Selenoamino Acid Metabolism pathway. SEPHS2 is directly involved in Se 
incorporation to selenoproteins through selenophosphate synthesis from 
selenide prior to Sec- tRNASec formation and Sec incorporation facilitated 
by the SECIS element in the 3’UTR of the selenoprotein mRNA. Also 
SEPHS2 contains a C-terminal binding domain that might promote 
ribosome binding (Caban and Copeland, 2012). On the other hand, 
MAT2B, a methionine adenosyltransferase, forma a heterodimer with 
MAT2A forming a complex that catalyses the synthesis of the enzyme S-
adenosyl methionine (Nordgren et al., 2011). A phylogenetic study of 
bacterial DNA for S-adenosyl methionine domain containing proteins 
found a sequence alignment of such proteins with the SECIS element. In 
one of them, the domain of S-adenosyl methionine interacts with the C-
terminal aligned to the stop codon of the S-adenosyl methionine protein 
family, containing a Cys-rich motif that could potentially regulate SBP2 and 
selenoprotein incorporation (Haft and Basu, 2011). MAT2B silencing in 
human hepatocytes led to apoptosis and MAT2B was found to be 
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overexpressed in cancer cells (Wang et al., 2008). The PBP identified on 
mouse colon (Kipp et al., 2009) and human lymphocytes (Pagmantidis et 
al., 2008) was not differentially expressed in the present study except for 
LAMB1, this is differentially expressed in the human lymphocyte and 
codes for lamin beta 1, with a -1.24 fold change and its overexpression is 
linked with the pathogenesis of epilepsy (Wu et al., 2008; Wu et al., 
2011b). 
 
IPA toxicology pathways identified oxidative stress and the 
mitochondrial respiratory pathway as being sensitive to Se supply. 
Mitochondrial dysfunction and oxidative stress were listed as 3 different 
toxicology pathways; they are linked by reactive oxygen species (ROS). 
Se has previously being suggested to have has protective effect on 
mitochondrial function (Tirosh et al., 2007; Wojewoda et al., 2012) and 
antioxidant effects through selenoproteins. Production of ROS, oxidizing 
agents that interact with and modify cellular macromolecules, is triggered 
by exogenous and endogenous mechanisms as part normal cell 
physiology where the aim is homeostasis. Nevertheless, ROS production 
can be pathological if the cell is unable to remove these damaging 
molecules, resulting in oxidative stress (Lenaz, 2012). The mitochondria 
respiratory chain is an endogenous mechanism of ROS production, 
complexes I and III producing the most oxidising molecules. Since 
glutathione reduces hydrogen peroxide and other radicals, the ROS 
concentration is glutathione dependent. GPX4 exists as a mitochondrial 
isoform and knockdown of GPX4 expression lead to increase to 
mitochondrial ROS production (Cole-Ezea et al., 2012). TrxR also helps 
ROS balance (Lenaz, 2012) with which GPX 1, GPX2 GPX3 and GPX4 
interact in the oxidative stress pathway from the toxicity list. A group of 
oxidative stress protectors (Vainio et al., 2011) metallothions (MT1E, 
MT1G, MT1F, MT1X, MT1A, and MT1H), which were up-regulated upon 
Se treatment, function like glutathione peroxidases; e.g. on cells with 
insulin sensitivity, metallothioneins act as antioxidant enzymes protecting 
cells from insulin damage (Park et al., 2011); they have also been 
suggested to protect colorectal cancer progression caused by oxidative 
damage (Hamouda et al., 2011). Metallothionein 1F (MT1F) was a 
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component of the Mitochondria respiration pathway. Evidence of oxidative 
stress protection by SELP has been observed in HEK-293 cells, where 
SELP enrichment and Se supplementation protected from oxidative stress, 
although the effect was lower than the observed for GPX4 (Rock and 
Moos, 2010). 
 
Even though Fibrinogen Gamma Chain (FFG) expression was up-
regulated by of 1.24, this gene was part of several canonical and 
toxicological pathways, like extrinsic prothrombotic activation pathway, 
coagulation system, and acute response signalling from the former; and 
positive acute response proteins for the latter. The only study of Se and 
fibrinogen levels is the cohort study Coronary Artery Risk Development in 
Young Adults, in which Se assessment in toenail from 18-30 year old 
healthy participants found no statistical difference between inflammation 
biomarkers and the levels of Se in toenails (Xun et al., 2010). 
 
The gene expression responses observed in microarray data from 
various tissues and cell lines to Se compounds show differences. For 
example when supplementing a cell model for studying wound healing 
because of their improper regeneration, keloid fibroblasts, COL15A1, 
COL5A3, COL3A1, COL1A1, COL6A3 and FLRT3 showed significant 
downregulation (De Felice et al., 2011); in the human thyroid cancer cell 
line FRO, a group of genes, mostly growth factors (GADD153, GADD34, 
EGFR, SGSH, SQSTM1, CAL2, PRKCH, DUSP5, GSK3B, IGF2R, and 
TRAF1) was up-regulated, while most of the down-regulated genes 
corresponded to splicing factors (RFX5, SFRS7, ALDHSA1, ZNF207, 
CDC2, FUBP1, SFPQ, H2AFV, and SFRS2) (Kato et al., 2010). None of 
these transcripts were detected as differentially expressed in the present 
study. This response of the genes when supplementation with different 
selenium compounds has been previously investigated in mice (Irons et 
al., 2006; Barnes et al., 2009; Kipp et al., 2009) and rats with a particular 
interest on a comparison between organic and inorganic forms of Se that 
were supplemented under similar conditions and showed different mRNA 
expression on certain genes (Barnes et al., 2009). The microarray data 
sets show different patterns of regulation genes depending on the Se 
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compound used but overall, the expression of selenoproteins showed. 
Interestingly on a human intervention study where plasma Se showed high 
concentrations, SELW, a low hierarchy selenoprotein, showed a 
downregulation after 10 days of Se supplementation on a human 
intervention study (Goldson et al., 2011). 
 
In order to get a broad idea of the similarities and differences 
among Se involving microarrays, the easiest way is to compare the 
expression of selenium-containing protein up regulation of TRXR-1, PGX1 
and GPX4 were found to be up-regulated in human colon carcinoma, no 
changes in expression were found in TRXR-2 (Yagublu et al., 2011) when 
TRXR1 and 2 were no expressed on Caco-2 cells. Effects in Gpx1 and on 
intervention studies where colorectal biopsies from 21 volunteers were 
supplemented with dairy-Se (150 μg/d) or yeast-Se (150 μg/d) for 6 weeks 
showed an mRNA upregulation of GPX 1 and 2 only when Se-dairy 
supplementation. SelP had a higher expression (regardless of the Se 
compound) that GPX1 and TRXR-1 was the least expressed. (Hu et al., 
2011). 
 
Comparison of microarray data intestinal tissue of mice fed either 
a Se-deficient diet or a Se sufficient diet containing selenomethionine 
showed a significant downregulation of Selw, Gpx1 and Gpx2, similar to 
the present study, but also Selh and Selm which were not differentially 
expressed in Caco-2 cells. When the expression of Gpx3, Selk, Sels, 
Txnrd1, Txnrd2, Txnrd3, Sep15, and Selt expression was investigated with 
QRT-PCR, a significant change expression was reported that was not 
evident on the microarray; similar trends in the expression of Gpx3, Selk 
and GPX3 and SELK were both were up-regulated by Se in mice and 
Caco-2 cells, although Gpx2 and Sephs2 in mice were down-regulated 
after feeding Se deficient diet (Kipp et al., 2009), while GPX2 and 
SEPHS2 showed the opposite effect in Caco-2 cells than the one reported 
in mouse colon (Kipp et al., 2009). 
 
In this chapter using IPA, canonical pathways and toxicological 
pathways were identified with the group of 53 Se-sensitive genes. Since 
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IPA is based on published data, the pathways built should represent an 
accurate picture of the gene interaction for the specific organism chosen 
for this study, H. sapiens. When searching for research papers that would 
link Se with the networks analysed by IPA, the links between the 
physiological functions of the genes identified on the transcriptomic 
experiment for H. sapiens were predominantly oxidative stress but also 
included selenocysteine, glutathione and arachidonic acid metabolism. 
However, calcium mobilization (Reeves et al., 2010), glucose metabolism 
(Olsson et al., 2011), and the protein folded response (Kasaikina et al., 
2011a), roles of Se previously reported were not identified as Se-sensitive 
pathways by IPA. 
 
To conclude, the trend in the expression of low hierarchy 
selenoproteins was observed on the microarray and QRT-PCR, where 
GPX1 and SELW were up-regulated under Se supplementation. Further 
supported earlier observed changes in the pattern of gene expression 
evidence for Se roles in oxidative stress, mitochondria respiration chain, 
and lipid metabolism when the Se-sensitive genes were grouped into 
networks. Finally, the changes in expression of the 53 Se-sensitive 
transcripts can now be matched with the Se-sensitive miRNAs. 
 
With the increasing evidence of the regulatory role of miRNA, 
several methods have been developed to bioinformatically predict mRNA-
miRNA interactions and protein-RNA binding. In this chapter a 
bioinformatic analysis predicted that MRE corresponding to several Se-
sensitive miRNAs are present within the Se-sensitive transcripts identified 
in Chapter 5. Interestingly, the three genes GPX2, GPX3 and SEHPS2 
were predicted to contain MRE for miR-185. GPX2 and GPX3 are known 
selenoproteins and SEHPS2 is necessary for two steps in incorporation of 
selenide into selenocysteyl-tRNASec during selenoprotein biosynthesis. On 
the basis that miR-185 was predicted to have multiple targets, that these 
targets were in the selenoprotein biosynthesis pathway (according to IPA 
nomenclature) and that miR-185 has been previously reported to be 
expressed in colorectal tissue (Akcakaya et al., 2011; Liu et al., 2011b), 
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functional effects of miR knockdown were experimentally investigated for 
miR-185.  
 
Knockdown of miR-185 was achieved by exposure to anti-miR for 
24h, 48h and 72h. This is the amount of time over which miRNA 
knockdown is generally assessed (Felgner et al., 1987; Hackl et al., 2010; 
Chiang et al., 2011). The extent of knockdown was of the order of 40-50%. 
miRNA silencing using antisense miRNAs often uses concentrations of 40 
nM when using an Anti-miR or 100 nM when LNA anti-miR 
oligonucleotides. The effects on the expression of a miRNA and their 
biological functions when miRNA knockdown experiment are conducted 
are never predictable; e.g. a miR-675 knockdown of ~50% was achieved 
on colon cancer cell lines 24h after transfection (with 40nM of Anti-miR-
675 in HT-29 cells and this reduced cell proliferation by ~30%; a ~40% 
silencing of the same miRNA on MIP101cells and decreased cell 
proliferation by ~35%) more than that reported in HT29 cells with a higher 
miRNA silencing; a similar phenomenon was observed in SW480 cells 
where 80% miR-675 silencing only reduced cell proliferation by ~30% 
(Tsang et al., 2010). Comparison between miRNA silencing on colon cell 
lines reported in the literature and the one presented in this thesis is often 
difficult. For example, even though the level of knockdown of miR-140 was 
not reported, when silencing of miR-140 with 100 nM of LNA anti-miR140 
for 72 h in CD133+hiCD44+hi colon cancer stem-like cells, blocked the 
beneficial effects of miR-140 which lead to DNA damage and increase in 
proliferation (Song et al., 2009). Also, assuming that miR-34a silencing 
was achieved (level of knockdown was not registered) with 150pmol of 
Anti-miR-34a in HT29 cells, miR-34a knockdown progressively increased 
its target BCL2 protein between 24 h and 72 h (Wang et al., 2010a). 
 
Analysis of the target transcripts after miR knockdown showed that 
expression of both GPX2 and SEPHS2 were increased after 48h of anti-
miR treatment. 
 
From the miRNA target prediction, the MRE for miR-185 in GPX3 
and SEPHS2 were within the predicted SECIS element (Table 13) 
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suggesting that miR-185 might have an effect on transcript stability and/or 
Sec incorporation. However, miR-185 knockdown did not have a 
significant effect on GPX3 mRNA expression.  
 
Under Se supplementation conditions, GPX2 and SEPHS2 were 
found to be down-regulated whereas GPX3 is up-regulated (Chapter 4). 
miR-185 knockdown at 48h showed a trend towards upregulation of two of 
its predicted targets (GPX2 and SEPHS2) whereas there was no 
significant change in expression of GPX3. The changes in GPX2 and 
SEPHS2 expression after knockdown are consistent with the observed 
down-regulation of miR-185 under Se supplementation. Thus, it appears 
that when miR-185 is down-regulated (either by Se supplementation or 
anti-miR) expression of GPX2 and SEPHS2 is increased. It is generally 
recognised that the role of miRNAs is to cleave their target transcripts and 
down-regulate their expression (Kong et al., 2008; Wahid et al., 2010; 
Huntzinger and Izaurralde, 2011). The results described in this chapter 
concur with this mechanism of action, because by inhibiting the miR-185, 
GPX2 and SEPHS2 transcripts would not have been cleaved and 
therefore their expression would have been up-regulated. Furthermore, 
when Caco-2 cells were grown under Se depleted medium, miR-185 was 
overexpressed while miR-185 targets GPX2 and SEPHS2 were down-
regulated; so miR-185 silencing in Caco-2 cells during Se supplementation 
would mimic the expression of the transcripts from cells grown under Se 
deficient conditions. 
 
Thus, the observed changes in expression of GPX2 and SEPHS2 
following knockdown of miR-185 suggest that there is a link between miR-
185 and these selenoproteins; especially in the case of SEPHS2, because 
the SEPHS2 MRE lies on the SECIS (Table 13), a UGA-SEC codon and a 
3′ UTR stem loop which is has a unique sequence and structure (Banerjee 
et al., 2012) and it is the key element that binds to SBP2 and Ser-
tRNASec for selenoprotein incorporation, it is plausible that miR-185 
regulates SEPHS2 expression through selenoprotein incorporation and 
that GPX2 change in expression is either due to the mRNA degradation by 
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miR-185 or because of a secondary effect from the SEPHS2 feedback 
mechanism. 
 
Further evidence for this being due to miR-mRNA interactions 
could be obtained by means of a luciferase reporter assay in which the 
MRE could be inserted and after endogenous miR-185 overexpression 
supplementing cells with Se, miR-185 would bind to the MRE and repress 
the expression of luciferase gene as illustrated in Figure 49. 
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Figure 49 Luciferase miRNA target expression vector. 
Luciferase reporter vector in which the MRE (magenta sequence) in inserted into the multiple cloning site (MCS). As the primary reporter gene is firefly luciferase, its 
expression indicates the cleavage of the miRNA to its target when miRNA upregulation is induced by Se. upon miRNA up-regulation. If GPX2 and SEHPS2 were 
miR-185 targets, a reduced or no luciferase activity would be expected. 
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Chapter 6 Final discussion 
 
The work described in this thesis began with a bioinformatic 
prediction using a group of downstream targets of Se identified in mouse 
colon (Kipp et al., 2009) and human lymphocytes (Pagmantidis et al., 
2008) to identify a miRNA or group of miRNAs that could regulate genes 
encoding mitochondrial translation factors, ribosomal and elongation factor 
identified as a protein biosynthetic pathway (Pagmantidis et al., 2008). 
Those bioinformatics predictions, miRNAs expressed in colon cell lines 
and tissues, and miRNAs used in PCR arrays were all included in the 
design of a miRNA microarray Human genome V2 Agilent chip. Using this 
chip and RNA isolated from Caco-2 cells grown in either Se sufficient/ Se 
deficient medium, 13 miRNAs were found to be regulated by 40nM sodium 
selenite supplementation after 72 h. Because the present study had a 
similar aim, namely to investigate the effects of Se on miRNA and mRNA 
expression, this cellular model of Se depletion was adopted from 
Pagmantidis et al., 2005; although the Se content from fetal calf serum 
varies, the expression of GPX1 and SELW of Caco-2 cells grown in Se-
depleted medium are similar to fetal calf serum containing medium 
(Gautrey et al., 2011) suggesting that normal, unsupplemented medium 
has a similar Se content to the SE deficient medium used here. 
 
The subsequent step was a transcriptomic experiment using the 
same RNA from which the 13 Se-sensitive miRNAs were identified and 
hybridized to Illumina HumanRef-8 v.3 Expression BeadChip; this resulted 
in the identification of 53 differentially expressed transcripts when Se-
supplemented and control cells were compared. In order to find a 
correlation between these two data sets, miRNA prediction tools described 
in Chapter 2 were used to predict Se-sensitive miRNA MREs on the Se-
sensitive mRNA, and a further pathway analysis with IPA identified the 
following pathways potentially Se sensitive semaphoring signalling 
pathway, axon guidance and nervous system development and 
regeneration associated proteins (Pasterkamp, 2012) with interesting 
immune functions such as antibody and cytokine production and 
expression in T and B cells (Mizui et al., 2009). This may explain the link 
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between Se supplementation and survival of HIV patients (Fawzi et al., 
2005; Hurwitz et al., 2007; Harthill, 2011). This pathway analysis 
suggested as well a link between Se-sensitive miRNAs and the 
cardiomyopathy observed in Se deficiency (Cui et al., 2012) (possibly 
Keshan disease), through the cardiac β-adrenergic signalling; the ability of 
the cardiac muscle to contract when this signalling pathway is 
compromised (Saucerman and McCulloch 2006).  
 
While cellular functions such as extracellular communication 
processes by activated by intracellular responses via ERK/MAPK 
signalling pathway (McKay and Morrison, 2007) were also identified by 
IPA; most pathways were related to cancer proliferation and invasiveness. 
This included integrin signalling pathway (cell cycle regulation that controls 
cancer progression through Cas, Crk proteins and IPP complex) (Cabodi 
et al., 2010), HMG1 signalling (cancer proliferation, inflammation and 
apoptosis regulator) (Jia et al., 2013); glioblastoma multiform pathway 
which is expressed in brain tumours where vascular proliferation, tumour 
chemoresistance and apoptosis are characteristics (Mao et al., 2012) and 
finally, pancreatic signalling pathways which has been linked to cell 
apoptosis and dysplasia in response to DNA damage (McCleary-Wheeler 
et al., 2012). 
 
Pathway analysis also suggested that the Se-sensitive miRNAs 
could have metabolic regulatory functions in Caco-2 cells. For example, 
the pathways potentially affected were: aryl hydrocarbon receptor 
signalling (a metabolic pathway activator) (Barouki et al., 2012); alternative 
carbohydrate and lipid metabolism functions of the p53 signalling pathway 
(Zhang et al., 2010), and fatty acid (Harvey and Leinwand, 2011) and 
glucose (Mihaylova and Shaw, 2011) metabolism from the cardiac 
hypertrophy signalling. 
 
Based on the bioinformatics predictions described in Chapter 5 
and the biological functions of the group of transcripts in which MRE were 
identified, miR-185 and its targets GPX3, SEPHS2, and GPX2 were 
chosen for functional analysis. In order to mimic endogenous expression 
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of miR-185 in Caco-2 cells, cells were supplemented with Se and miR-185 
knockdown achieved with an antisense oligonucleotide complementary to 
miR-185. The knockdown was monitored at 24, 36, and 72h and the 
expression of GPX3, SEPHS2, and GPX2 was assessed by QRT-PCR 
from which data, at 48h, the expression of SEPHS2, and GPX2 was found 
to be up-regulated compared to the control. 
 
miRNA are flexible in their recognition of target mRNA sequences 
through an imperfect base pairing. This gives them the possibility to 
regulate a group of genes (Brodersen and Voinnet, 2009; Schnall-Levin et 
al., 2011; Subramanyam and Blelloch, 2011). Several algorithms and 
pathway analysis tools have been developed in order to identify possible 
miRNA-mRNA interactions (Grocock et al.; Betel et al., 2008; Ingenuity, 
2008; Antonov et al., 2009; Dweep et al., 2011); however, tissue 
localization, biological functions, and miRNA-mRNA interactions that are 
do not occur in the seed region or are not conserved among species will 
not be predicted by those tools because those are part of the criteria of 
exclusion to avoid false positives. 
 
From the 750 entities included on the miRNA chip design, 145 
miRNA were expressed in Caco-2 cells. 71 of these were part of the 194 
miRNAs on the chip that had previously been found to be expressed in 
intestinal cells or tissues; 15 miRNAs expressed were bioinformatically 
predicted and do not correspond to either to any previously described in 
the intestinal microRNAome or included on PCR arrays or microarrays. 
Discussing which would be the most efficient bioinformatics tool for this 
research would not be relevant because these predictions were done 
originally in a group of transcripts that were not differentially expressed 
upon Se supplementation/depletion. 
 
Little or nothing (in the case of miR-532-5p) is known about the 
Se-sensitive miRNAs identified in Chapter 4. As regards miR-625 and 
miR-429, mir-429 has been reported to be expressed at low levels in colon 
cell lines (Stratmann et al., 2011; Sun et al., 2011b; Zhang et al., 2011b) 
and suggested to be a colorectal cancer biomarker (Zhang et al., 2011b). 
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The experimentally validated target of an isoform of miR-429 in colorectal 
tissues is C-MYC which is a cell cycle and apoptosis promoter silenced by 
miR-429b (Sun et al., 2011b), which could classify it as a cancer 
suppressor miRNA. Recently, miR-625 was detected as at high expression 
levels in human oocytes (Xu et al., 2011) and overexpressed in neoplastic 
pancreatic biopsies compared to healthy tissue counterparts (Yu et al., 
2012).  
 
Interestingly, Se supplementation led to the expression of miR-
375* whereas the mature miRNA, miR-375, was expressed in the Caco-2 
cell line but there was no change of expression between Se supplemented 
cells and controls. miR-375* is down-regulated in bone marrow from 
leukaemia patients (Ju et al., 2009), melanoma cells and primary human 
melanocyte (Satzger et al., 2010), and overexpressed in retinoblastoma 
(Zhao et al., 2009). Oncogene miR-30b is highly expressed in invasive 
urothelial carcinoma of the bladder, (Wszolek et al., 2011) and 
medulloblastoma (Lu et al., 2009), but is a tumour suppressor in 
hepatocytes (Gaziel-Sovran et al., 2011). 
 
There is even more limited information about the roles of the Se-
sensitive miRNA in the colon. High levels of miR-10b were related to 
malignancy in Irish colorectal cancer samples (Chang et al., 2011). 
Overexpression of miR-196b cancer in gastric biopsies (Tchernitsa et al., 
2010b); in colon cancer biopsies (Wang et al., 2010b), as well as in 
circulating blood from cancer patients (Tsujiura et al., 2010) was found in 
infiltrative cancer. Tumour suppression properties of miR203 were 
observed in HT29 cells and gastric and colorectal biopsies(Li et al., 2011). 
Down-regulation of miR10b has been related to lower tumour growth 
(Chiang et al., 2011).  
 
The exogenous overexpression of miR-28-5p in HCT116 and RKO 
cells led to a possible downregulation of CCND1 and HOX83 and 
decreased tumour proliferation (Almeida et al., 2012). In HT29 cells, miR-
22 overexpression was linked to increased apoptosis (Zhang et al., 
2011a); and cell viability was decreased by the up-regulation of miR-494 
 185 
followed by the downregulation of its target KIT, an apoptotic inhibitor (Kim 
et al., 2011c; Casar-Borota et al., 2012). 
 
miR-185 expression was not detected on the miRNA microarray 
under Se depletion conditions, but the addition of Se had a large an effect 
on this miRNA. Using QRT-PCR, miR-185 showed one of the biggest 
changes after Se supplementation when normalized to let-7b and the 
change was statistically significant when normalized to RNU6B. miR-185 
roles in colorectal progression cancer were recently proposed; for example 
metastasis and low cancer survival were found during miR-185 
overexpression (Akcakaya et al., 2011) and miR-185 downregulation 
SW1116 cells mimicked RhoA/Cdc42 (Liu et al., 2011b). 
 
Because miRNA roles are different from tissue/cell line to 
tissue/cell line, it was important to determine the expression of the 
miRNAs on our experimental model Caco-2. Identifying their targets was 
then the next step for which a total transcriptome experiment hybridized to 
Illumina HumanRef-8 v.3 was performed so causation between the Se-
sensitive miRNAs and the Se-sensitive genes could be found among these 
dataset. 53 genes were differentially expressed on the microarray from 
which SEPHS2, GPX2, DCUN1D4, ME1, PIR, HTATIP2, KLF5, GCNT3, 
C6ORF192, CEACAM6, GGH, LAMB1, OIP5, OSTC, SLC1A3, ATP1B3, 
and GPT2 were down-regulated; from this group, only GPX2 and SEPHS2 
were known to be linked to Se metabolism. 
 
Transcripts other than Se proteins were identified after Se 
supplementation in the human lymphocyte, including 61 which are 
ribosomal, mitochondrial, elongation factors were differentially expressed 
after 100 µg sodium selenite (Pagmantidis et al., 2008), except for LAMB1 
which codes for an extracellular matrix glycoprotein, laminin beta 1 (Wu et 
al., 2011b). In a different study, COL15A1, COL5A3, COL3A1, COL1A1, 
COL6A3 and FLRT3 showed significant downregulation in keloid 
fibroblasts supplemented with 20 μg/day of selenocystine (De Felice et al., 
2011); human thyroid cancer cells supplemented with 150 µM seleno-l-
methionine GADD153, GADD34, EGFR, SGSH, SQSTM1, CAL2, PRKCH, 
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DUSP5, GSK3B, IGF2R, and TRAF1 (growth factors) were up-regulated 
whereas splicing factors RFX5, SFRS7, ALDHSA1, ZNF207, CDC2, 
FUBP1, SFPQ, H2AFV, and SFRS2 were down-regulated (Kato et al., 
2010). None of the mentioned mRNA changes were found in the present 
study. 
 
Of the differentially expressed selenoproteins identified in different 
gastrointestinal tissues or cell lines, GPX1 and GPX4 were up-regulated 
(Yagublu et al., 2011) when cancer and healthy colonic tissue were 
compared. Effects on SELP were greater than GPX1 in an intervention 
study of 21 volunteers supplemented with dairy-Se (150 μg/d) or yeast-Se 
(150 μg/d) (Hu et al., 2011). In the present study, SELP was not 
differentially expressed, possibly because tissues are more exposed to 
circulating blood in which SELP is localized (Rock and Moos, 2010). In a 
human intervention study, SELW was surprisingly down-regulated after 10 
days of Se supplementation (Goldson et al., 2011) where this 
selenoprotein is rapidly saturated when Se is abundant. Selenoproteins 
SELP, TRXR1 and 2 were not expressed in the present Caco-2 study, but 
have been reported to be expressed in colon carcinoma tissue (Yagublu et 
al., 2011) and colorectal biopsies (Hu et al., 2011). 
 
Further bioinformatic analysis of the 53 Se-sensitive transcripts 
revealed some networks related with biological roles of Se, as described in 
Chapter 5; one of these was arachidonic acid metabolism. Previous work 
has suggested that Se-antioxidant systems, particularly TrxR, influence 
regulation of arachidonic acid metabolism (Kurosawa et al., 2009). 
Interestingly, there are similarities in pathways affected by 
dehydroepiandrosterone (DHEA), a chemopreventive and antiproliferative 
steroid, and the ones found after pathway analysis with the Se-sensitive 
genes from the present study. DHEA was used to incubate Sk-Gi and Sk-
Sc cells (derived from the liver adenocarcinoma cell line SK-HEP-1) and a 
number of metabolites were chromatographically obtained, from which 
pathways were mapped with GeneSpring MS software revealing lipid 
metabolism, glutathione metabolism, and s-adenosylmethionine (SAM) 
metabolism to be affected (Cheng et al., 2011). In addition, in BAEC cells 
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Se depletion accelerated oxidation of lipids associated with arachidonic 
acid metabolism (Rock and Moos, 2010), supporting the hypothesis that 
Se has a role in arachidonic metabolism. GPX1, GPX2, GPX3, GPX4 and 
EPXH2 are listed as part of the arachidonic acid metabolism as according 
to IPA. Indeed there is experimental evidence for a role of EPXH2 in 
arachidonic metabolism (Vainio et al., 2011; Morisseau et al., 2012).  
 
Bioinformatic analysis linked Se-sensitive miRNAs with Se-
sensitive mRNAs. ME1, CACYBP, ATP6V1B1 and GPX1had MRE for 
miR-625, SELK for miR-492, HTATIP2 and GPT2 for miR-373*; GTP2 for 
miR-22, EPHX2 for miR-532-5p, GPX2 and MT1F for miR-106b, GPX3 for 
miR-30b; and finally GPX2, GPX3, and SEPHS2 for miR-185. miRNA 
targets for miR-625, miR429, miR-373*, miR-22, miR-532-5p do not have 
any evident link to Se metabolism or biological functions. miRNA targets 
for miR-106b, miR-30b, and miR-185 showed a more evident link.  
 
From those three, miR-185 targets are part of the selenoprotein 
metabolism and the MRE for GPX3 and SEPHS2 are within the sequence 
predicted to form the SECIS element according to the SECIS prediction 
software (Kryukov et al., 2003). The latter observation suggests that GPX3 
and SEPHS2 biosynthesis may be mediated by miR185. Since the SECIS 
functions by recruiting binding proteins into the Secys-tRNA incorporation 
complex, it is possible that miR-185 could regulate GPX3 and SEPHS2 
expression not only by regulating mRNA degradation through the RISC 
complex but also by regulating their translation.  
 
Knockdown of miR-185 was achieved in Se-supplemented cells 
after incubation for 24, 36, and 72 h. In spite of a greater miR-185 
knockdown being obtained at 24h compared with 48 h, miRNA targets only 
showed statistically significant changes in expression at 48 h, with an up-
regulation of GPX2 and SEPHS2. This is consistent with the predicted 
miRNA target cleavage and miRNA silencing reported mechanism of 
action (Kong et al., 2008; Wahid et al., 2010; Huntzinger and Izaurralde, 
2011). The changes in expression only at 48 h with no effect at 24 or 72 h 
could be due to the experimental design in which up-regulation of miR-185 
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by Se was done 48 h prior to miRNA knockdown and as a result 
knockdown over 24 h might not give enough time to the cells to trigger any 
feedback mechanism or for the mRNA to recover from miRNA cleavage. 
Even though knockdown was achieved at 72 h, the miR-185 expression 
was not down-regulated to as great an extent as at 24 or 48 h and this 
phenomenon could be explained by a weak effect of the anti-miR at 72 h 
because at 72 h the antisense oligonucleotide has been degraded or 
because during this simultaneous treatment, the addition of Se that 
upregulates miR-185 expression is more efficient than miR-185 silencing 
despite the high Anti-miR concentration of 70nM. 
 
In conclusion, the main findings of the study described in this 
thesis are that: 
 
1) Se supplementation of Caco-2 cells did not only change the 
expression of specific selenoproteins, but also altered a 
number of non-selenoprotein genes, pathways, downstream 
targets, and 13 miRNAs. 
2) The miRNAs are predicted to have MRE in some of the 
transcripts affected by Se supply. 
3) Knockdown of miR-185 affected GPX2 and SEPHS2 
expression consistent with Se depleted cells microarray data. 
 
On the basis of these finding, I propose that after Se 
supplementation, changes in expression lead to an unknown biological 
events that modulates expression of GPX2 and SEPHS2 through miRNAs. 
This is illustrated in Figure 50, Se mechanisms of action are represented 
by selenium incorporation into selenoproteins through a selenoprotein 
hierarchy which could be regulated through miRNAs targeting the SECIS 
element and/or regulating genes involved in selenoprotein biosynthesis. 
 
As a result of the target prediction of the Se-sensitive miRNAs and 
further pathways analysis, metabolic pathways like fatty acid and glucose; 
physiological pathways like β-adrenergic receptors disruption that leads to 
cardiomyopathy and immune system enhancement; and at a cellular level, 
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cell cycle regulatory function and cancer signalling pathways that control 
cancer invasiveness, proliferation and apoptosis, were recognised as 
possible Se-sensitive miRNA mechanisms of action. 
 
From the IPA analysis from the transcriptomic experiment, Se-
related pathways like selenoamino acid and glutathione metabolism and 
the toxicological responses like oxidative stress and decrease 
mitochondrial respiration. 
 
If more time had been available, this hypothesis could have been 
tested by assessing the expression GPX3, GPX2, and SEPHS2 at the 
protein level so as to investigate the effects of miR-185 on translation; 
future work could also include the cloning of the MRE followed by 
overexpression of miR-185 with Se to test directly whether the observed 
effects are due to a miRNA-mRNA interaction. 
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Figure 50 Mechanisms of action of Se involving miRNAs: A hypothesis.  
Se supplementation on Caco-2 cells affects the expression of miRNAs and mRNAs which may regulate cellular functions through three 
possible mechanisms:  
A) The 53 genes for which expression was up or down-regulated upon Se supplementation were analysed by IPA, and the canonical 
pathways identified were arachidonic acid metabolism linked to decreased oxidation of arachidonic acid; glutathione metabolism, 
selenoamino acid metabolism; toxicity lists identified oxidative stress and mitochondrial dysfunction both of which are processes related to 
ROS and the antioxidant effects of selenoproteins related cellular processes.  
B) Se supplementation up-regulated 13 miRNAs; pathway analysis with the predicted targets of these Se-sensitive miRNAs suggested that 
survival of immune compromised patients, myocardial lesion development (under Se deficiency), cancer proliferation and invasiveness and 
lipid and carbohydrate metabolism (alternative functions of the p53 and Akt signalling pathways) as well as extracellular communication 
were suggested Se-sensitive miRNA regulatory mechanisms. 
C) Knockdown of miR-185, a Se-sensitive miRNA, affected the expression of SEPHS2 and GPX2 two selenoproteins predicted to be miR-
185 targets. MRE for SEPHS2 matches the SECIS, which suggests that miR-185 may regulate selenoprotein incorporation; and that GPX2 
overexpression in response to miR-185 knockdown could be either a direct interaction between the mRNA-miRNA cleavage that would lead 
to GPX2 mRNA degradation under Se-supplementation conditions (which up-regulates miR-185), or an indirect interaction between 
SEPHS2 SECIS’ MRE and miR-185. 
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Appendix A miRNA microarray chip design 
 
Table 14 lists the miRNAs included on the miRNA microarray design human genome V2 Agilent customised 8x15K slide. Chapter 3 describes the 
bioinformatics analysis, literature review and array platforms from which Table 14 was obtained. 
 
miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org MicroCosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-let-7a MIMAT0000062 *       *   [1-3]  
hsa-let-7a* MIMAT0004481           *   
hsa-let-7b MIMAT0000063 *       *    [1,2] 
hsa-let-7b* MIMAT0004482           *   
hsa-let-7c MIMAT0000064 *       *    [1,3] 
hsa-let-7c* MIMAT0004483           *   
hsa-let-7d MIMAT0000065 *       *    [1, 3, 4] 
hsa-let-7d* MIMAT0004484           *   
hsa-let-7e MIMAT0000066 *       *    [1, 3] 
hsa-let-7e* MIMAT0004485           *   
hsa-let-7f MIMAT0000067 *       *    [1-3] 
hsa-let-7f-1* MIMAT0004486           *   
hsa-let-7f-2* MIMAT0004487           *   
hsa-let-7g MIMAT0000414 *       *    [1-3, 5] 
hsa-let-7i MIMAT0000415 *       *    [1-3] 
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org MicroCosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-1 MIMAT0000416 * *          [3, 6] 
hsa-miR-100 MIMAT0000098 *            [3, 4] 
hsa-miR-101 MIMAT0000099 *     * *    [3] 
hsa-miR-103 MI000108              [3-5] 
hsa-miR-103a MIMAT0000101        
hsa-miR-105 MIMAT0000102       * *    [5] 
hsa-miR-106a MIMAT0000680 *   * * *    [3-5] 
hsa-miR-106b MIMAT0004672              [3] 
hsa-miR-107 MIMAT0000104         *    [3] 
hsa-miR-10a MIMAT0000253 *     *      [3-5] 
hsa-miR-10a* MIMAT0004555           *   
hsa-miR-10b MIMAT0000254 *   * *      [3, 6] 
hsa-miR-10b* MIMAT0004556           *   
hsa-miR-1178 MIMAT0005823           *   
hsa-miR-1180 MIMAT0005825           *   
hsa-miR-1185 MIMAT0005798           *   
hsa-miR-1197 MIMAT0005955           *   
hsa-miR-1201 MIMAT0005864           *   
hsa-miR-1202 MIMAT0005865           *   
hsa-miR-1204 MIMAT0005868           *   
hsa-miR-1205 MIMAT0005869           *   
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-1206 MIMAT0005870           *   
hsa-miR-122 MIMAT0000421 * *          [5] 
hsa-miR-1224-3p MIMAT0005459           *   
hsa-miR-1224-5p MIMAT0005458           *   
hsa-miR-1225-3p MIMAT0005573           *   
hsa-miR-1225-5p MIMAT0005572           *   
hsa-miR-1226 MIMAT0005577           *   
hsa-miR-1231 MIMAT0005586           *   
hsa-miR-1237 MIMAT0005592           *   
hsa-miR-1238 MIMAT0005593           *   
hsa-miR-124 MIMAT0000422 *            [3, 7] 
hsa-miR-124* MIMAT0004591           *   
hsa-miR-1243 MIMAT0005894           *   
hsa-miR-1244 MIMAT0005896           *   
hsa-miR-1245 MIMAT0005897           *   
hsa-miR-1246 MIMAT0005898           *   
hsa-miR-1247 MIMAT0005899               
hsa-miR-1251 MIMAT0005903               
hsa-miR-1257 MIMAT0005908           *   
hsa-miR-1258 MIMAT0005909           *   
hsa-miR-1259 MIMAT0005910           *   
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-125a-3p MIMAT0004602           *   
hsa-miR-125a-5p MIMAT0000443 *             
hsa-miR-125b MIMAT0000423 *       *    [3-5] 
hsa-miR-125b-1* MIMAT0004592           *   
hsa-miR-125b-2* MIMAT0004603           *   
hsa-miR-126 MIMAT0000445 *            [3, 5, 6] 
hsa-miR-126* MIMAT0000444               
hsa-miR-1260 MIMAT0005911           *   
hsa-miR-1261 MIMAT0005913           *   
hsa-miR-1262 MIMAT0005914           *   
hsa-miR-1263 MIMAT0005915           *   
hsa-miR-1265 MIMAT0005918           *   
hsa-miR-1266 MIMAT0005920           *   
hsa-miR-1268 MIMAT0005922           *   
hsa-miR-1269 MIMAT0005923           *   
hsa-miR-1270 MIMAT0005924           *   
hsa-miR-1272 MIMAT0005925           *   
hsa-miR-1273 MIMAT0005926           *   
hsa-miR-127-3p MIMAT0000446 *             
hsa-miR-1274a MIMAT0005927           *   
hsa-miR-1275 MIMAT0005929           *   
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-128a MIMAT0000424            [3, 5] 
hsa-miR-128b MIMAT0005799           *  [3, 5] 
hsa-miR-1284 MIMAT0005941           *   
hsa-miR-1287 MIMAT0005878           *   
hsa-miR-1288 MIMAT0005942           *   
hsa-miR-1289 MIMAT0005879           *   
hsa-miR-129* MIMAT0004548           *   
hsa-miR-1290 MIMAT0005880           *   
hsa-miR-1291 MIMAT0005881     *         
hsa-miR-1292 MIMAT0005943           *   
hsa-miR-1293 MIMAT0005883           *   
hsa-miR-129-3p MIMAT0004605 *             
hsa-miR-1294 MIMAT0005884 *         *   
hsa-miR-129-5p MIMAT0000242               
hsa-miR-1298 MIMAT0005800               
hsa-miR-1303 MIMAT0005891               
hsa-miR-1308 MIMAT0005947     * *   *   
hsa-miR-130a MIMAT0000425 *     *      [3-6] 
hsa-miR-130a* MIMAT0004593           *   
hsa-miR-130b MIMAT0000691 * *          [3, 5] 
hsa-miR-130b* MIMAT0004680           *   
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-132 MIMAT0000426 * *          [3] 
hsa-miR-132* MIMAT0004594              [7] 
hsa-miR-1321 MIMAT0005952               
hsa-miR-1322 MIMAT0005953               
hsa-miR-1324 MIMAT0005956               
hsa-miR-133a MIMAT0000427              [3, 6] 
hsa-miR-133b MIMAT0000770              [1, 2, 3, 7] 
hsa-miR-134 MIMAT0000447 *            [5] 
hsa-miR-135a MIMAT0000428 * *          [3, 5] 
hsa-miR-135a* MIMAT0004595               
hsa-miR-135b MIMAT0000758 * *          [1, 3, 6, 7] 
hsa-miR-135b* MIMAT0004698               
hsa-miR-136 MIMAT0000448         *    [3, 6] 
hsa-miR-136* MIMAT0004606           *   
hsa-miR-137 MIMAT0000429 *       *     
hsa-miR-138 MIMAT0000430 *            [3] 
hsa-miR-138-1* MIMAT0004607           *   
hsa-miR-138-2* MIMAT0004596           *   
hsa-miR-139-3p MIMAT0004552           *   
hsa-miR-139-5p MIMAT0000250 *       *     
hsa-miR-140-3p MIMAT0004597 *             
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-140-5p MIMAT0000431 *             
hsa-miR-141 MIMAT0000432 * *   * *    [2, 3, 4] 
hsa-miR-141* MIMAT0004598       *       
hsa-miR-142-3p MIMAT0000434 *            [3, 5] 
hsa-miR-142-5p MIMAT0000433 *       *    [3, 5, 6] 
hsa-miR-143 MIMAT0000435 *            [1-3] 
hsa-miR-143* MIMAT0004599           *   
hsa-miR-144 MIMAT0000436 * *   *   *  [3] 
hsa-miR-144* MIMAT0004600       *       
hsa-miR-145 MIMAT0000437           *  [1, 2, 3, 5, 7] 
hsa-miR-145* MIMAT0004601               
hsa-miR-1468 MIMAT0006789           *   
hsa-miR-146a MIMAT0000449 *            [3] 
hsa-miR-146a* MIMAT0004608           *   
hsa-miR-146b-3p MIMAT0004766           *   
hsa-miR-146b-5p MIMAT0002809               
hsa-miR-147 MIMAT0000251         *    [5] 
hsa-miR-147b MIMAT0004928           *   
hsa-miR-148a MIMAT0000243 *            [2, 3, 5] 
hsa-miR-148a* MIMAT0004549           *   
hsa-miR-148b MIMAT0000759              [3] 
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-148b* MIMAT0004699               
hsa-miR-149 MIMAT0000450 *       *    [3, 5] 
hsa-miR-149* MIMAT0004609           *   
hsa-miR-150 MIMAT0000451 *       *    [3] 
hsa-miR-150* MIMAT0004610           *   
hsa-miR-151-3p MIMAT0000757 *             
hsa-miR-151-5p MIMAT0004697 *             
hsa-miR-152 MIMAT0000438 * *          [3] 
hsa-miR-153 MIMAT0000439         *    [3] 
hsa-miR-1537 MIMAT0007399               
hsa-miR-154 MIMAT0000452              [3] 
hsa-miR-154* MIMAT0000453              [5] 
hsa-miR-155 MIMAT0000646 * *     *   [1, 3]  
hsa-miR-155* MIMAT0004658           *   
hsa-miR-15a MIMAT0000068 *   *   *    [1, 3, 5] 
hsa-miR-15a* MIMAT0004488               
hsa-miR-15b MIMAT0000417 *   *   *    [2, 3, 5] 
hsa-miR-15b* MIMAT0004586           *   
hsa-miR-16 MIMAT0000069 * * *   *    [1-3, 5] 
hsa-miR-16-1* MIMAT0004489           * 
 hsa-miR-16-2* MIMAT0004518              
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-17 MIMAT0000070 * *   * *    [1] 
hsa-miR-17-5p MIMAT0000071 *     *      [4, 5] 
hsa-miR-181a MIMAT0000256 *            [3, 5] 
hsa-miR-181a-2* MIMAT0004558           *   
hsa-miR-181b MIMAT0000257 *            [3, 5, 6] 
hsa-miR-181c MIMAT0000258 *            [3] 
hsa-miR-181c* MIMAT0004559           *   
hsa-miR-181d MIMAT0002821              [3] 
hsa-miR-182 MIMAT0000259 *       *    [3, 5, 6] 
hsa-miR-182* MIMAT0000260              [5] 
hsa-miR-1825 MIMAT0006765           *   
hsa-miR-1826 MIMAT0006766           *   
hsa-miR-1827 MIMAT0006767           *   
hsa-miR-183 MIMAT0000261 *     * *   [3, 7]  
hsa-miR-183* MIMAT0004560           *   
hsa-miR-184 MIMAT0000454              [3, 5] 
hsa-miR-185 MIMAT0000455 *   * *       
hsa-miR-185* MIMAT0004611           *   
hsa-miR-186 MIMAT0000456 * *     *    [3, 5] 
hsa-miR-186* MIMAT0004612               
hsa-miR-187 MIMAT0000262   *          [5, 6] 
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-187* MIMAT0004561           *   
hsa-miR-188-3p MIMAT0004613           *   
hsa-miR-188-5p MIMAT0000457               
hsa-miR-18a MIMAT0000072              [3] 
hsa-miR-18b MIMAT0001412 *            [3] 
hsa-miR-190 MIMAT0000458   *          [3, 5] 
hsa-miR-191 MIMAT0000440 *            [3, 5] 
hsa-miR-192 MIMAT0000222 *            [3, 6] 
hsa-miR-192* MIMAT0004543               
hsa-miR-193a-3p MIMAT0000459       *       
hsa-miR-193a-5p MIMAT0004614 *       *     
hsa-miR-193b MIMAT0002819 *     *      [3] 
hsa-miR-194 MIMAT0000460 *            [3, 5, 6] 
hsa-miR-195 MIMAT0000461 *       *    [3, 5] 
hsa-miR-196a MIMAT0000226 * *   * *    [3, 6] 
hsa-miR-196a* MIMAT0004562       *       
hsa-miR-196b MIMAT0001080 * *     *    [3] 
hsa-miR-197 MIMAT0000227 *       *    [3, 5, 6] 
hsa-miR-198 MIMAT0000228   *           
hsa-miR-199a-3p MIMAT0000232 *         *   
hsa-miR-199a-5p MIMAT0000231         *     
  
2
0
2
 
miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-199b-5p MIMAT0000263         *     
hsa-miR-19a MIMAT0000073 * *          [3, 5, 7] 
hsa-miR-19a* MIMAT0004490           *   
hsa-miR-19b MIMAT0000074 *       *    [3, 6] 
hsa-miR-19b-1* MIMAT0004491               
hsa-miR-19b-2* MIMAT0004492           *   
hsa-miR-200a MIMAT0000682       * *    [2-5] 
hsa-miR-200a* MIMAT0001620       *       
hsa-miR-200b MIMAT0000318       * *    [2-5] 
hsa-miR-200b* MIMAT0004571       *       
hsa-miR-200c MIMAT0000617 *     * *    [2, 3, 5] 
hsa-miR-200c* MIMAT0004657       *       
hsa-miR-202 MIMAT0002811 *         *  [6] 
hsa-miR-203 MIMAT0000264 *   * * *    [3, 5] 
hsa-miR-204 MIMAT0000265         *    [3] 
hsa-miR-205 MIMAT0000266 *            [3] 
hsa-miR-206 MIMAT0000462   *           
hsa-miR-208a MIMAT0000241           *   
hsa-miR-208b MIMAT0004960           *   
hsa-miR-20a MIMAT0000075 * *     *    [2-4] 
hsa-miR-20a* MIMAT0004493               
  
2
0
3
 
miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-20b MIMAT0001413 *       *    [3] 
hsa-miR-20b* MIMAT0004752           *   
hsa-miR-21 MIMAT0000076 * *   *      [1, 2, 3, 5, 7] 
hsa-miR-21* MIMAT0004494       *       
hsa-miR-210 MIMAT0000267 *            [3, 5] 
hsa-miR-211 MIMAT0000268         *     
hsa-miR-212 MIMAT0000269           *   
hsa-miR-214 MIMAT0000271 * *     *    [3, 5] 
hsa-miR-214* MIMAT0004564           *   
hsa-miR-215 MIMAT0000272              [3] 
hsa-miR-216 MIMAT0000273              [5] 
hsa-miR-216a MIMAT0004959           *   
hsa-miR-216b MIMAT0000274   *     *     
hsa-miR-218 MIMAT0000275 *            [3, 5] 
hsa-miR-218-1* MIMAT0004565   *       *   
hsa-miR-218-2* MIMAT0004566   *       *  [4] 
hsa-miR-219-1-3p MIMAT0004567         *     
hsa-miR-219-2-3p MIMAT0004675         *     
hsa-miR-219-5p MIMAT0000276       * *     
hsa-miR-22 MIMAT0000077 *   * *      [2, 3, 6] 
hsa-miR-22* MIMAT0004495               
  
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-220b MIMAT0004908         *     
hsa-miR-220c MIMAT0004915           *   
hsa-miR-221 MIMAT0000278              [3-5] 
hsa-miR-222 MIMAT0000279 * *   *      [3-5] 
hsa-miR-222* MIMAT0004569       *       
hsa-miR-223 MIMAT0000280 *     *   *  [2, 3, 5] 
hsa-miR-223* MIMAT0004570               
hsa-miR-224 MIMAT0000281              [3, 5] 
hsa-miR-23a MIMAT0000078 * *     * *  [2, 3] 
hsa-miR-23a* MIMAT0004496               
hsa-miR-23b MIMAT0000418 * *     *    [2-4] 
hsa-miR-23b* MIMAT0004587           *   
hsa-miR-24 MIMAT0000080 *            [2, 3, 6] 
hsa-miR-24-1* MIMAT0000079           *   
hsa-miR-24-2* MIMAT0004497           *   
hsa-miR-25 MIMAT0000081 * *          [3, 5] 
hsa-miR-25* MIMAT0004498           *   
hsa-miR-26a MIMAT0000082 *       *    [2, 3, 5] 
hsa-miR-26a-1* MIMAT0004499           *   
hsa-miR-26a-2* MIMAT0004681           *   
hsa-miR-26b MIMAT0000083 *       *    [2, 3] 
  
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-26b* MIMAT0004500           *   
hsa-miR-27a MIMAT0000084 * *   *      [2, 3, 5] 
hsa-miR-27a* MIMAT0004501       *       
hsa-miR-27b MIMAT0000419 * *          [2, 3] 
hsa-miR-27b* MIMAT0004588               
hsa-miR-28-3p MIMAT0004502 *             
hsa-miR-28-5p MIMAT0000085 *   * *       
hsa-miR-296-3p MIMAT0004679           *   
hsa-miR-296-5p MIMAT0000690         *     
hsa-miR-298 MIMAT0004901         *     
hsa-miR-299-3p MIMAT0000687              [3] 
hsa-miR-299-5p MIMAT0002890              [3] 
hsa-miR-29a MIMAT0000086 *     *      [3, 4] 
hsa-miR-29a* MIMAT0004503       *       
hsa-miR-29b MIMAT0000100 *            [2-4] 
hsa-miR-29b-1* MIMAT0004514           *   
hsa-miR-29b-2* MIMAT0004515           *   
hsa-miR-29c MIMAT0000681 *     *      [3] 
hsa-miR-29c* MIMAT0004673       *       
hsa-miR-300 MIMAT0004903     *   *     
hsa-miR-301a MIMAT0000688 *             
  
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-301b MIMAT0004958 *             
hsa-miR-302a MIMAT0000684 *       *    [3] 
hsa-miR-302a* MIMAT0000683               
hsa-miR-302b MIMAT0000715 *            [3] 
hsa-miR-302c MIMAT0000717 *       *    [3] 
hsa-miR-302c* MIMAT0000716               
hsa-miR-302d MIMAT0000718         *    [3] 
hsa-miR-302d* MIMAT0004685           *   
hsa-miR-302e MIMAT0005931           *   
hsa-miR-302f MIMAT0005932           *   
hsa-miR-30a MIMAT0000087 *             
hsa-miR-30a* MIMAT0000088           *   
hsa-miR-30b MIMAT0000420 *   * *      [2, 3, 5] 
hsa-miR-30b* MIMAT0004589               
hsa-miR-30c MIMAT0000244 *            [2, 3, 5] 
hsa-miR-30c-1* MIMAT0004674           *   
hsa-miR-30c-2* MIMAT0004550           *   
hsa-miR-30d MIMAT0000245 *            [3] 
hsa-miR-30d* MIMAT0004551               
hsa-miR-30e MIMAT0000692 *             
hsa-miR-31 MIMAT0000089   *          [1, 3, 4, 5, 7] 
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-31* MIMAT0004504               
hsa-miR-32 MIMAT0000090 *       *    [3] 
hsa-miR-32* MIMAT0004505           *   
hsa-miR-320a MIMAT0000510   *       *   
hsa-miR-320b MIMAT0005792   *       *   
hsa-miR-320d MIMAT0006764   *       *   
hsa-miR-323-3p MIMAT0000755       * *     
hsa-miR-323b-5p MIMAT0001630               
hsa-miR-324-3p MIMAT0000762         *    [3] 
hsa-miR-324-5p MIMAT0000761 *            [3, 5] 
hsa-miR-325 MIMAT0000771   *          [5] 
hsa-miR-326 MIMAT0000756              [3, 5] 
hsa-miR-328 MIMAT0000752              [5, 7] 
hsa-miR-329 MIMAT0001629       * *     
hsa-miR-330-3p MIMAT0000751         *     
hsa-miR-330-5p MIMAT0004693           *   
hsa-miR-331-3p MIMAT0000760 *             
hsa-miR-331-5p MIMAT0004700           *   
hsa-miR-335 MIMAT0000765 *            [3, 5] 
hsa-miR-335* MIMAT0004703               
hsa-miR-337-3p MIMAT0000754           *   
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-337-5p MIMAT0004695           *   
hsa-miR-338-3p MIMAT0000763 *             
hsa-miR-338-5p MIMAT0004701         *     
hsa-miR-339-3p MIMAT0004702 *             
hsa-miR-339-5p MIMAT0000764 *       *     
hsa-miR-33a MIMAT0000091               
hsa-miR-33a* MIMAT0004506           *   
hsa-miR-33b MIMAT0003301           *   
hsa-miR-33b* MIMAT0004811           *   
hsa-miR-340 MIMAT0004692         *    [5] 
hsa-miR-340* MIMAT0000750           *   
hsa-miR-342-3p MIMAT0000753         *     
hsa-miR-342-5p MIMAT0004694               
hsa-miR-345 MIMAT0000772 *       *    [3] 
hsa-miR-346 MIMAT0000773           *   
hsa-miR-34a MIMAT0000255 *     *      [3, 5] 
hsa-miR-34a* MIMAT0004557           *   
hsa-miR-34b MIMAT0004676              [6] 
hsa-miR-34b* MIMAT0000685           *   
hsa-miR-34c-3p MIMAT0004677         *     
hsa-miR-34c-5p MIMAT0000686 *       *     
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-361-3p MIMAT0004682           *   
hsa-miR-361-5p MIMAT0000703 *       *     
hsa-miR-362-3p MIMAT0004683         *     
hsa-miR-362-5p MIMAT0000705         *     
hsa-miR-363 MIMAT0000707 *       *    [3] 
hsa-miR-363* MIMAT0003385           *   
hsa-miR-365 MIMAT0000710 *            [3] 
hsa-miR-367 MIMAT0000719       *      [3] 
hsa-miR-367* MIMAT0004686               
hsa-miR-369-3p MIMAT0000721               
hsa-miR-369-5p MIMAT0001621           *   
hsa-miR-370 MIMAT0000722              [5] 
hsa-miR-371-3p MIMAT0000723           *   
hsa-miR-371-5p MIMAT0004687           *   
hsa-miR-372 MIMAT0000724 *            [3] 
hsa-miR-373 MIMAT0000726 *            [3] 
hsa-miR-373* MIMAT0000725     * *       
hsa-miR-374a MIMAT0000727 *     * *     
hsa-miR-374a* MIMAT0004688           *   
hsa-miR-374b MIMAT0004955 *       *     
hsa-miR-374b* MIMAT0004956           *   
  
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-375 MIMAT0000728 *            [3] 
hsa-miR-376a MIMAT0000729 *     * * *   
hsa-miR-376a* MIMAT0003386           *   
hsa-miR-376b MIMAT0002172         *     
hsa-miR-376c MIMAT0000720 *             
hsa-miR-377 MIMAT0000730         *    [3] 
hsa-miR-377* MIMAT0004689           *   
hsa-miR-378 MIMAT0000732 *            [3] 
hsa-miR-378* MIMAT0000731           *   
hsa-miR-379 MIMAT0000733 *       *    [3] 
hsa-miR-379* MIMAT0004690           *   
hsa-miR-380 MIMAT0000735         *     
hsa-miR-381 MIMAT0000736     * * *    [3] 
hsa-miR-382 MIMAT0000737              [3] 
hsa-miR-383 MIMAT0000738         *     
hsa-miR-384 MIMAT0001075           *   
hsa-miR-409-3p MIMAT0001639              [3] 
hsa-miR-409-5p MIMAT0001638           *   
hsa-miR-410 MIMAT0002171 *            [3] 
hsa-miR-411 MIMAT0003329 *       *     
hsa-miR-411* MIMAT0004813           *   
  
2
1
1
 
miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-412 MIMAT0002170         *     
hsa-miR-421 MIMAT0003339 *       *     
hsa-miR-422b MIMAT0001339           *  [3, 4] 
hsa-miR-423-3p MIMAT0001340 *             
hsa-miR-423-5p MIMAT0004748 *             
hsa-miR-424 MIMAT0001341 *   * * *    [3] 
hsa-miR-424* MIMAT0004749       *       
hsa-miR-425 MIMAT0003393 *       *    [3] 
hsa-miR-425* MIMAT0001343               
hsa-miR-429 MIMAT0001536     * * *    [2, 3] 
hsa-miR-431 MIMAT0001625 *             
hsa-miR-431* MIMAT0004757           *   
hsa-miR-432 MIMAT0002814         *     
hsa-miR-432* MIMAT0002815           *   
hsa-miR-433 MIMAT0001627       * *     
hsa-miR-448 MIMAT0001532         *     
hsa-miR-449a MIMAT0001541           *   
hsa-miR-449b MIMAT0003327           *   
hsa-miR-450a MIMAT0001545           *   
hsa-miR-450b-3p MIMAT0004910           *   
hsa-miR-450b-5p MIMAT0004909           *   
  
2
1
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-451 MIMAT0001631              [3] 
hsa-miR-452 MIMAT0001635 *            [3] 
hsa-miR-452* MIMAT0001636               
hsa-miR-454 MIMAT0003885 *            [3] 
hsa-miR-454* MIMAT0003884           *   
hsa-miR-455-3p MIMAT0004784 *             
hsa-miR-455-5p MIMAT0003150       *       
hsa-miR-483-3p MIMAT0002173         *     
hsa-miR-483-5p MIMAT0004761         * *   
hsa-miR-484 MIMAT0002174 *             
hsa-miR-485-3p MIMAT0002176           *   
hsa-miR-485-5p MIMAT0002175           *   
hsa-miR-486-3p MIMAT0004762           *   
hsa-miR-486-5p MIMAT0002177 *             
hsa-miR-487a MIMAT0002178         *     
hsa-miR-487b MIMAT0003180           *   
hsa-miR-488 MIMAT0004763 *     * *     
hsa-miR-488* MIMAT0002804       *       
hsa-miR-489 MIMAT0002805         *     
hsa-miR-490-3p MIMAT0002806           *   
hsa-miR-490-5p MIMAT0004764           *   
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-491-5p MIMAT0002807           *   
hsa-miR-492 MIMAT0002812         *     
hsa-miR-493 MIMAT0003161         *     
hsa-miR-493* MIMAT0002813           *   
hsa-miR-494 MIMAT0002816     * *      [3] 
hsa-miR-495 MIMAT0002817       *      [3] 
hsa-miR-497 MIMAT0002820 *   * * *    [3] 
hsa-miR-497* MIMAT0004768       *       
hsa-miR-498 MIMAT0002824           *  [3] 
hsa-miR-499-3p MIMAT0004772           *   
hsa-miR-499-5p MIMAT0002870           *   
hsa-miR-500a MIMAT0004773               
hsa-miR-500a* MIMAT0002871               
hsa-miR-501-3p MIMAT0004774         *     
hsa-miR-501-5p MIMAT0002872           *   
hsa-miR-502-3p MIMAT0004775         * *   
hsa-miR-502-5p MIMAT0002873           *   
hsa-miR-503 MIMAT0002874 *       *     
hsa-miR-504 MIMAT0002875           *   
hsa-miR-505 MIMAT0002876 *     * *    [3] 
hsa-miR-505* MIMAT0004776       *       
  
2
1
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-506 MIMAT0002878           *   
hsa-miR-507 MIMAT0002879         *    [3] 
hsa-miR-508-3p MIMAT0002880           *   
hsa-miR-509-3-5p MIMAT0004975         * *   
hsa-miR-509-3p MIMAT0002881         *     
hsa-miR-509-5p MIMAT0004779       * *     
hsa-miR-510 MIMAT0002882         *     
hsa-miR-511 MIMAT0002808           *   
hsa-miR-512-3p MIMAT0002823         *    [3] 
hsa-miR-512-5p MIMAT0002822           *  [3] 
hsa-miR-513a-3p MIMAT0004777         * *   
hsa-miR-513a-5p MIMAT0002877         *     
hsa-miR-513b MIMAT0005788           *   
hsa-miR-513c MIMAT0005789           *   
hsa-miR-514 MIMAT0002883              [3] 
hsa-miR-515-3p MIMAT0002827         *     
hsa-miR-515-5p MIMAT0002826     *   *     
hsa-miR-516a-3p MIMAT0006778               
hsa-miR-516b MIMAT0002859         * *   
hsa-miR-517* MIMAT0002851           *   
hsa-miR-517a MIMAT0002852 *            [3] 
  
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-517b MIMAT0002857               
hsa-miR-517c MIMAT0002866              [3] 
hsa-miR-518a-3p MIMAT0002863           *   
hsa-miR-518a-5p MIMAT0005457         *     
hsa-miR-518b MIMAT0002844 *            [3] 
hsa-miR-518c MIMAT0002848 *     *       
hsa-miR-518c* MIMAT0002847           *   
hsa-miR-518e MIMAT0002861       *   *   
hsa-miR-518e* MIMAT0005450       *       
hsa-miR-518f MIMAT0002842           *   
hsa-miR-518f* MIMAT0002841               
hsa-miR-519b-3p MIMAT0002837           *   
hsa-miR-519c-3p MIMAT0002832         *     
hsa-miR-519d MIMAT0002853         * *   
hsa-miR-519e MIMAT0002829           *   
hsa-miR-519e* MIMAT0002828           *   
hsa-miR-520a-3p MIMAT0002834           *   
hsa-miR-520a-5p MIMAT0002833           *   
hsa-miR-520b MIMAT0002843               
hsa-miR-520c-3p MIMAT0002846           *   
hsa-miR-520d-3p MIMAT0002856           *   
  
2
1
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-520e MIMAT0002825               
hsa-miR-520f MIMAT0002830         *     
hsa-miR-520g MIMAT0002858         *    [3] 
hsa-miR-520h MIMAT0002867         *    [3] 
hsa-miR-521 MIMAT0002854         *    [3] 
hsa-miR-522 MIMAT0002868         *     
hsa-miR-523 MIMAT0002840           *   
hsa-miR-524-3p MIMAT0002850           *   
hsa-miR-525-3p MIMAT0002839           *   
hsa-miR-525-5p MIMAT0002838         * *   
hsa-miR-526b MIMAT0002835           *   
hsa-miR-526b* MIMAT0002836           *   
hsa-miR-532-5p MIMAT0002888 *   * * * *   
hsa-miR-539 MIMAT0003163         *     
hsa-miR-541 MIMAT0004920           *   
hsa-miR-541* MIMAT0004919           *   
hsa-miR-542-3p MIMAT0003389           *   
hsa-miR-542-5p MIMAT0003340           *   
hsa-miR-543 MIMAT0004954         *     
hsa-miR-544 MIMAT0003164           *   
hsa-miR-545 MIMAT0003165 *     * *     
  
2
1
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-545* MIMAT0004785       *       
hsa-miR-548a-3p MIMAT0003251         *     
hsa-miR-548b-3p MIMAT0003254         *     
hsa-miR-548c-3p MIMAT0003285     *   *     
hsa-miR-548c-5p MIMAT0004806 *             
hsa-miR-548d-3p MIMAT0003323       * *     
hsa-miR-548d-5p MIMAT0004812           *   
hsa-miR-548e MIMAT0005874     *         
hsa-miR-548f MIMAT0005895           *   
hsa-miR-548g MIMAT0005912           *   
hsa-miR-548h MIMAT0005928           *   
hsa-miR-548i MIMAT0005935           *   
hsa-miR-548j MIMAT0005875           *   
hsa-miR-548k MIMAT0005882           *   
hsa-miR-548l MIMAT0005889           *   
hsa-miR-548m MIMAT0005917           *   
hsa-miR-548n MIMAT0005916     *     *   
hsa-miR-548o MIMAT0005919           *   
hsa-miR-548p MIMAT0005934           *   
hsa-miR-549 MIMAT0003333         *     
hsa-miR-550a MIMAT0004800               
  
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-551a MIMAT0003214           *   
hsa-miR-551b MIMAT0003233           *   
hsa-miR-551b* MIMAT0004794           *   
hsa-miR-552 MIMAT0003215         *     
hsa-miR-553 MIMAT0003216           *   
hsa-miR-554 MIMAT0003217           *   
hsa-miR-555 MIMAT0003219         *     
hsa-miR-556-3p MIMAT0004793           *   
hsa-miR-556-5p MIMAT0003220           *   
hsa-miR-557 MIMAT0003221           *   
hsa-miR-558 MIMAT0003222         * *   
hsa-miR-559 MIMAT0003223           *   
hsa-miR-561 MIMAT0003225         *     
hsa-miR-563 MIMAT0003227           *   
hsa-miR-564 MIMAT0003228         *     
hsa-miR-566 MIMAT0003230           *   
hsa-miR-567 MIMAT0003231               
hsa-miR-568 MIMAT0003232           *   
hsa-miR-569 MIMAT0003234           *  [2] 
hsa-miR-570 MIMAT0003235     *   *     
hsa-miR-571 MIMAT0003236           *   
  
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-572 MIMAT0003237         *     
hsa-miR-573 MIMAT0003238         *     
hsa-miR-574-3p MIMAT0003239         *     
hsa-miR-574-5p MIMAT0004795         *     
hsa-miR-575 MIMAT0003240         *     
hsa-miR-576-5p MIMAT0003241         *     
hsa-miR-577 MIMAT0003242     *         
hsa-miR-578 MIMAT0003243         *     
hsa-miR-579 MIMAT0003244         *     
hsa-miR-580 MIMAT0003245         *     
hsa-miR-582-3p MIMAT0004797         *     
hsa-miR-582-5p MIMAT0003247         *     
hsa-miR-584 MIMAT0003249         *     
hsa-miR-585 MIMAT0003250           *   
hsa-miR-586 MIMAT0003252         *     
hsa-miR-587 MIMAT0003253         *     
hsa-miR-588 MIMAT0003255         *     
hsa-miR-589 MIMAT0004799           *   
hsa-miR-589* MIMAT0003256           *   
hsa-miR-590-3p MIMAT0004801 *   *         
hsa-miR-590-5p MIMAT0003258           *   
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-591 MIMAT0003259           *  [2] 
hsa-miR-592 MIMAT0003260         *     
hsa-miR-593 MIMAT0004802           *   
hsa-miR-593* MIMAT0003261           *   
hsa-miR-595 MIMAT0003263         *     
hsa-miR-596 MIMAT0003264         *     
hsa-miR-597 MIMAT0003265         *     
hsa-miR-598 MIMAT0003266           *   
hsa-miR-599 MIMAT0003267           *   
hsa-miR-600 MIMAT0003268         *     
hsa-miR-601 MIMAT0003269               
hsa-miR-602 MIMAT0003270         *     
hsa-miR-603 MIMAT0003271       * *     
hsa-miR-604 MIMAT0003272         *     
hsa-miR-605 MIMAT0003273         *     
hsa-miR-606 MIMAT0003274           *   
hsa-miR-607 MIMAT0003275     *   *     
hsa-miR-608 MIMAT0003276         *     
hsa-miR-609 MIMAT0003277         *     
hsa-miR-610 MIMAT0003278         *     
hsa-miR-611 MIMAT0003279         *     
  
2
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-612 MIMAT0003280         *     
hsa-miR-613 MIMAT0003281           *   
hsa-miR-614 MIMAT0003282           *   
hsa-miR-615-3p MIMAT0003283           *   
hsa-miR-615-5p MIMAT0004804           *   
hsa-miR-616* MIMAT0003284           *   
hsa-miR-617 MIMAT0003286       * *     
hsa-miR-618 MIMAT0003287         *     
hsa-miR-619 MIMAT0003288         *     
hsa-miR-620 MIMAT0003289         *     
hsa-miR-621 MIMAT0003290         *     
hsa-miR-622 MIMAT0003291           *   
hsa-miR-623 MIMAT0003292           *   
hsa-miR-624 MIMAT0004807         *     
hsa-miR-624* MIMAT0003293           *   
hsa-miR-625 MIMAT0003294 *   * * *     
hsa-miR-625* MIMAT0004808           *   
hsa-miR-626 MIMAT0003295           *   
hsa-miR-627 MIMAT0003296         *     
hsa-miR-628-3p MIMAT0003297         *     
hsa-miR-628-5p MIMAT0004809           *   
  
2
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-629 MIMAT0004810 *             
hsa-miR-629* MIMAT0003298               
hsa-miR-630 MIMAT0003299         *     
hsa-miR-631 MIMAT0003300         *     
hsa-miR-632 MIMAT0003302               
hsa-miR-633 MIMAT0003303           *   
hsa-miR-634 MIMAT0003304         *     
hsa-miR-635 MIMAT0003305         *     
hsa-miR-636 MIMAT0003306         *     
hsa-miR-637 MIMAT0003307         *     
hsa-miR-638 MIMAT0003308         *     
hsa-miR-639 MIMAT0003309           *   
hsa-miR-640 MIMAT0003310           *   
hsa-miR-641 MIMAT0003311     *   *     
hsa-miR-642a MIMAT0003312               
hsa-miR-643 MIMAT0003313           *   
hsa-miR-644 MIMAT0003314         *     
hsa-miR-645 MIMAT0003315         *     
hsa-miR-646 MIMAT0003316         *     
hsa-miR-647 MIMAT0003317         *     
hsa-miR-648 MIMAT0003318           *   
  
2
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-649 MIMAT0003319         *     
hsa-miR-650 MIMAT0003320           *   
hsa-miR-651 MIMAT0003321           *   
hsa-miR-652 MIMAT0003322 *             
hsa-miR-653 MIMAT0003328         * *   
hsa-miR-654-3p MIMAT0004814               
hsa-miR-654-5p MIMAT0003330       * *     
hsa-miR-655 MIMAT0003331       * *     
hsa-miR-657 MIMAT0003335         *     
hsa-miR-658 MIMAT0003336           *   
hsa-miR-659 MIMAT0003337         *     
hsa-miR-660 MIMAT0003338         *     
hsa-miR-661 MIMAT0003324         *     
hsa-miR-662 MIMAT0003325           *   
hsa-miR-663 MIMAT0003326         *     
hsa-miR-663b MIMAT0005867           *   
hsa-miR-664 MIMAT0005949           *   
hsa-miR-664* MIMAT0005948           *   
hsa-miR-665 MIMAT0004952           *   
hsa-miR-668 MIMAT0003881         *     
hsa-miR-671-3p MIMAT0004819           *   
  
2
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-671-5p MIMAT0003880         *     
hsa-miR-675 MIMAT0004284           *   
hsa-miR-7 MIMAT0000252 * *     *    [3] 
hsa-miR-708 MIMAT0004926         *     
hsa-miR-708* MIMAT0004927           *   
hsa-miR-7-1* MIMAT0004553   *       *   
hsa-miR-7-2* MIMAT0004554   *       *   
hsa-miR-720 MIMAT0005954           *   
hsa-miR-744 MIMAT0004945 *     *       
hsa-miR-744* MIMAT0004946       *       
hsa-miR-760 MIMAT0004957           *   
hsa-miR-765 MIMAT0003945         *     
hsa-miR-766 MIMAT0003888         *     
hsa-miR-767-3p MIMAT0003883         *     
hsa-miR-767-5p MIMAT0003882         *     
hsa-miR-769-3p MIMAT0003887         *     
hsa-miR-769-5p MIMAT0003886         *     
hsa-miR-770-5p MIMAT0003948               
hsa-miR-802 MIMAT0004185           *   
hsa-miR-873 MIMAT0004953           *   
hsa-miR-874 MIMAT0004911         *     
  
2
2
5
 
miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-875-3p MIMAT0004923       * *     
hsa-miR-875-5p MIMAT0004922           *   
hsa-miR-876-3p MIMAT0004925           *   
hsa-miR-876-5p MIMAT0004924           *   
hsa-miR-877 MIMAT0004949 *             
hsa-miR-877* MIMAT0004950           *   
hsa-miR-885-3p MIMAT0004948           *   
hsa-miR-885-5p MIMAT0004947           *   
hsa-miR-886-3p MIMAT0004906           *   
hsa-miR-886-5p MIMAT0004905           *   
hsa-miR-888 MIMAT0004916         *     
hsa-miR-888* MIMAT0004917           *   
hsa-miR-889 MIMAT0004921           *   
hsa-miR-890 MIMAT0004912           *   
hsa-miR-891a MIMAT0004902           *   
hsa-miR-891b MIMAT0004913         *     
hsa-miR-892a MIMAT0004907           *   
hsa-miR-892b MIMAT0004918           *   
hsa-miR-9 MIMAT0000441 *       *    [6] 
hsa-miR-9* MIMAT0000442              [3, 6] 
hsa-miR-920 MIMAT0004970           *   
  
2
2
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miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-922 MIMAT0004972         *     
hsa-miR-924 MIMAT0004974           *   
hsa-miR-92a MIMAT0000092 *     * *     
hsa-miR-92a-1* MIMAT0004507           *   
hsa-miR-92a-2* MIMAT0004508           *   
hsa-miR-92b MIMAT0003218       *       
hsa-miR-92b* MIMAT0004792       *       
hsa-miR-93 MIMAT0000093 *       *    [2, 3] 
hsa-miR-93* MIMAT0004509               
hsa-miR-933 MIMAT0004976           *   
hsa-miR-935 MIMAT0004978         *     
hsa-miR-936 MIMAT0004979           *   
hsa-miR-937 MIMAT0004980           *   
hsa-miR-938 MIMAT0004981           *   
hsa-miR-939 MIMAT0004982           *   
hsa-miR-940 MIMAT0004983           *   
hsa-miR-941 MIMAT0004984           *   
hsa-miR-942 MIMAT0004985         *     
hsa-miR-944 MIMAT0004987     *   *     
hsa-miR-95 MIMAT0000094   *   *      [3, 5] 
hsa-miR-96 MIMAT0000095 * *     *    [1, 3, 5, 7] 
  
2
2
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Table 14 miRNA microarray design 
This table shows the miRNAs that were identified from scientific papers (Intestinal microRNAome), the databases used for miRNA prediction and the miRNAs 
from commercial arrays that were the sources for the chip design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA ID Accession 
miRNA PCR arrays 
commercially 
available 
IPA microRNA.org Microcosm GeneSet2miRNA 
Microarray 
platforms 
Colorectal 
microRNAome 
hsa-miR-96* MIMAT0004510           *   
hsa-miR-98 MIMAT0000096 *            [3] 
hsa-miR-99a MIMAT0000097 *            [5,3,6] 
hsa-miR-99a* MIMAT0004511           *   
hsa-miR-99b MIMAT0000689   *   *      [3] 
hsa-miR-99b* MIMAT0004678           *   
  
2
2
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miRNA ID Accession 
mmu-miR-217 MIMAT0000679 
mmu-miR-30b* MIMAT0004524 
mmu-miR-483 MIMAT0004782 
mmu-miR-107 MIMAT00000647 
mmu-miR-216b MIMAT0003729 
mmu-miR-135a MIMAT0000147 
mmu-miR-27b MIMAT0000126 
mmu-miR-187 MIMAT0004782 
mmu-miR-150 MIMAT0000160 
mmu-miR-302d MIMAT0003377 
Table 15 Negative control miRNAs 
miRNAs from M muluscus included on the miRNA design to monitor false positives. 
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Appendix B QRT-PCR Melting curves and amplification curves 
 
According to the guidelines for Minimum Information for Publication for 
Quantitative Real Time-PCR Experiments when using dyes like SYBR 
Green specificity has to be assessed by running the primer sequences 
thought BLAST on the NCBI website and by sunning a melting curve 
analysis on the amplification system used (LightCycler for this study); the 
efficiency by means of serial dilutions to produce a standard curve which 
would also ensure reproducible results (Bustin et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51 QRT-PCR analysis in the LightCycler480 of GAPDH.  
Samples were amplified using GAPDH primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of GAPDH was 1.972.  
 
 
 
A 
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Figure 52 QRT-PCR analysis in the LightCycler480 of SEPHS2.  
Samples were amplified using SEPHS2 primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of SEPHS2 was 1.965. 
A 
B 
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Figure 53 QRT-PCR analysis in the LightCycler480 of GPX1.  
Samples were amplified using GPX1 primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of GPX1 was 1.953. 
A 
B 
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Figure 54 QRT-PCR analysis in the LightCycler480 of GPX2.  
Samples were amplified using GPX2 primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of GPX2 was 2.002. 
A 
B 
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Figure 55 QRT-PCR analysis in the LightCycler480 of GPX3.  
Samples were amplified using GPX3 primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of GPX3 was 1.968. 
A 
B 
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Figure 56 QRT-PCR analysis in the LightCycler480 of ACBT.  
Samples were amplified using ACBT primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of ACBT was 2.057. 
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Figure 57 QRT-PCR analysis in the LightCycler480 of SELK.  
Samples were amplified using SELK primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of SELK was 1.968. 
 
A 
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Figure 58 QRT-PCR analysis in the LightCycler480 of PIR.  
Samples were amplified using PIR primers and with a fluorescent dye. Product 
accumulation was monitored by the LightCycler. A) PCR products generating a melting 
curve showed only one peak meaning sequence specificity; a different peak appears 
when a sample is over diluted samples or it is produced by the negative control. B) a ten-
fold serial dilution is produced from PCR amplified cDNA in order to calculate C) the 
standard curve, from which efficiency of the enzymatic amplification is calculated and it is 
also used as external control to compare the expression of different experiments 
amplified by the same set of primers. Efficiency of PIR was 1.763. 
A 
B 
C 
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